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Chapter 1 
SCOPE OF THIS THESIS 

This thesis contains the results of a research project aimed at obtaining cell lines of 
seminomas, relatively rare human tumors. Seminoma cell lines, thus far lacking, would 
be important in the study of the pathobiology of human genn cell tumors. 
Seminomas represent one of the two types of human testicular geml cell tumors of 
adolescents and adults (TGCTs), the other type being the nonseminomatous TGCTs. 
Seminoma cells are considered to represent the neoplastic counterpart of primordial geon 
cells, embryonic cells that give rise to the stem cells of gametogenesis. Nonseminomatous 
TGCTs are neoplastic caricatures of normal embryonic development. Because of this, 
TGCTs might be used as a model system to study aspects of human developmental 
biology. 
Chapter 2 contains an overview of the present knowledge of TGCTs, addressing 
epidemiology and possible causes, tumor histology, and the pathobiological relation 
between the TGCT precursor (carcinoma ill situ), seminoma and nonseminomatous 
TGCTs. The last part of this chapter will focus on the micro-enviromnent of carcinoma 
ill situ and seminoma cells. Knowledge of this environment could be essential for the 
development of an ill vitro culture system for seminoma cells and the subsequent 
derivation of cell lines. 
Recently, a growth factor-receptor system has been characterized that appeared very 
important for primordial germ cell development. In addition, this system of stem cell 
factor and c-KIT receptor has been shown to be involved in the development of various 
tumors. Chapter 3 will focus on the importance of the stem cell factor/c-kit system for 
primordial germ cells and their neoplastic derivatives, since the described findings might 
also be applicable to TGCTs, especially carcinoma ill situ and seminoma cells. 
Previous attempts to culture seminoma cells ill vitro have only been partly successful, 
while cell lines have never been obtained. A reason for this failure could be the immediate 
onset of apoptosis or programmed cell death once the tumor cells are removed from their 
natural micro-enviromnent. Chapter 4 gives a brief overview of the current knowledge of 
apoptosis (detection, genetic control, effects of growth factors, hormones and extracellular 
matrix) and serves as a basis to investigate whether the onset of apoptosis is indeed 
causing the difficulties encountered in attempts to culture seminoma cells. 
Chapter 5 describes the aims of the various studies carried out in the course of the 
project. The results are presented and discussed in the Chapters 6 through 11. A 
discussion of the data and indications for future research are presented in Chapter 12. 
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Chapter 2 
TESTICULAR GERM CELL TUMORS 
OF ADOLESCENTS AND ADULTS 

2.1. Epidemiology "lid possible causes 
Testicular germ cell tumors of adolescents and adults (TGCTs) constitute one third 
of all cancers in the age group of 15 to 45 years, being the most frequent cancer in this 
population. They account for 1-3% of all malignancies in caucasian males (I). Two 
entities of TGCTs can be distinguished: seminomas (SEs) and nonseminomatous TGCTs 
(NSs) (2). SEs preferentially occur in the fourth decade of life, while NSs become 
clinically manifest in the third decade (1,3,4). SEs and NSs account for 50% and 40% of 
the total of TGCTs, respectively (5,6). The remaining 10% comprizes tumors with both 
a SE and a NS component. These tumors occur around the age of 30 (3,4). 
In about 5% of all patients both testicles are affected (bilateral TGCTs) (7,8). 
Familial occurrence of TGCTs has been reported (9). In blacks the epidemiology differs 
from that in whites. The incidence of TGCTs in blacks is lower than in whites and SEs 
become clinically manifest at a younger age. Intra-abdominal TGCTs are more frequent 
in blacks, most likely due to the unexplained higher incidence of undescended testis in this 
population (see below) (10,11). 
The incidence of TGCTs has steadily increased, and now is three times as high as in 
1940 (1,5,6, (2). Thus far the factors causing the development of TGCTs and its rising 
incidence are unclarified (13). Established risk factors are undescended testis, prior 
TGCT, family history of TGCT and gonadal dysgenesis, anlOng others associated with 
Klinefelter's syndrome (14,15). In addition, inguinal hernia, early puberty, sedentary 
lifestyle, testicular trauma and sexually transmitted disease have been documented as risk 
factors (16-18). An involvement of endogenous and exogenous oestrogens (19), as well 
as of androgens (especially during puberty) is suggested (20). 
Besides in the testis, germ cell tumors (GCTs) of the adult testicular type occur at 
other anatomical localizations. The fact that these GCTs occur at specific sites, i. e. the 
gonads, mediastinum and midline of the brain (21-24), could indicate that a specific 
micro-environment is needed for their development. The extragonadal GCTs of the adult 
testicular type and the (inmlature) teratomas and yolk sac tumors found in infants and 
children (25), will not be addressed in this chapter, but the relation of the latter with 
TGCTs will be discussed in Chapter 12. 
2.2. Histology 
Skakkeb",k showed for the first time that carcinoma ill situ (CIS) cells are the 
precursors of both SEs and NSs (26,27). Like spermatogonia, CIS cells are in close 
contact with Sertoli cells, located between the basal membrane of seminiferous tubules and 
the tight junctions of Sertoli cells. Clear cytoplasm, distinct cell borders and 
hyperchromatic, enlarged nuclei morphologically characterize CIS cells (28-30). 
SEs have a monotonous histology of solid fields of uniform tumor cells, surrounded 
by connective tissue septa, which contain varying numbers of infhunmatory cells, in 
particular lymphocytes (Fig. 2.IA). SE cells are indistinguishable from CIS cells, except 
for their invasive behavior (13,26). Both have morphological, ultrastructural, and im-
munohistochemical similarities with primordial germ eels (PGCs) (26,28-30). 
IS 
Figul'e 2.1. Histology of a seminoma (A) and a spermalocytic seminoma (8), hematoxylin alld eosin 
staining. 
In contrast to SEs, NSs can have a highly varied histology (2,5). They can be 
composed of one or more of the following histological types: embryonal carcinoma (EC), 
immature or mature teratoma, yolk sac tumor and choriocarcinoma. The different cell 
types, which form neoplastic caricatures of embryonic or extra-embryonic tissues, can be 
mixed or present in separate areas. 
Besides TGCTs composed of only SE or NS, a group of tumors containing both cell 
types exists. This type of tumor is referred to as NS in the classification of the World 
Health Organization (2), and as combined tumor in the British classification (31). 
In addition to SE and NS, another type of GCT can be distinguished in the testes of 
elderly men, namely spermatocytic seminoma. This tumor represents less than 5 % of all 
GCTs. It is composed of sheets of small, medium and large cells with round nuclei (Fig. 
2.1B). The chromatin is dense in the small, more open in the medium sized and often 
filamentous in the large nuclei. Thus for these morphological, as well as pathogenetic, 
clinical and histochemical reasons, spermatocytic seminoma is considered a separate GCT 
entity composed of neoplastic germ cells at a stage of maturation between spermatogonia 
and spermatocytes, that is not derived from CIS cells (32-35). 
2.3. Pathobiological relation of seminomas and nOllseminomas 
Although it is known that both SE and NS develop from a CIS cell, the exact 
pathobiological relation between CIS, SE and NS is still unclarified. Two main hypotheses 
on the development of TGCTs exist. One hypothesis, the independent origin model, is 
based on the assumption that all SEs and NSs independently develop from their specific 
CIS cells (36-39). The other hypothesis, the linear progression model, assumes 
progression of a conmlOn CIS cell via a seminomatous stage, which is not necessarily 
clinically manifest, to NS (3,40-43) (Fig. 2.2). 
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CIS -> SE 
CIS -> SE -> NS 
CIS -> NS 
A. B. 
Figure 2.2. Representation of the two pathogenetic models for the deve{opmellf of testicular germ 
cell nunors of adoiescellls and adults: tile independent originlllodel (A) and tile linear progression 
lIIodel (B). 
The linear progression model is supported by findings in studies on human leukocyte 
antigens, ploidy, chromosomes, histochemistry, the reported borderline histology between 
SEs and NSs, and the presence of nOllsemillomatous components in metastases derived 
from testicular pure SEs (41,44-55). In spite of these supportive data, the linear 
progression model has not been proven. 
2.4. Study of primary tumors alld cell lines 
The study of human NSs is facilitated by the existence of cell lines representing most 
nonseminomatous cell types (56-69) and the use of xenografts (61,67,70-73). Experiments 
can be performed using cell lines of pluripotent EC cells, which can be induced to 
differentiate by exposure to certain agents (e.g. retinoic acid, hexamethylene bisacetamide 
and bromodeoxyuridine), for example allowing analysis of changes in gene expression 
responsible for, or coinciding with, the process of differentiation (74,75). Some of these 
studies have focussed on the expression of cell surface glycolipids, i.e. molecules 
composed of a carbohydrate and a lipid moiety. Various groups of glycolipids can be 
distinguished according to their basic molecular structure (76). The three main groups are 
the so called globo-, lacto-, and ganglia-series (77). Among others, glycolipids are 
involved in early embryonic development and in mediation/modification of growth factor 
action (78-82). Therefore, glycolipids might be important in the development of TGCTs. 
The patterns of glycolipid expression in nonseminomatous cell lines correlate with their 
differentiation lineage. Andrews et al. (83,84) and Wenk et al. (85) have shown that 
undifferentiated EC cell lines are characterized by the expression of globo-series 
glycolipids. Upon induced or spontaneous differentiation of these cells into the various 
nonseminomatous cell types, the synthesis of globo-series glycolipids is down-regulated, 
while the synthesis of lacto- and ganglia-series glycolipids increases. Specific 
combinations of glycolipids are correlated with specific cell histological types and the way 
in which the various cell types are related can be studied using glycolipid analysis. No 
extensive data on the glycolipid pattern of primary SEs and NSs have been reported 
(86,87) and therefore the suggested close correlation between SEs and ECs (13) may be 
further studied using glycolipid assays. 
Human SEs appear to form a unique tumor type, for which no animal model, no 
xenograft system (88), no cell lines and no sufficient ill vilro culture system (89) are 
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available thus far. To gain more insight into the development of TOCTs and the relation 
between SEs and NSs one or more of the forementioned are needed. Optimal in vivo or 
in vitro culture conditions should result in survival and proliferation of SE cells, and 
eventually in the establishment of cell lines. Elucidation of the processes underlying the 
spontaneous or induced reprogrannning of SE to NS, as suggested by the linear 
progression model, would then be possible. 
2.5. The micro-environment of carcinoma ill situ and seminoma ceUs 
CIS and SE cells are assumed to be the malignant counterparts of POCs, among 
others because of the presence on these cells of immunohistochemical markers for human 
fetal germ cells, including genn cell-specific alkaline phosphatase (detectable with 
antibodies to placental alkaline phosphatase, PLAP (3» (90-93). This implicates that CIS 
is initiated at the stage of embryonal development when POCs are present. POCs first 
appear in a defined part of the yolk sac from where they migrate to the genital ridges 
(Fig. 2.3). Because of the forementioned relatively high incidence of bilateral TOCTs 
(7,8), it is assumed that CIS cells can already develop before colonization of the genital 
ridges takes place, i.e. before week 6 of development (94,95). 
In seminiferous tubules (with spermatogenesis), a specific environment is created by 
the gonadal stroma cells, including Sertoli, Leydig and peri tubular myoid cells. Sertoli 
cells nurse spermatogonia and maturing spermatogenic cells through the production of 
many factors (96), which might also be essential for CIS cells (Fig. 2.4). Among these 
A B 
genital ridge ------\h>F 
~dL_73!J::J==::.:::'hind gut--;;;~==~=+=~~~~~~ genital ridge 
;/~~~---1:l~~====p;;'~imOrdjat germ cclls---l-Jl,;h-----'--j-, 
mcsoncphro''-----''tfhF-'7ff+ 
cloaca, __ =-+ 
--_73"----- yolk sac 
Figure 2.3. I11ree weeks old embryo. Tile primordial germ cells are located ill a parI of Ihe yolk 
sac, close to the allantois (A), 17w primordial germ cells migrate along tlte hindgut alld the dorsal 
mesellfery to the genital ridges (B). 
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factors are transport/binding proteins, proteases, extracellular matrix components, cellular 
metabolites, and growth factors (96-98). One of these growth factors is stem cell factor 
(SCF) which has recently been shown to affect PGC survival and gametogenesis (99). 
Matsui el al. (100) reported that SCF is produced by the stromal cells lining the migration 
route of PGCs as well as by the cells of the gonadal ridges, while PGCs were found to 
express the SCF receptor c-kil (101). This receptor was also demonstrated on CIS and SE 
cells (102,103), suggesting that SCF supports these cells as well. 
The Sertoli cell-germ cell interactions are not one-way events (104-110). A few germ 
cell-produced factors are known to affect Sertoli cell function: an as yet unidentified 
molecule increases Sertoli cell-transferrin mRNA levels (III), while nerve growth factor 
(112), for which receptors are present on Sertoli cells, is a candidate to explain some 
other effects, e.g. increased secretion of androgen-binding protein and inhibin, and an 
inhibition of aromatase activity in Sertoli cells (111,113-115). Interestingly, addition of 
nerve growth factor to ill vitro cultures of seminiferous tubules containing CIS cells 
resulted in enhanced survival of these cells (116). 
During fetal life, rat Sertoli cells normally express cytokeratins and vimentin. At the 
end of the fetal period and in the first days of postnatal life, cytokeratin expression is 
down regulated. In adults, only vimentin can be detected (117-119). The disappearance 
of cytokeratins coincides with the stop of rat Sertoli cell proliferation, the formation of 
the blood-testis barrier, the appearance of the first meiotic spermatocytes and the pubertal 
rise in androgens. Whether the intermediate filament expression is under hormonal control 
and/or related to the maturation status of the testis has not yet been elucidated. The fact 
A D 
Figure 2.4. ParI of a seminiferous tubule containing spermatogenetic cells (A), or carcinoma in situ 
(B). The carcinoma in situ cells are at the site normally occupied by spermatogonia: ill close cOlllact 
wilh Serlali cells and benvtell Ihe basal membralle alld SerIO Ii cell light jUllcliollS. 
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that, in men, the ceased expression of cytokeratins can be "reversed!! in situations of 
testicular disorders (120) could implicate a reversal to or mimicking of earlier stages of 
normal development (119). Recent immunohistochemical studies (our unpublished 
observations) showed that in CIS-containing and/or atrophic seminiferous tubules, the 
Sertoli cells express cytokeratins in combination with vimentin. This confirms previous 
observations (120) and suggests that atrophy and the development of CIS affect the 
intermediate filament expression of Sertoli cells by an unknown mechanism. The absence 
of meiotic spermatocytes from CIS-containing tubules and/or the early-embryonic nature 
of CIS cells could be related to this phenomenon. 
The enviromnent of CIS cells (and spermatogonia) is not influenced by Sertoli cells 
alone. The critical role of Leydig and peritubular myoid cells in the regulation of 
spermatogenesis and the androgenic status of the male has recently been recognized (96). 
As for Sertoli cell-CIS interactions, very little is known about the Leydig cell-CIS and 
peritubular myoid cell-CIS interactions. The interactions between the forementioned 
specialized gonadal cells and SE cells also remain unclarified. However, the presence of 
androgen receptors on CIS and SE cells (20) suggests an involvement of (Leydig cell-
produced) androgens in the development of TGCTs, which could be related to an onset 
of TGCT development around puberty. 
2,6. Animal models 
In the l29J murine strain, which has been used in the study of human NSs (121-125), 
no seminoma-like tumors have been described. However, testicular seminomas have been 
reported to occur in dogs, stallions, bulls, rams and bucks (126,127). Canine seminomas 
macroscopically, histologically and ultrastructurally resemble human SEs (126,128). Like 
SEs, they are yellowish-white, lobulated and moderately soft, containing clear tumor cells 
and infiltrating lymphocytes. In spite of these similarities, it has been suggested but not 
proven that these tumors are the counterpart of human spermatocytic seminomas rather 
than of SEs (129,130). This suggestion is based on the presence in the canine tumors of 
giant cells resembling those in human spermatocytic seminomas. In addition, canine 
seminomas are never found in combination with nonseminomatous components, whereas 
these elements can be found together with human SEs. Further characterization of canine 
seminomas appears necessary to clarify whether they resemble human spermatocytic 
seminomas or can be used as an animal model representative of human SEs. 
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Chapter 3 
THE C-KIT/STEM CELL FACTOR SYSTEM 
IN THE DEVELOPMENT OF PRIMORDIAL GERM CELLS 
AND PATHOLOGY 

3.1. C-KIT and stem cell factor 
Identification of the feline sarcoma virus oncogene v-kit (1). led to the cloning and 
mapping to the White spotting (W) locus on human chromosome 4qll-ql3 of the cellular 
proto-oncogene c-kit (2,3). This gene was shown to encode a type III transmembrane 
receptor kinase with extensive homology to the receptors for colony-stimulating factor-I 
(encoded by c-fms) and the receptors for platelet-derived growth factor-a and -6 (1-3). 
Upon binding of the ligand, c-KIT autophosphorylates and associates with 
phosphatidylinositol3'-kinase and phospholipase C-')'l (4,5), while RAS is also activated 
(6). This intracellular cascade could be involved in the transduction of survival and/or 
proliferation signals. 
Recently, a mouse fibroblast-derived factor was purified and characterized as the ligand 
for the c-KIT receptor (7). Subsequently, several groups simultaneously reported the 
cloning and sequencing of the gene encoding this ligand, which they named Stem Cell 
Factor (scf/SCF, the designation used here) (8-10), Kit Ligand (11), Mast Cell Growth 
Factor (12-14), or Steel Factor (5,15). In 1991, scfwas mapped to the Steel (Sf) locus on 
human chromosome 12q22-q24 (16-18). From the cell-associated precursor of the ligand 
the soluble form is released upon proteolysis, similar to the secretion of colony-stimulating 
factor-l and transforming growth factor-a from their membrane-associated precursors 
(8-11,14,19,20). 
A variety of cellular programs is influenced by c-KIT and SCF: adherence, migration, 
survival, proliferation, differentiation/maturation, and secretion. The main cell types 
affected are those of the genn cell, mast cell, melanoblast, and hematopoietic lineages 
(21-23). Moreover, the c-KIT signaling pathway also appears to be involved in the 
development of placenta, nervous system, heart septa, lung, facial chondrogenic nuclei, 
and midgestational kidney. The diverse responses to SCF may reflect, among other 
factors, the density at the cell surface of the cell-associated form, the concentration of the 
soluble form, and its presentation in context with other cell-associated, soluble, or 
extracellular matrix-associated molecules (24). 
3.2. Effects of c-KIT and stem cell factor on primordial germ cells 
In mice homozygous for severe (lethal) Walleles, germ cells can be detected at 8 days 
post coitllm (d.p.c.) but no further proliferation occurs (25). Several lines of evidence, 
including analyses of the effects of SCF on PGCs ill vitro (26-28) and of Sl mutations on 
PGC development ill vivo indicate that normal c-KIT/SCF function is required for the 
survival and/or proliferation of PGCs. 
Murine PGCs are first distinguishable in the extraembryonic mesoderm proximal to the 
primitive streak around 7 d.p.c. (29). As eady as 7.5 d.p.c., c-kit mRNA can be detected 
in PGCs (30). At 8 d.p.c. 10-100 PGCs can be found at the base of the allantois (31). 
During the migration from the hindgut to the genital ridges and the first 1-2 days upon 
reaching these sites, the PGC number increases to 2500-5000. At that time (12.5 d.p.c.), 
the gonadal ridge has undergone male or female differentiation (32). C-kit expression is 
detectable throughout the proliferation and migration period, and decreases as the female 
cells enter meiosis and the male cells become quiescent (30). 
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Genital ridges have been found to exert long-range effects on murine PGC numbers and 
direction of migration in culture (33). In addition, inverse gradients of scI and c-kit 
expression were detected along the murine PGC migratory route (24), with scI being 
highly expressed in the genital ridges and c-kit in the dorsal mesentery. ScI expression 
along the migratory route ceases when PGCs have reached the gonad, while expression 
in the genital ridges remains high. It has been suggested that the stromal cells along the 
migratory route produce cell-associated SCF, while soluble SCF is produced in the gonads 
(24). In analogy to the findings for mast cells (34), a gradient of soluble SCF would then 
elicit a chemotactic response in the PGCs, resulting in migration to the genital ridges. 
This migration might also be a haptotactic response to a concentration gradient of 
insoluble SCF, being cell- or extracellular matrix-associated. 
The use of SCF-producing cell lines has resulted in the establishment of improved ill 
vitro culture methods for murine PGCs (26-28). Cell-associated SCF, produced by feeder 
cell lines, was found to promote the adhesion of murine PGCs and sustain their survival, 
without induction of proliferation. The cell-associated form of SCF was superior to 
soluble SCF for survival of murine PGCs, although under some conditions the application 
of soluble SCF further improved the culture conditions. In analogy to the ill vitro culture 
results for murine PGCs grown on SCF-producing feeders in the presence or absence of 
soluble SCF, it was found that cell-associated SCF supported long term hematopoiesis ill 
vitro, while the soluble form could only support transient hematopoiesis. Interestingly, 
high concentrations of soluble SCF could partially overcome the lack of the cell-associated 
form (35). 
SCF was shown to act in synergy with other growth factors and extracellular matrix 
proteins to support cells of the hematopoietic lineages (24). Synergy of SCF with leukemia 
inhibitory factor (LIF) and basic fibroblast growth factor (bFGF) resulted in the survival 
and extended proliferation of murine PGCs ill vitro, allowing the subsequent derivation 
of pluripotent embryonic germ cells (36). This finding is interesting in view of the linear 
progression model, which assumes the reprogramming of SE cells to pluripotent stem 
cells, subsequently giving rise to embryonic andlor extraembryonic tissues in NSs (37). 
3.3. Pathology related to the c-KIT/stem cell factor system 
Evidence exists that the c-KIT/SCF system is involved in the development of a variety 
of tumors, including hematopoietic tumors, mast cell leukemia, melanoma, and brain, lung 
and breast cancer (24). High levels of c-kit transcripts were found in a high percentage 
of human SEs, but only in a few NSs examined in the same studies (38-41). 
Innnunohistochemically, c-KIT was detected in SEs, but only rarely in NSs (39). SCF was 
found to be expressed in a low percentage of SEs and a high percentage of NSs in one 
study (40), while in another study a low expression was observed in all TGCTs examined 
(39). No evidence of amplification or gross rearrangements in the c-kit gene was found 
in any of the TGCTs examined so far. Although Murty et al. (40) identified sites of 
candidate tumor suppressor genes on the long arm of chromosome 12, one of which 
includes the scI locus, no relationship between expression of scI in some GCTs and the 
candidate tumor suppressor gene has been described. 
It was recently confilmed that human piebaldism, a disorder of melanocyte development 
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associated with patches of unpigmented skin and hair, arises from aberrant c-KIT function 
(42-45). Defects in hematopoiesis and germ cell development have never been reported 
in heterozygous piebald individuals. The only rep0l1ed human with homozygous 
piebaldism, a nine months old boy, had pigmentless skin and hair, blue irides, facial 
dysmorphia, deafness, developmental delay, but no anemia. Data on gonadal development 
were not presented (46). 
In the murine system, many pathological germ-line W or Sl mutations have been 
reported, which in the homozygous state can result in (more or less severe) anemia, mast 
cell deficiency, white fur and sterility (16,47-50). In heterozygotes, these mutations cause 
a pattern of lacking coat pigmentation (spotting), while fertility, and red cell or mast cell 
numbers are normal (49-51). Similar mutations have been found in rats, but in 
homozygous mutants the anemia improves with age and the rats are fertile (52-54). 
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Chapter 4 
APOPTOSIS 
IN NORMAL DEVELOPMENT AND CARCINOGENESIS 

4.1. Apoptosis 
Rather recently, an important phenomenon controling cell fate during embryonal and 
adult life has been discovered and termed apoptosis (from the Greek word for" falling of 
leaves from a tree") or programmed cell death (1-5). Apoptosis is involved in elimination 
of specific cell subsets during embryogenesis and morphogenesis, thus affecting, among 
others, formation of the extremities, intestine, nervous system and degeneration of the 
female sexual organs in the male (6,7). Tissue homeostasis in adult organisms results from 
a balance of proliferation, differentiation and apoptosis, for example in the intestinal 
crypts (8). In the thymus, T-lymphocytes directed against self-antigens are apoptotically 
removed, while normal immune responses are modulated through apoptosis (9). In 
addition, the immune system can induce apoptosis throughout the organism to eliminate 
cells that might threaten homeostasis, e.g. virus-infected or damaged cells (9). 
Tissue homeostasis can be disturbed in the sense that cell proliferation is no longer 
balanced by cell elimination through apoptosis. When the proliferation rate exceeds the 
apoptosis rate or when the apoptosis rate is decreased as compared to the homeostatic 
situation, tumor formation can occur. 
4.2. Characteristics of apoptotic cells 
A wide variety of events takes place in apoptotic cells, resulting in changes at the 
microscopic and molecular level. Regarding the apoptosis-inducing agents/situations, the 
features of apoptotic cells and the apoptosis-related genes that will be discussed in the 
following paragraphs, it has to be emphasized that these are all general aspects of 
apoptosis to which many exceptions and counter-examples have been found. 
Microscopic features of apoptotic cells include condensed cytoplasm and chromatin, 
and cellular and nuclear buds (6,10,11). So called apoptotic bodies are formed upon 
breaking up of the nucleus into discrete fragments surrounded by a double-layered 
membrane, and by budding of the cell (Fig. 4.1). A major participation of the cytoskeletal 
elements fi-tubulin and actin in the formation of cellular buds and apoptotic bodies 
(12,13), associated with major deformation of the cell surface (14,15), is suggested. 
Changes of carbohydrates on the surface of apoptotic bodies allow recognition by 
neighbouring cells and macrophages (16,17). The macrophage vitronectin receptors have 
been implicated in this recognition process (18,19). Upon recognition, rapid phagocytosis 
ensures the elimination of apoptotic bodies before they can lyse (17,20). 
In several cell types the activation of tissue trans glutaminase during apoptosis is 
reported (5,21-24). This enzyme is involved in the cross-linking of intracellular proteins 
and is found at the highest concentrations in apoptotic bodies. It is suggested that 
transglutaminase activity leads to the formation of a rigid framework within apoptotic 
bodies, thus maintaining their integrity and preventing the leakage of intracellular 
substances to the extracellular space. This prevention of leakage, together with the 
forementioned phagocytosis, explains the absence of inllanIDlatory reactions at the site of 
apoptosis (17,20). 
At the molecular level, a main hallmark of apoptosis is intemucleosomal DNA cleavage 
by endogenous endonuclease activity, resulting in the formation of oligonucleosome-sized 
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Figure 4.1. Schematic represellfafioll of the apoplolic process. Upon receipt of all apop/osis-
inducing signal, all adherent cell (A) rounds up (8) alld its DNA marginates and condenses alollg 
the !luclear membrane (e), passiblya consequence ojDNAjragmelltatioll. This is rapidly followed 
by separation of the nucleus illto discrete masses of condensed chromaUIi (D), alld finally 
fragmentatioll of f/ie cell illto apoptolic bodies(E), which can be recognized and phagocytosed by 
macrophages or neighbouring cells (F). 
DNA fragments with the length of integer multiples of 180-200 base pairs (25). These 
fragments can be visualized as typical ladder patterns on electrophoresis gels. Preceding 
the fornlation of these ladders, large oligonucleosomes with lengths of 300,000 and/or 
50,000 base pairs might be detected (26). These large fragments may also be formed 
without further digestion of the DNA. Therefore, internucleosomal fragments are 
important but not essential features of apoptosis. The presence of single or double strand 
DNA nicks can be visualized using DNA end labeling, either ill situ on tissue sections 
(27) or in combination with flow cytometry (28). 
Being important as intracellular messenger, calcium ions playa role in apoptosis (29). 
An influx of calcium ions coincides with the onset of some of the above mentioned events. 
Cytoskeletal components are sensitive to high levels of free calcium ions, while 
transglutaminase (5) and one of the candidate endonucleases, DNase I (30), are calcium-
dependent. The fact that another candidate endonuclease, DNase II, is calcium-
independent could explain the occurrence of DNA ladders under essentially calcium-free 
conditions (31,32). 
4.3. Genetic control of apoptosis 
An intricate and complicated interplay of many genes/proteins regulates apoptosis. In 
this section the effects of BCL-2, RAS and P53 will be briefly discussed. Table 4.1 
provides an overview of other apoptosis-related genes described thus far. 
The first gene identified as inhibitor of apoptosis was bcl-2 (57). This gene is 
overexpressed in non-Hodgkin's B-celllymphoma as a result of a translocation (14,18) 
which couples the gene to an inununoglobulin-encoding sequence (58-60). Observations 
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in normal germinal center B-cells, gene transfer experiments using several cell types, and 
studies with transgenic mice confirmed that bcl-2 exerts its effect by inhibiting cell loss 
rather than by stimulation of proliferation (61). BCL-2 has been located to the inner 
mitochondrial membrane, the nuclear envelope and the endoplasmatic reticulum (62). The 
biochemical mode of action of BCL-2 remains unknown, although recent evidence 
suggests a role in the detoxification of reactive oxygen intermediates, anlOng others 
generated as a result of aerobic life (63). 
Besides the "specific" apoptosis gene bcl-2, well-known oncogenes and tumor 
suppressor genes can be involved in the control of apoptosis. The ras proto-oncogene, 
playing a role in the development of various tumors (64), may inhibit apoptosis (65) 
induced by certain chemotherapeutics (66) or by disruption of cell-matrix interactions (67). 
This effect of mutant ras is further discussed in the section on apoptosis and extracellular 
matrix. The tumor suppressor gene p53 also appears to be important in the control of 
apoptosis. P53 is involved in a cell cycle checkpoint for DNA integrity at the GliS 
transition, which has to be passed before proliferation is allowed (68-70). The presence 
of chromosomal damage, e.g. radiation-induced breaks, results in the onset of P53-
dependent apoptosis (71). Recently, P53 has also been implicated in apoptosis that is not 
induced by DNA damage (72,73). The presence of mutant p53 which is no longer able 
to induce apoptosis in response to DNA dan13ge or subsequent mutations in other genes 
can result in tumor formation and will contribute to tumor progression (69). 
4.4. Apnptosis upon growth factor or hormone withdrawal 
Interleukin-2 was one of the first growth factors described to be involved in prevention 
of apoptosis. T-Iymphocytes enter the apoptotic pathway upon withdrawal of this factor 
(74). Many other cell types are now known to depend upon growth factor or hormonal 
stimulation to survive (and proliferate): prostate or breast cells on steroids (75,76), 
vascular endothelial cells on fibroblast growth factor (77), mouse embryo cells on 
epidermal growth factor (78) and glial cells on platelet-derived growth factor (79). Stem 
cell factor suppresses apoptosis in various cell types, including primordial germ cells 
(80,81) and mast cells (82). These findings suggest that all cells in an organism depend 
on specific "survival factors" to escape apoptosis (I). 
The cellular dependence on "survival factors" can be overcome by transfection and 
overexpression of bcl-2. Apoptosis of hematopoietic cell lines upon interleukin-3 
withdrawal (57) and of neurons upon deprivation of nerve growth factor (83) is inhibited 
by BCL-2. It has been suggested that down-regulation of "survival gene" expression 
(including bcl-2) could follow growth factor deprivation (57). However, the loss of bcl-2 
expression does not precede apoptosis when interleukin-3 is removed from certain 
interleukin-3-dependent cells (84). P53 is probably involved in stimulation of apoptosis 
upon removal of at least some growth factors. This is suggested by the finding that loss 
of wild-type P53 function allows interleukin-6-dependent cells to survive upon factor 
removal (73). 
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Table 4.1. Genes involved in the regulation and/or execution of apoptosis. 
Name Species Apoptosis Nature Reference 
al mouse ? 
-, 33 
1lIe1-1 human ? I 34 
bel-xI avian/mouse/human I 35 
bel-x, avian/mouse/human + I- bC/-2 homolog 35 
bax mouse/human + I 36 
bad mammalian + I 37 
eed9 nematode -' 38 
bag-I mammalian BCL-2 binder 39 
c-llIyc rat/hamster + -, 40 
ede2 human + I 41,42 
grb3.3 human + I 43 
iif-I mouse + I 44 
rb human I cell cycle/ 45 
e2f human + ~ transcription 45 
eJa viral + I regulator. 45 
myd1l8 mouse + I 46 
gadd45 human/hamster + I 46 
myd1l6 mouse + I 46 
gadd34 hamster + -' 46 
ice murine + cysteine protease 47 
eed3 nematode + -, 48 
epp32 human + I 50 
icll-l l chick/human + I- iee homolog 52 
iell-I s chick/human I 52 
nedd-2 mouse + -' 53 
eppl murine + serine protease 49 
price chick/human + protease 51 
crmA cowpox virus ice inhibitor 54 
lradd human + -, 55 
fadd human + I 55 
rip human + ~ death domain gene 55 
fas human + I 9,55 
Infrl human + I 55 
rpr fruil fly + -' 55,56 
fast human + ligand for FAS 9,55 
Illf human + ligand for TNFRI 55 
ced4 nematode + ? 48 
? hamster/rat + endonuclease 30-32 
?, not known; +. enllances apoptosis; -, abrogates apoptosis. 
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4.5. Apoptosis upon disruption of cell-matrix interactions 
Apoptosis is influenced by cell-matrix interactions (67,85). The interaction of cells with 
their surrounding extracellular matrix depends on the nature of the matrix components 
(e.g. fibronectin, vitronectin, collagen and laminin) and the matrix receptors (integrins) 
expressed on the cell surface. Frisch and Francis (67) have shown that the disturbance of 
epithelial cell-matrix interactions results in apoptosis. The term "anoikis" (derived from 
the Greek word for homelessness) was suggested for this form of apoptosis. An 
abrogation of anoikis by activated RAS was reported. These results corroborate the 
findings by Schlaepfer et at. (86) who have shown that interactions of cellular fibronectin 
receptors with the extracellular matrix component fibronectin supply the cells with a 
survival signal that is most likely mediated via the RAS pathway. 
The fact that cells from certain tumor types can metastasize to various locations in the 
body indicates that these tumor cells do not die from anoikis once they are outside their 
normal micro-environment. In addition, they appear to be able to succesfully "adjust" to 
their new matrix and growth factor environment and give rise to new tumor nodules. The 
metastatic potential of tumor cells could thus correlate with the expression of 
apoptosis/anoikis blocking genes (67,85), for exanlple through autocrine stimulation by 
growth and survival factors. 
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Chapter 5 
RESEARCH AIMS 

Glycolipid characteristics of nonseminomatous cell lines are well defined. We 
analyzed the glycolipid patterns of primary seminomas (SEs) and nonseminomatous 
testicular germ cell tumors of adolescents and adults (TGCTs), of which no extensive 
glycolipid data are available, to investigate whether the data on nonseminomatous cell 
lines can be applied to primary tumors and to shed light on the relation between SEs and 
nonserninomatous TGCTs (Chapter 6). 
No animal model for human SEs is currently available. With the aim of finding such 
a model, we investigated whether canine seminomas are comparable to human SEs, using 
a multidisciplinary approach (Chapter 7). 
No optimal ill vivo or ill vitro culture system, allowing prolonged survival and 
proliferation of SE cells is available at present. We aimed at improving the ill vitro culture 
conditions for SE cells, using a well-defined feeder layer and medium with fetal calf 
serum, stem cell factor, leukemia inhibitory factor and basic fibroblast growth factor 
(Chapter 8). 
We analyzed the occurrence of apoptosis in intact SE tissue and SE cell suspensions 
to reveal whether the problems encountered thus far in the attempts to culture SE cells ill 
vitro are due to the onset of apoptosis upon disruption of the cellular micro-enviromnent, 
prior to culturing (Chapter 9). 
To investigate the importance of ras mutations in the development of TGCTs, we 
screened a large series of primary SEs and nonseminomatous TGCTs for the presence of 
mutant N- or K-ras. Because of the ability of mutant ras to abrogate apoptosis induced 
by disruption of cell-matrix interactions, we also wanted to know whether the presence 
of a mutant N- or K-ras correlated with the results of our ill vitro culture and apoptosis 
studies on SE cells (Chapter 10). 
The data presented in Chapter 9 indicate that SE cells are susceptible to induction of 
apoptosis. To gain insight in the factors that possibly influence the onset of apoptosis in 
SE cells, as well as in the possible role in SE cells of regulators of apoptosis, we 
reviewed the literature. Findings possibly relevant for abrogation of apoptosis in SE cells, 
the application of which may allow the development of an ill vitro culture system, are 
presented in Chapter 11. In this chapter, results from previous chapters and unpublished 
findings are discussed. 
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Chapter 6 
GLYCOLIPIDS OF HUMAN 
PRIMARY TESTICULAR GERM CELL TUMORS 
R.A. Olie, B. Fenderson, K. Daley, 
J.W. Oosterhuis, J. Murphy and L.H.J. Looijenga 
Submitted 

Backgrouud: The glycolipid content of germ cell tumor cell lines correlates with their 
differentiation lineage. Whether this reflects the situation in primary germ cell tumors 
is not known. Analysis of the glycolipid content of seminomas, which have not been 
extensively studied because of a lack of cell lines, might reveal their relationship with 
other germ cell tumor types. 
Experimental design: The glycolipids of 38 human primary testicular germ cell 
tumors of adolescents and adults, comprising 19 seminomas, five embryonal 
carcinomas, five yolk sac tumors and nine (mixed) nonseminomas were analyzed, 
using thin-layer chromatography in combination with carbohydrate immunostaining. 
Samples of two testicular parenchyma containing abundant carcinoma in situ, two 
normal parenchyma with spermatogenesis, and one spermatocytic seminoma were also 
studied. 
Results: Lactosylceramide (CDR) was detected in all embryonal carcinomas, but in 
less than half of the seminomas. Seminomas and embryonal carcinomas both contained 
globo-series glycolipids, including: globotriosylceramide (Gb3), globoside (Gb4) , 
galactosyl globoside (Gb5) and sialyl galactosyl globoside (GL7). The lacto-series 
glycolipid Le' was found in all embryonal carcinomas, but only in one seminoma. 
Gangliosides GD3 and GT3 were detected in many seminomas, but rarely in 
embryonal carcinomas. Yolk sac tumors displayed a heterogeneous glycolipid profile. 
Compared to seminomas and pure embryonal carcinomas, differentiated nonseminomas 
had reduced levels of globo-series glycolipids, especially Gb3 and Gb5, while CDR, 
Le" GD3 and GT3 were found in the majority of cases. Compared to normal testicular 
parenchyma, carcinoma ill situ-containing parenchyma exhibited increased expression 
of globo-series glycolipids, most notably Gb3 and Gb5. The spermatocytic seminoma 
did not express GL7 and Le'. 
Conclusions: For the first time, we extensively studied the glycolipid content of 
seminomas. In addition, we show that the glycolipid content of nonseminomatous germ 
cell tumor cell lines reflects the situation in primary tumors. Globo-series glycolipids 
are similarly expressed in seminomas and embryonal carcinomas. The expression of 
Gb3 and Gb5 is reduced in nonseminomas upon differentiation. Le' expression in 
nonseminomas including embryonal carcinomas, allows discrimination from 
seminomas. Expression of gangliosides in seminomas might indicate their maturation 
from gangliosides-negative precursor cells. Reprogramming of these precursors would 
result in the fonnation of Le'-expressing embryonal carcinomas. 
Introduction 
The differentiation status of embryonal carcinoma (EC) and other nonseminoma 
(NS) cell lines derived from human testicular germ cell tumors of adolescents and 
adults (TGCTs) correlates with the expression of certain combinations of glycolipids in 
the plasma membrane (1-3). In EC cell lines, high levels of globo-series glycolipids, 
including globotriosylceramide (Gb3), globoside (Gb4) , galactosylgloboside (Gb5) and 
sialyl galactosylgloboside (GL7) have been detected (3). Upon somatic differentiation, 
including the formation of neural cells, these glycolipids are down-regulated, while 
lacto- and ganglio-series glycolipids (including Le" and GD3/GT3, respectively) 
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Table 6.1. Glycolipid specificity of monoclonal antibodies used 
Antibody 
G1obo-Series 
# 
# 
Glycolipid Structure*" 
GlcBI4Cer 
Galfil-+4GIcBl~er 
Gala t -+4Galfi l-+4GIcB I ~er 
GalNAcB I ~3Gala l-+4GaHll-+4Glcfi I ~er 
Gaml~3GaINAc61--)o3Galal-+4Galfil-+4GIcBl~er 
lA4-ElO 
MC630 
MC630 
MC813 
MC813 
NeuAca2~3Gaml~3GaINAcBI--)o3Galal-+4Gaml-+4GIcBl~er 
GaINAcfi I ~3GalJ3l ~3GaIN Acfil--)o3Gaia l-+4GaW l-+4GlcBI--)oCer 
3 
NeuAa24 3GaUlI 
Lacto-Series 
MC480 GaWI-+4GlcNAc/3143Gal.O I-+4Glc/3l~er 
3 
t 
Fuca! 
MC480 GalJJl->4GJcNAc61~3GaI61->4GlcNAc61~3Ga16I->4Glc61~er 
3 3 
Fuca! 
Ganglio-Series 
Glycolipid Name 
CMH 
CDH 
Gb3 (CTH) 
Gb4 (globoside) 
Gb5 (SSEA-3) 
GL7 (SSEA-3/4) 
GL9 (SSEA-3/4) 
Le' (SSEA-l) 
ex,Le' (SSEA-l) 
R24 NeuAca2--)o8NeuAca2--)o3Gal.Ol-+4Glc/31~er GD3 
A2B5 NeuAca2--)o8NeuAca2--)o8NeuAca2--)o3Galfil-+4Glc/31~er GT3 
* Globo-series glycolipids colllaill Gala144Ga/,' lacto-series giycolipids colllaill GlcNAcjJl-,*3GaI; ganglio-
series contain NellAca2~3GaI; gala-series cOllfain GalfJl-'*Ceramide. II No antibodies to detect CMH and 
CDH are available,' these molecules are detected lIsing orcinol staining. 
become delectable in specific combinations and quantities depending on the lineage of 
differentiation, inducible by various agents, e.g. retinoie acid and hexamethylene 
bisacetamide (3-5). Cell lines derived from yolk sac tumors (YSs) can contain Gb3, 
Gb4 and gangliosides, while choriocarcinoma cell lines mainly express Gb3 and the 
stage-specific embryonic antigen 1 (SSEA-I)-carrying lacto-series glycolipid Le' (3). 
It is not known to which degree the data on cell lines are representative for primary 
tumors. In addition, data on seminoma (SE) cells are lacking, mainly since SE cell 
lines do not exist. Since glycolipids are expressed in a stage and I ineage specific 
manner, data on the glycolipid profile of SEs may shed light on the relationship 
between SEs and NSs, which is still a matter of debate. Several investigators suggest 
that SE and NS are biologically independent (6-8), while others assume that NS 
develops through a, not necessarily clinically manifest, SE stage (9-12). According to 
this so-called linear progression model, SE cells become "reprogrammed" to EC cells, 
the undifferentiated stem cells of human NSs. This hypothesis is supported by 
morphological, ultrastructural, immunohistochemical, (interphase) chromosomal and 
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clinical analyses (11,13-19). We now studied the glycolipid content of primalY 
TGCTs, including SEs and carcinoma ill situ (CIS), the precursor of all TGCTs (20), 
to reveal the relationship between SEs and NSs, especially ECs. 
Experimental design 
A series of 49 orchidectomy specimens suspected of a GCT were used in this 
study. Tumor diagnosis was based on microscopic interpretation of a hematoxylin and 
eosin-stained 5 I'm frozen tissue section and subsequently confirmed using 
immunohistochemical analyses on paraffin-embedded material. Representative fresh 
tumor parts were snap frozen in liquid nitrogen or dissociated in culture medium using 
crossed scalpel blades to obtain single cell suspensions that were cryopreserved. Since 
it is known that infiltrating lymphocytes can be present in SEs in variable amounts 
(7,21), we investigated whether these cells influenced the glycolipid analysis of SE 
cells. Therefore, the results of cryopreserved suspensions from five SEs, containing 
tumor cells and lymphocytes, were compared to those of the same suspensions after 
lymphocyte depletion. Upon lyophilization of all samples, glycolipids were extracted 
according to standard procedures (22,23) and analyzed using thin-layer 
chromatography in combination with carbohydrate immunostaining (4,5). The 
glycolipid specificity of the monoclonal antibodies used is depicted in Table 6.1. 
Results and discnssion 
The glycolipid expression patterns of nonseminomatous cell lines has been shown to 
be related to the differentiation lineage of the cells (3-5). No extensive studies on 
primary NSs have been performed, nor has the glycolipid content of SEs been 
specifically studied (24-27), mainly due to a lack of cell lines. We analyzed the 
glycolipid expression in primary SEs and NSs to get more insight into the relationship 
between SE and EC. The results of our orcinol and immunostaining analyses are 
shown in Figure 6.1. All data concerning the glycolipid profiles of the analyzed 
samples are listed in Table 6.2 and summarized in Table 6.3. 
Seminomas and carcinoma in situ 
SEs are known to contain infiltrating lymphocytes (7,21), which could influence our 
tumor glycolipid analysis. Therefore, magnetic anti-CD2 coated beads were used to 
remove these inflammatory cells from SE cell suspensions. Thin-layer chromatography 
and subsequent orcinol or immunostaining for SSEA-l, SSEA-3 and SSEA-4, using 
pellets of either untreated or lymphocyte-depleted cell suspensions, revealed that 
lymphocyte depletion did not result in a marked change in glycolipid profile (Fig. 6.1). 
Orcinol staining revealed an additional band of unknown origin in the beads-treated 
samples which did not react with any of the monoclonal antibodies included in this 
study. Whether this band is specific for SEs needs further investigation. Gb3 and Gb4 
were the major glycolipids in all five SE samples. Since lymphocytes did not interfere 
with our glycolipid analysis, we proceeded to use lyophilized tissue blocks from snap 
frozen samples for subsequent analyses. 
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Of 21 SEs analyzed, all tumors expressed the globo-series glycolipid GL7, while 
CDH was found in nine, Gb3 in 19, Gb4 in 20 and Gb5 in 10 SEs. None of the SEs 
(except one) expressed Le'. The ganglia-series glycolipids GD3 and GT3 were present 
in 14 and 10 SEs, respectively. The expression level of the distinct glycolipids varied 
among the SEs. Especially concerning GL7, two groups of SEs could be distinguished: 
one with a low and one with a high level of expression. Since tumor cell enrichment 
by lymphocyte depletion did not result in a marked change in detection levels of the 
glycolipids and similar size tumor blocks were used for glycolipid extraction, the high 
and low glycolipid levels found in the tumor blocks apparently reflect differences in 
expression level and not a variation in the amount of tumor cells present in each 
sample. 
The two CIS-containing parenchyma were characterized by the presence of Gb3 and 
Gb5 and the abundant expression of Gb4 and GL7. Le' was absent, while trace 
amounts of gangliosides were detectable. These results attest to the phenotypic 
similarity of CIS and SE cells. 
Two tumors, TLl049 and TL3544, were found to have high levels of glycolipid 
expression and contained an extended GL7 glycolipid, referred to as GL9, previously 
shown to be present in NT2/D 1 cells (5). Interestingly, these tumors have previously 
been shown to contain a mutant ras gene (28) and exhibit an aberrant in vitro behavior 
(29). Sixteen other SEs, comprising 3 ras mutant and 13 wild-type tumors, did not 
show a correlation between the presence of a ras mutation and high glycolipid 
expression, while none of these ras mutant SEs expressed GL9. 
Since expression of gangliosides is regarded a marker of differentiation (4), the 
finding of GD3 and GT3 in many SEs confirms the thought that SEs form a 
heterogeneous population. It can be speculated that the gangliosides-containing SE cells 
are derived from precursor cells which only express globo-series glycolipids. Whether 
primordial germ cells, the benign counterparts of SE cells, also show heterogeneity 
concerning glycolipid expression could be analyzed in future studies, using 
immunohistochemistry . 
No SE cell lines are available today, although one cell line, designated S2, has been 
described to have some seminomatous characteristics (30). Analysis of the glycolipid 
profile revealed that S2 cells contain some Gb3, but mainly express CDH, Gb4, GL7 
and Le" while Gb5 is not present (3). We confirmed the reported data on S2 in a blind 
test during this study, which allowed identification of the S2 origin of the sample (not 
shown). In combination with our findings of CDH and Le' mainly in primary ECs (see 
below), and the absence of Gb5 in half of the SEs, the suggestion that S2 represents a 
tumor cell with an intermediate phenotype between SE and EC, but not a pure SE 
(3,30), is supported. 
Embryonal carcinomas 
The ECs expressed CDH, globo-series glycolipids and Le'. All SEs (except one) 
lacked this latter marker, which can thus be used for the differential diagnosis between 
SE and EC, Two ECs were found to weakly express GD3, while only one tumor 
contained GT3. 
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Orcinol 
'5' •. 11) 
SSEA-4 
~CDH 
-Gb3 
'Ob4 
Figure 6.1. Effect of lymphocyte depletioll all glycolipid colllellI of hlllllall semillomas. Upper 
and lower phase g/yco/ipids were obtained from cell suspensions that were either untreated (-) or 
treated (+) willi magnetic immullobeads to rell/ove lymphocytes (A). 171in-layer chromatography 
immullostain;'lg analysis of globo-series g/ycolipd expression ill lower phase and upper phase 
extracts of human testicular germ cell tumors (B). Glycolipid slandards are bleluded 011 the right 
side of each plate (S). Plates were developed with cllloroformimethalloliwater (50:40:10) 
cOlltaining 0.05% calcium chloride Gild either stained for carbohydrate using orcinol/sulfuric 
acid spray (Orcillol) or labeled with mOlloc/ollal antibody directed to either SSEA-l, SSEA-3 or 
SSEA-4. LolVer phase glycolipids lVere illc/uded all Orcillol alld SSEA-3 plates; IIpper phase 
glycolipid" were illeluded all SSEA-1 alld SSEA-4 plates. Results represellt bOlllld alltibody 
detected using alkaline phosphatase-conjugated second an';body. Asterisks (*) lIofe a 
contaminant ill lymphocyte depleted samples (Orcino!). and non-specific binding of second 
allfibody to lipids present in lower phase extracts (SSEA-3). Samples are idelltified by number ill 
Table 7.2. 
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The expression of CDH is markedly enhanced in primary tumors, as compared to 
cell lines. This could mean that CDH is more rapidly converted into the derived globo-
series glycolipids in cell lines cultured ill vitro, especially since the expression of 
globo-series glycolipids is similar in primary tumors and cell lines. Results obtained in 
a NATO advanced study workshop (Andrews et al., to be published elsewhere) on the 
expression of cell surface antigens by TGCT cell lines, applying inununohistochemistry 
and immunoflow cytometry, largely confirm our data on Le" detected with antibodies 
to SSEA-I (as well as those on SSEA-3 and SSEA-4 expression). However, our data 
and those presented by Wenk et al. (3) show some differences with those obtained by 
Andrews et al.. The latter detected SSEA-I antigen on all cells from the EC cell lines 
HI2.1 and HI2.2, whereas Wenk et al. could not detect this marker on these cell 
lines, using glycolipid analysis. Most likely, this is due to the fact that although SSEA-
I antigen can be carried on glycolipids, it is mainly presented at the cell surface as 
glycoprotein (31). The presented data suggest that this is true for the H12.1 and H12.2 
cell lines. However, our results implicate that EC cells in primary tumors express the 
SSEA-I antigen on the Le' glycolipid, alone or in addition to expression on 
glycoproteins (which was not investigated in our study), whereas in vitro, this antigen 
is mainly carrried on glycoproteins. 
Taken together, the studies on cell lines indicate that EC cell lines heterogeneously 
express SSEA-I and reduced expression of this marker in cell lines could indicate its 
loss upon prolonged ill vitro culture. Our data, those from the NATO workshop and 
those presented by Wenk et al. (3) implicate the presence in Ees of a large, globo-
series glycolipids-expressing stem cell population, which (heterogeneously) expresses 
SSEA-I, in vitro mainly carried on glycoproteins and ill vivo (also) on glycolipids. 
Our data are not in keeping with those obtained by Motzer et al. (25) and 
Damjanov et al. (32), who could not immunohistochemically detect SSEA-I expression 
in ECs. The use of MAb PI2 by Motzer et al., while we used MAb MC480 might 
account for this difference. The use of MC480 in combination with a 2-step detection 
method by Damjanov et al. might account for their findings, since they also failed to 
detect SSEA-3 expression in SEs (using the 2-step approach), which was detected by 
us in the present study and in an immunohistochemical analysis using the avidin-biotin 
method (not shown). 
Yolk sac tumors 
The glycolipid patterns of the two pure YSs, TLlOl3 and TL37R21, the latter 
derived from a xenografted NS with a YS component, are similar to those described 
for YS cell lines. 
The four primary YSs with minor populations of other nonseminomatous cell types 
(as indicated in Table 6.2), did not display a clearly defined glycolipid profile. These 
heterogeneous glycolipid profiles could not be related to the types of tumor 
morphology distinguished by Pera et al. (33), i.e. solid and reticulated YS resembling 
rodent visceral and parietal endoderm, respectively. In contrast to four previously 
described YS cell lines (one lacking all detectable glycolipids) (3), these four primary 
YSs contain Le'. Presence of this glycolipid could probably be attributed to EC or 
teratoma cells, that were immunohistochemically detected in these YSs as minor cell 
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!!.. Tumor 
CIS and seminomas 
13. TLl804 (CIS/SE) 
35. TL3724 (CISmS) 
l. TL1513 
2. TL614 
14. TLJI14 
IS. TL287 
16. TL8225 
19. TL220m 
26. TLl481 
27. TL229 
29. TL220TfI 
31. TL8831 
38. TL9089 
39. TUI2 
41. TL8163 
42. TL14 
45. TU888 
41. TLS39 
48. TLl049 
49. TLJ54-t. 
SO. TL8285 
51. TL924-t. 
52. TL4813 
Embryonal cMcioomas 
5. TLS201 
7. TU20Tf2 
17. TLJ635 
28. TU24 
43. TL269 
46. TL81 
Yolk sac tumors 
30. TLJ1R2l 
40. TLlOiJ 
4. TL18?3 (MD' 
9. TL6322 (Eq' 
25. TUm (Ee,IT)' 
36. TL'l162 (Eq' 
Nomemioomas 
8. TL674S (MT) 
10. TL3819 (IT,MT,YS,CH) 
11. TLJ03S (MT,YS) 
22. TUrf I (EC,IT,MT,YS) 
23. TL6936 (MT,IT,YS) 
31. TLI89 (WT) 
32. TL1348 (EC,IT,MT,YS) 
33. 11,3m (MT ,EC) 
34. Tl8007 (EC,IT,MT,YS) 
Srermatocytic seminoma 
44. Tl8743 
Non-germ cell tumors 
3. Tl8558 (DC) 
18. TL4224 (L) 
20. Tl6661 (L) 
Testicular pareochyma 
12. Tl1540 
24. TLl541 
Table 6,2, Glycolipids of human germ cell tumors 
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RtJufls reprtstnl a SYTllhuis of t;un-/ayu cllfomatograp?ry orcinol and fmmur!rulaining data. The scale Is /legatire (no symbol) to strong posidl'" 
(+++). If ant/gen IIlli carrifd on multiple glycolipid species. Abbr .. ,latiom: CII, clwriocarcinoma; CISISE, CISINS, carcinoma in situ 
cQlltaining usticu/QI JXIrtnclrjllUl adjaClnl 10 a uminoma and nonseminonUl, rtJpectil'dy; DC, dermoid 0'51; EC, emhryonal carcinoma: fr, 
Immature teratoma; [" lymphoma of the Intis; forT, mamr, Uraloma; YS, yolk sac lumor. 'Four YSs comained minor amOWlIS of non·YS Cl!fJ, as 
Indicaud; wr, usticulal Wilms' fIlmar oj germ all origin. 
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Table 6.3. Glycolipid expression in human germ cell tumors 
Glycolipid Cell type 
N (2) CISISE (23) EC (6) YS (6') NS (8) 
Globo-series 
CDH I, + II, + 6, ++ 3, + 6, ++ 
Gb3 21, ++ 6, ++ 3, + 6, + 
Gb4 2, ++ 22, ++ 6, +++ 3, ++ 7, ++ 
Gb5 12, + + 6, ++ 2, ++ 5, + 
GL7 2, + 23, +++ 6, ++ 2, ++ 7, ++ 
Lacto-series 
Le' I, + 6, ++ 4, ++ 6, ++ 
Ganglio-series 
GD3 I, + 15, ++ 2, + 4, ++ 7, ++ 
GT3 II, + I, + 2, + 7, + 
The /lumber of samples (oj the totall/umber analyzed, indicated ill brackets) expressing file indicated marker 
alld tile average immunostailling intensity are showl/. Glycolipid structures were identified ill lids report by: 
i) co-migration Oil thin-layer chromatography plates with pure glycolipid standards and ii) by 
immunos/ailling using specific anti-glycolipid mOl/oclonal antibodies. CIS, carcinoma in situ containing 
testicular parenchyma; EC, embl)'olwl carcinoma,' N, normal testicular parenchyma,' NS, 1I0llsemblOmatous 
testicular genn cell tumor: SE, seminoma; YS, yolk sac filmor. 'Four YSs contained minor amollllts oj other 
Ilonseminoma/olls cell types, as indicated ill Table 6.2. The results oj a testicular Wilms' tumor were not 
included ill the average staining in/emily oj lIollSemillomas, E"tpression is from absent (110 symbol) 10 strong 
(+++). 
populations. Damjanov et al. (32) inununohistochemically detected Le' in the YS cells 
of tumors containing at least EC and YS components, while pure YSs were not 
analyzed. 
We conclude that pure YSs are characterized by at least lacking Gb5, GL7 and Le'. 
Other lIollsemillomatolis TGCTs 
Compared to SEs and ECs, the nine (mixed) NSs had reduced levels of globo-series 
glycolipids, especially Gb3 and Gb5, while CDR and Le' were found in the majority 
of the samples. Eight NSs contained GD3 and GT3. The highest ganglioside levels 
were found in tumors with at least a mature teratoma component. One pure mature 
teratoma had trace amounts of Gb3, Gb4 and GL7, besides high levels of GD3 and 
GT3. 
Our data on pure ECs and NSs with differentiated components, are in agreement 
with those reported for the cell line NT2 (3). EC cells express almost exclusively large 
amounts of globo-series glycolipids (apart from Le'). The NSs with differentiated 
components are characterized by a lower expression of the glob a-series glycolipids, 
especially Gb3 and Gb5, expression of the laclo-series glycolipid Le' in Ihe majority of 
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maturation! 
differentiation 
CIS, globo: Gb3, Gb4, Gb5, GL7 
invasion 
SE, globo: Gb3, Gb4, Gb5, GL7 
reprogramming 
SE, globo: Gb3, Gb4, Gb5, GL7 
ganglio: G03, GT3 
EC, globo: Gb3, Gb4, Gb5, GL7 
lacto: Le~ 
maturation! 
differentiation 
NS, lacto: Le' 
ganglio: G03, GT3 
Figure 6.3. Speculative model of the development of testkular germ cell tumors from carcinoma 
in situ, taking into consideration the glycolipid expressioll patterns of the various tumor types. 
the tumors and presence of the gangliosides G03 and GT3, at the highest levels in 
tumors with at least a mature teratoma component. These data confirm the 
morphological observations of the presence of a minor stem cell population in 
differentiated NSs. 
Spermatocytic seminoma, non-germ cell tumors and testicular parenchyma 
The only spennatocytic seminoma in our series of primary testicular tumors was 
clearly distinguishable from all TGCTs in that it did not contain GL 7 and Le'. This 
supports the contention that spermatocytic seminoma is a separate GCT entity, not 
derived from CIS cells (34,35). 
The dennoid cyst expressed Gb3, Gb4, GL7, GD3 and GT3. One B-celllymphoma 
contained some CDH, while the other had low levels of CDH, Gb4, GL7 and Le". 
In normal testicular parenchyma Gb3 and Gb5 could not be detected. However, Gb4 
and GL 7 were present, although at lower levels than in CIS-containing parenchyma. 
Based on their glycolipid content, the spermatocytic seminoma, non-GCTs and the 
normal parenchyma of the testis could readily be discriminated from TGCTs and 
parenchyma containing CIS. . 
Concluding remarks 
Our analysis of the glycolipid content of human primary TGCTs confirms the data 
obtained on nonseminomatous cell lines (3). Globo-series glycolipids are highly 
expressed in ECs, while the expression of especially Gb3 and Gb5 is reduced in 
differentiated nonseminomatous elements. In addition, we show that the globo-series 
glycolipids are expressed at comparable levels in CIS, SEs and ECs. The expression of 
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Le' by ECs allows discrimination between this tumor type and SEs, which do not 
express this marker. Gangliosides are found in many SEs and almost all differentiated 
NSs, but are rare in ECs. 
These results could be integrated in the speculative model shown in Figure 6.3. 
Primitive cells, i.e. CIS and SE cells, are characterized by globo-series glycolipids. 
These tumor cells could develop along two pathways. Either they mature (differentiate) 
in the germ cell lineage and start expressing gangliosides, or they are reprogrammed to 
become pluripotent EC cells and start expressing lacto-series Le'. When these 
reprogrammed cells mature (differentiate) into various lineages they start expressing 
gangliosides as well. 
The present data fit into the lineal' progression model, but do not prove it. Studies 
comparing the glycolipid profile of CIS and adjacent tumor, either SE or NS, should 
be performed to further investigate this model. 
Methods 
TlIIllor handling 
Fourty-nine orchidectomy specimens, suspected of a TGCT were collected at the 
operation theater or pathology department of collaborating hospitals. Representative 
parts of tumor and adjacent normal parenchyma were snap-frozen using liquid 
nitrogen. The remaining parts were put in culture medium (DMEM/FI2, with 103 
ku/L penicillin, 103 mg/L streptomycin, 43 mg/L gentamycin, 365 mg/L-glutamin, 
Gibco, Paisley, UK) and taken to the laboratory for further processing. Tumor 
diagnosis was based on microscopic interpretation of a hematoxylin and eosin-stained 5 
I'm frozen tissue section. Fresh representative samples of all tissue components were 
fixed in 4 % (v/v) formalin for paraffin embedding, or snap frozen in liquid nitrogen. 
Remaining tumor parts were dissociated in culture medium at room temperature, using 
two crossed scalpel blades. Tissue fragments were allowed to settle in a 50 mI tube in 
30 mI culture medium. The supernatant, containing mostly single cells (as analyzed by 
phase contrast microscopy using a Zeiss Axiovell microscope), was washed twice with 
culture medium. To the cell suspension 10% (final volume) dimethylsulfoxide was 
added slowly. The suspension was aliquotted, frozen in a Kryo 10 Series 2 automated 
freezer (Planer Biomed, Sunbury-an-Thames, UK), and stored in liquid nitrogen. 
TUlIlor characterization 
Typing according to the classification of the World Health Organization (7,21) was 
based on histology and immunohistochemical analysis of expression of germ cell 
specific alkaline phosphatase (detected with antibodies to placental alkaline 
phosphatase), ",-feto protein, human chorionic gonadotropin (Dako, Glostmp, DK) and 
cytokeratins 8 and 18 (Beckton Dickinson, San Jose, USA) using representative paraf-
fin and frozen tissue sections (11). 
Classification revealed 19 SEs and 19 NSs, the latter comprising five pure ECs, one 
mature teratoma (MT), five YSs (one pure and foul' with minor amounts of other 
nonseminomatous cell types, as indicated in Table 6.2), one testicular Wilms' tumor of 
germ cell origin (36), and seven mixed tumors. The mixed NSs comprised two tumors 
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with EC, immature teratoma (IT), MT and YS, one with IT, MT, YS and 
choriocarcinoma, one with MT and YS, and one with IT, MT and YS. Separate tumor 
nodules were used from two other mixed tumors; one with EC, IT, MT and YS 
besides EC with MT, the other with two SE nodules besides an EC component. The 
separate sanlples from these two tumors are referred to as T1, T, and T, (for the 
latter), and are regarded as individual tumors. Besides the above mentioned tumors, 
samples of two normal parenchyma with spermatogenesis and of two parenchyma with 
abundant CIS were analyzed, as were a spermatocytic seminoma, one pure YS 
(TL37R21) derived from a xenografted mixed NS (TL37) , one dermoid cyst and two 
testicular B·cell lymphomas. 
Lymphocyte depletion 
Cryopreserved single cell suspensions from five SEs, containing SE cells and Iym· 
phocytes, were rapidly thawed at 37°C, washed in 10 ml culture medium, and counted. 
The suspensions were treated with a 2.5 fold excess (relative to the total cell number) 
of magnetic beads coated with anti·CD2 monoclonal antibody (Dynal, Skoyen, N) to 
deplete lymphocytes. After 15·20 min incubation at room temperature with gentle 
shaking, 4 ml of culture medium was added, and the beads were removed using a 
magnetic particle collector (Dynal). The supernatant, containing enriched SE cells was 
removed. The beads were washed twice with culture medium and all supernatants were 
pooled. Removal of the lymphocytes was verified by microscopic examination of a 
cytospin preparation with hematoxylin and eosin staining. After treatment with 
magnetic beads, all suspensions contained less than 15% lymphocytes. Similar volumes 
of packed cells from untreated or beads·treated samples were used for glycolipid 
extraction. 
Lyophilization and glycolipid extraction 
The SE cell suspensions (either treated with magnetic beads or not) and the frozen 
tumor blocks were lyophilized overnight in a Freeze Mobile 12SL (Virtis Sentty, 
Gardiner, USA). Upon lyophilization, sanlples were sent to Philadelphia in numbered 
tubes, without information on tumor histology to assure an objective assay. Glycolipids 
were extracted from an approximately equal volume of packed tumor cells using 
isopropyl alcohol:hexane:water (55:25:20, v/v/v), as previously described (22). Total 
lipid extracts were partitioned into an upper and lower phase according to the method 
of Folch·Pi (23). The upper phase was desalted using CI8 reverse phase columns 
(Analytichem, Harbor City, USA). 
Glycolipid analysis 
Major glycolipids were detected using orcinol stamlllg. Specific glycolipids were 
identified by co·migration with pure glycolipid standards and by immunostaining with 
specific monoclonal anti·carbohydrate antibodies (4,5). Briefly, 5 1'1 of each glycolipid 
sample was streaked onto Whatman HP·FK silica gel plates and subjected to ascending 
chromatography using a solvent system of chloroform:methanol:water (50:40:10 v/v/v) 
containing 0.05 % (w/v) calcium chloride. After drying, the thin.layer chromatography 
plates were coated with 0.5% (w/v) polyisobutyl·methacrylate (Aldrich, Milwaukee, 
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USA) in diethyl ether for I min, blocked for 2 hr with 5% bovine serum albumin 
(Sigma, St. Louis, USA) in phosphate-buffered saline, and then reacted with primary 
antibody overnight at 4'C. Bound antibody was detected using a 2 hr incubation at 4'C 
with alkaline phosphatase-conjugated goat anti-mouse antibody (RyClone, Logan, 
USA) diluted I: 1000. Color reaction was obtained through incubation with 
bromochloroindolyl phosphate (Fisher Biotech, New Jersey, USA) and nitroblue 
tetrazolium (Sigma) for I hr at room temperature (37). 
MOI/oclollal allfibodies 
Anti-carbohydrate monoclonal antibodies (MAbs) were obtained and used as 
described previously (4). Gb3 was detected using MAb IA4-ElO (4); Gb4 and Gb5 
were detected using MAb MC630 to SSEA-3 (38); GL7 was detected using MAb 
MC813 to SSEA-4 (39); Le' was detected using MAb MC480 to SSEA-I (40,41); 
GD3 was detected using MAb R-24 (42); GT3 was detected using MAb A2B5 (43); 
The glycolipid carbohydrate structures recognized by these reagents are listed in Table 
6.1. Gangliosides are designated according to the nomenclature of Svennerholm (44). 
Glycolipids are designated according to the reconnnandations of the IUPAC 
Nomenclature Committee (45). 
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Chapter 7 
SEMINOMAS OF THE CANINE TESTIS; 
COUNTERPART OF SPERMATOCYTIC SEMINOMA OF MEN? 
L.H.J. Looijenga, R.A. Olie, I. van der Gaag, F.J. van Sluijs, 
J. Matoska, J. Ploem-Zaaijer, C. Knepfi6, J.W. Oosterhuis 
Modified from Lab Invest 74, 490-496, 1994 

Background: Dogs develop genu cell tumors of the testis at a relatively high rate. It is 
not known to what degree these tumors resemble various human testicular neoplasms. 
Experimental design: The epidemiology and morphology of a series of spontaneous 
canine testicular tumors, collected between 1985 and 1991, was analyzed, and 
compared with human testicular germ cell tumors. DNA content analysis of 
representative samples was performed using flow cytometry and image cytometry. 
Eight human spenuatocytic seminomas were studied in parallel. 
Results: All canine tumors had the histopathologic features reported as typical for dog 
testicular seminomas. These tumors could show both an intratubular and an invasive 
component. Most of them were pure (78%), while they could be combined with a 
Leydig cell tumor, a Sertoli cell tumor, or both. No somatic, placental or yolk sac 
cells were identified, and there was no carcinoma ill situ. A bimodal age distribution, 
with a peak around 1 year of age and between 4 and 16 years of age, was found for all 
pure and mixed testicular tumors, except for those composed of a Leydig cell and a 
seminoma component. These tumors were all present in dogs older than 7 years, being 
significantly older (p<O.OI) than dogs with a pure tumor of either type. All Sertoli 
cell and Leydig cell tumors were diploid. No consistent peri triploid DNA content, 
characteristic of human testicular germ cell tumors, was found for canine seminomas, 
which most often had a diploid DNA content. Human spermatocytic seminomas always 
contained diploid tumor cells, and showed a relatively low number of high ploidy cells, 
comparable to canine seminomas of the testis. 
Conclusions: The so-called seminomas of the canine testis are tumors of old age. 
Histologically, these tumors are composed of a single cell type with some variation 
without evidence of differentiation. It is proposed that canine seminomas correspond to 
human spenuatocytic seminomas. It is thought that the Leydig elements in these 
tumors represent a reactive change rather than biphasic differentiation of a single stem 
cell capable of germinal and sex-cord cell development. 
Introduction 
The tumors of the human adult testis, comprising approximately 95 % genu cell 
tumors (GCTs) and 5% gonadal stromal tumors, are in general rare tumors (1-3% of 
all cancers in males). In spite of this, these testicular germ cell tumors of adolescents 
and adults (TGCTs) are the most cOlmnon malignancy in young men, and a still 
increasing incidence is reported (1). 
Multidisciplinary research resulted in increasing understanding of the biology of 
these tumors. Clinico-pathologically they can be divided into seminomas (SEs) (50%) 
and nonseminomatous TGCTs (NSs) (40%), and those composed of both histologies, 
the combined tumors (CTs) (10%) (2,3). They all originate from carcinoma ill situ 
(CIS) (4), which can frequently be found in the adjacent parenchyma of an invasive 
tumor (5 for review). Polyploidization is suggested as an early event in the 
pathogenesis because of the consistent peritriploidy of these tumors as well as of CIS 
(6-9). Evolution of these tumors is most probably associated with net loss of (parts of) 
chromosomes (6,10 for review). The majority of human TGCTs are clinically manifest 
at postpubertal age, with a median age for NSs of 25 year, for SEs of 40 year, and for 
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Figure 7.1. Represelltative hematoxylin alld eosin-stained tissue sections showillg the 
morphology of calli"e semilloma lA, x640), all illlralubular IB) alld all illvasive compollelll Ie) of 
the same case (.'(/60). Note the lymphocytic illjiltrates ill the illvasive tumor. 
CTs in between the two (1,6,10). 
To study the factor(s) involved in the initiation, promotion, and progression of 
human TGCTs, a proper animal model would be of great value. The only available 
and intensely studied model, the murine teratocarcinomas (spontaneous or induced), is 
not satisfactory because it lacks SE and CIS (II). In addition, the spontaneous tumors 
in this model develop prepubertally. In general, domestic animals show a low 
incidence of TGCT-like tumors (II), with the exception of dogs, who show an 
incidence even higher than that in humans (1,3,12,13). To address the question 
whether canine testis tumors are a proper model for human TGCTs, we studied the 
morphology, epidemiology, and DNA content of a large series of spontaneous canine 
testicular tumors. 
Experimental design 
A series of 187 testicular tumors of dogs collected at the Veterinary Faculty of the 
University of Utrecht between 1985 and 1991 was included in this study. Re-
examination of the representative hematoxylin and eosin-stained paraffin sections of 
106 tumors, supposed to contain at least one seminoma component, showed no 
discrepancies with the original diagnosis. Therefore, the tumors not re-examined 
(n= 10), and reported to contain a seminoma according to the original diagnosis, were 
also included in this study. All samples were thoroughly histologically screened for the 
presence of NS-like as well as CIS-like components. In addition, the presence of 
nongerm cell tumor components, e.g. Sertoli cell andlor Leydig cell tumors, was 
scored. The age of the affected dogs (when available) was studied in correlation with 
the histology of the tumor. 
Because of the possible pitfalls of DNA flow cytometry (FCM) for DNA content 
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Table 7.1. Distribution of the histology of spontaneous canhle testicular 
tUlllors in total (n=187=100%), and separately for those with at least 
one seminoma component (11=116=100%, indicated in brackets). 
non-geml cell--------------- genn cell 
38.0 62.0 (100%) 
~ 
Sertoli cell Leydig cell 
29.4 8.6 
seminoma, 
Leydig and 
Sertoli cell 
0.4 (0.8) 
seminoma and 
Sertoli cell 
5.7 (8.7) 
seminoma and 
Leydig cell 
7.9 (12.9) 
pure seminoma 
48.0 (77.6) 
no slides available: 
intratubular: 
invasive: 
intratubular/invasive: 
0.4 (0.8) 
1.3 (1.9) 
2.2 (3.4) 
0.0 (0.0) 
2.2 (3.4) 
2.1 (3.4) 
3.2 (5.2) 
2.6 (4.3) 
4.3 (6.9) 
9.6 (15.5) 
20.2 (32.7) 
13.9 (22.5) 
measurements, e.g. inability to distinguish diploid and tetraploid tumor cells from 
normal host cells, and especially in paraffin-embedded tissue the risk of missing minor 
aneuploid cell populations (14,15), we also used image cytometry (lC) in this study. 
This technique solves the latter problems, but results in a lower stem line resolution 
due to the lower number of nuclei analyzed. Using both approaches, DNA content 
analysis was perfonned on representative samples of different canine testicular tumors. 
The percentage of hyperpentaploid cells, determined by IC, was compared with the 
FCM data. In addition, eight human spermatocytic seminomas (SSs), tumors composed 
of more mature germ cells with a different pathogenesis than TGCTs (16 for review), 
were analyzed. 
Results and discussion 
For morphological and epidemiological reasons, the spontaneous or induced murine 
teratocarcinomas are less suitable as models for human TGCTs (1,3,4,10,11,17,18). 
We suggest that they are the counterparts of GCTs of the human infantile testis (19 for 
review). In addition to mice, other animals show a low incidence of germ cell tumors, 
except dogs (11 for review). We studied the morphology (n= 116), epidemiology 
(n= 187), and ploidy (n=33) of spontaneous testicular germ cell tumors of dogs to 
analyse whether these tumors are a proper model for human TGCTs. 
Morphology 
The tumors of our series, as well as the non included tumors available at the 
Pathology Department of the Veterinary Faculty of the University of Utrecht, the 
Netherlands, showed no nonsemin9matous components, in agreement with earlier 
71 
.... " 
" 
" 
w j " 
" 
" 
A, , , 
.I .. ] U 
3 4 5 6 1 8 t to 11 12 t) II IS f& 
AGE (YEARS) 
B, 
c:::J ," - .. ~'" 
"r-----------------, 
1 ~ 3 4 S & 1 a ~ to 11 12 n If n 16 
AGE (YEARS) 
Figure 7.2, Schematic representatioll of the age (years) at time of presellfatioll of the differellt 
histologic categories of canine testicular tumors; cOlltaining at least a seminoma componellf (A); 
without a seminoma componellt (B). (SE, seminoma; SER, Sertoli cell tumor,' LEY, Leydig cell 
tumor), 
publications (20 for review), but in contrast to the reported intracranial canine genu 
cell tumors (21-23), Neither was carcinoma ill situ identified in the parenchyma 
adjacent to the canine testicular tumors, All testicular germ cell tumors in dogs were 
morphologically identical seminomas, showing solid sheets of moderately pleomorphic 
mononuclear cells, with round to ovoid nuclei, a dense chromatine structure and a 
single large nucleolus, The cells showed a moderate amount of basophilic cytoplasm 
and usually distinct cell borders (Figure 7,IA), Identical seminoma cells could grow 
within the seminiferous tubules (Figure 7, lB) (intra tubular variant) or as invasive 
tumor (Figure 7,1C), Lymphocytic infiltrates, localized in the stromal compartment of 
the tumor were distributed throughout the invasive tumors, but also frequently in the 
surroundings of an intratubular seminoma component. In 95 % of the specimens 
containing invasive seminomas (n~79), of which interpretable adjacent parenchyma 
was available, an intratubular component could be detected, which was most often 
multifocal, Typically, the intratubular seminoma cells occupied the whole croSs section 
of the tubules, Multifocal origin for seminomas was earlier described (24), 
Epidemiology 
In contrast to the rather low overall incidence of human TGCTs (I to 3%), a 10 
times higher incidence of testicular germ cell tumors in dogs is reported (1,12,13,25), 
Testicular genu cell tumors in dogs and humans share certain epidemiological features, 
in particular, the risk factor cryptorchidism (26-28), The incidence of seminomas and 
gonadal stromal tumors in our series is summarized in Table 7,1, showing that 38 % 
(n ~71) were Sertoli cell and/or Leydig cell tumors, while the remaining (n~ 116, 
62 %) contained at least one seminoma component. Most seminomas were pure 
(77,6%), whereas some were combined with gonadal stromal tumors, In contrast to the 
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Ploidy 
Table 7.2. Summary of the ploidy analysis of the canine testicular tumors and 
human spermatocytic seminomas using flow cytometry (FCM) and 
the presence of hyperpcntaploid cells as measured by image cytometry (Ie). 
Histology 
inv se intra! se inv/intral se Leydig Sertoli SS 
FCM IC FCM IC FCM IC FCM IC FCM IC FCM IC 
+ + + + + + 
diploid 7 5 2 9 5 0 14 0 0 4 2 0 6 2 0 5 4 I 
peridiploid 4 0 2 3 I 0 2 0 0 0 0 0 0 0 0 0 0 0 
total II 5 4 12 6 0 16 0 0 4 2 0 6 2 0 5 4 
hyperdiploid 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 I 0 I 
hypo tetraploid 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 0 2 
Abbre\1arions: inv se, inl'Osil'e seminoma; illlrat se, intratubular seminoma; illv/intrat se, mixed invusil'e and intratubufar 
seminoma; Leydig, uydig all tumor; Sertofi, Sertofi cell /Ilmor; SS, II/mum spennalocync seminoma; FCM, DNA flow 
cytometr}',' Ie, image cytomelry; -, less than 0.5% lI)perpenraploid cells; +. more tholl 0.5% hyperpenlaploid cells. 
rarity of the combination of Sertoli andlor Leydig cell tumors with human TGCTs 
(29), this combination was found in 22.4% in this series of canine tumors, in 
agreement with earlier reports (13,27). Our results (not shown) confirm the reported 
histologic similarities between gonadal stromal tumors of the canine and human testis 
(11,20). 
The distribution of tumor histologies in our series with at least a seminoma is similar 
to that in the subgroup of which the age at presentation is known (not shown). Within 
this latter group (Figure 7.2A), two peaks of incidence for tumors composed of only a 
seminoma or a seminoma mixed with a Sertoli cell tumor were identified, the first at I 
year of age (n=8), and the second (n=44) after 3 years of age. A bimodal age 
distribution was also suggested by the data of Innes (25). The peak of incidence for 
seminomas, around the 10th year of age is in agreement with other studies (27,30-32). 
Pure Sertoli cell and pure Leydig cell tumors, or the combinations (collected within the 
same time period between 1985 and 1991), also show a bimodal age distribution 
(Figure 7.2B). The dogs with a mixed seminoma and Leydig cell tumor (mean 12.1 
years ± 2.6, n= 10) were significantly older than the dogs with the purecounterparts 
(seminoma: 8.5 years ± 3.7, n=43; Leydig cell tumors: 8.7 years ± 4.9, n=29) 
(Mann-Whitney U test; p<O.OI). This suggests a secondary development of those 
Leydig cell tumors which are mixed with a seminoma, possibly due to a prolonged 
gonadotropin drive resulting from atrophy induced by the seminoma component (33). 
Therefore, it is questionable whether the Leydig cell components are neoplastic or 
hyperplastic, a theme already discussed some 50 years ago (25 for review). 
DNA contem 
Because of the complementary value of FCM and IC for DNA content analysis 
(14,15), we used both techniques on representative samples of canine testicular tumors. 
All controls (six normal parenchyma and five epididymis samples) showed similar 
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Figure 7.3. Representative exalllpies of a DNA colllelll allalysis usillg flow cytollletry (FCM) alld 
image cytometry (IC) of canine testicular seminoma cells, showing a diploid tullIor without 
hyperpelllaploid cells (A); a diploid tUlllor with hyperpelllaploid cell, (8); and II Ilyperdiploid 
tl/Illor with hyperpentaploid cells (C). 
results using both approaches (not shown). Hyperpentaploid cells were found in less 
than 0.5%, in the same range as published (34 for review). The results obtained by 
FeM (DNA-index) and Ie (ratio of hyperpentaploid cells) are summarized in Table 
7.2. A high G2M population was found in all samples studied by FeM. The stem line 
data of the tumors derived from FeM are in agreement with the Ie DNA-index 
measurements when obvious tumor populations could be identified (not shown). Three 
representative examples are shown in Figure 7.3; a diploid seminoma without 
hyperpentaploid cells (A), a diploid seminoma with hyperpentaploid cells (B), and a 
hyperdiploid seminoma with hyperpentaploid cells (e). Ploidy analysis showed that 
Sertoli and Leydig cell tumors, either pure or combined with other components, were 
always diploid. Less than 0.5% of hyperpentaploid cells was present. 
FeM showed hyperdiploidy in 4 out of II invasive and 3 out of 12 intratubular 
seminomas. In addition, 2 out of 16 samples with both intratubular and invasive 
seminoma components were hyperdiploid. Both hyperdiploid invasive seminomas 
studied by Ie contained hyperpentaploid cells. In addition, Ie revealed a heterogeneous 
DNA content in two diploid invasive seminomas by FeM, with the presence of 
hyperpentaploid cells. The diploidy of five intratubular seminomas was confirmed 
using Ie, and no hyperpentaploid cells were detected. The presence of hyperpentaploid 
cells was already suggested by the highly pleomorphic cells detected by morphological 
screening (illustrated in Figures 7.1B and C). No correlation between ploidy and age 
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Figure 7.4. Two represelllative examples of a diploid (A) and an aneuploid (8) human 
spermatocytic seminoma, analyzed by image cytometry. 
of the dog or histology of the tumor was found. After correction for background 
(0.5% hyperpentaploid cells), four invasive seminomas showed the presence of 
hyperpentaploid cells (range 0.5-5.9%, mean 2.9) (not shown). This is in contrast with 
data on human SEs and NSs (unpublished data), showing a relatively high frequency of 
hyperpentaploid cells, and a consistently near triploid DNA content (6-8). 
Human spermatocyric seminomas 
Because of the higher incidence of testicular seminomas in older dogs, as well as the 
absence of carcinoma ill situ and nonseminomas, we hypothesize that these tumors are 
similar to human SSs. This tumor shows the histology of more mature spermatocytic 
cells, and has a different pathogenesis than TGCTs (16,35). Cryptorchidism is not 
reported as a risk factor (36). Ploidy may be an informative parameter to support our 
hypothesis. Thus far, published data on ploidy of SSs are discordant. One IC study 
reported five diploid, three tetraploid and three aneuploid SSs (36). While using the 
same technique, a consistent aneuploidy is found in another study (n = 7) (37). One 
FCM study reported 33% diploid and 67% aneuploid SSs (n=9) (38). In addition, 
57% were also found to be aneuploid (two near diploid, one tetraploid and one 
aneuploid) using FCM (35). In addition to our study (this chapter), a comparative 
DNA content analysis using both IA and FCM of SSs was recently published (39). All 
three SSs included were aneuploid, but diploid tumor cells were present. We 
performed IC on eight SSs (see Table 7.2), of which three were aneuploid (one 
hyperdiploid and two hypotetraploid) and five were diploid using FCM (35,38). Two 
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representative examples are illustrated in Figure 7.4, showing a diploid sample without 
hyperpentaploid cells (A), and an aneuploid sample (B), with hyperpentaploid cells. No 
discrepancies in ploidy were present between the FCM and IC data (not shown). Four 
out of eight SSs samples contained more that 0.5% hyperpentaploid cells (mean 2.1 %, 
range 0.5 to 5.6%). The presence of hyperpentaploid cells is concordant with the 
histology of this tumor (40). The specific keratin expression pattern in human SSs 
(cytoplasmatic punctate) (40) might be an additional marker. 
COllcludillg remarks 
Histologically, no carcinoma ill situ and nonseminomatous components have been 
found in this large series of canine testicular germ cell tumors. The seminomas 
clinically present at a relative high age, and are combined with sex cord elements in 
approximately 25% of the cases. DNA content analysis pointed to a similarity of 
canine seminomas and human SSs. This is supported by the benign behavior of human 
SSs (16 for review) and canine seminomas, showing metastases in 12.5 % according to 
data of the Department of Pathology of the Veterinary Faculty of the University of 
Utrecht, and 6 to 11 % according to the literature (41). In contrast, human SEs present 
with metastases in 20 to 30% (42). 
Our findings are in favor of the hypothesis, already put forward in the early 60s 
(30), that canine seminomas are more similar to human SSs than to human SEs. 
Therefore, we propose to reclassify canine testicular seminomas as spermatocytic 
seminoma. 
Methods 
Histology 
One hundred and eighty seven spontaneous canine testicular tumors collected at the 
Veterinary Faculty, University of Utrecht (The Netherlands) from 1985 through 1991, 
were classified according to the World Health Organization classification (3,13) on the 
basis of representative paraffin hematoxylin and eosin-stained slides. Histologically, the 
following pure or combined tumors (n= 187) were distinguished: seminomas 
(intratubular or invasive), Sertoli cell tumor and Leydig cell tumor. The slides of 106 
tumors containing a seminoma component were reviewed (10 were not available, i.e. 
eight seminomas and two seminomaslSertoli cell tumors according to the original 
diagnosis). The age of 62 seminoma-bearing dogs of which the histologic diagnosis 
was checked was known. 
Single parameter DNA flow cytometry 
Representative samples (n=49) of all histological tumor types of 33 cases were 
analyzed by DNA flow cytometry (FCM); i.e. 12 intratubular, II invasive and 16 
combined iotratubular and invasive seminoma components, four Leydig cell tumors 
and six Sertoli cell tumors. In addition, six normal and five epididymis samples were 
measured. A 5-l'm thick hematoxylin and eosin-stained slide was used for a histologic 
check for the tumor components processed for FCM. Depending on the amount of 
material, 2 or 3 50-I'm thick sections were used for single cell isolation. Either 
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complete tissue sections were used, or parts of tissue sections in which a single 
component was isolated. Flow cytometry was carried out as described (43) with some 
minor modifications (based on 44). Briefly, tissue sections were deparaffinated, 
rehydrated by sequential washes in 100, 95, 70, and 50% (v/v) ethanol, and stored in 
distilled water overnight at room temperature. Dissociation was performed for 30 min 
at 37"C using I ml 1% (w/v) pepsine (Sigma Chemical Company, SI. Louis Missouri) 
in 0.9% NaCl solution, pH 1.5, while vortexing every 5 min. Isolated cells were 
washed in buffered saline solution, centrifugated at I,OOOxg for 5 min, and passed 
through a IOO-"m filter. After another washing step, the pellet was resuspended while 
vortexing in 250 "I solution A (low salt stain: containing 3 % PEO 8000, 0.05 mglml 
of propidium iodide, 180 unitslml of RNAse A, 0.1 % Triton X-IOO, 4 "mollml 
sodium citrate) and incubated for 20 min at 37'C, after which 250 "I solution B 
(containing 3% PEO 8000, 0.05 mglml of propidium iodide, 0.1 % Triton X-lOO, 400 
"mollml sodium citrate) was added, and stored in the dark at 4"C, overnight. Before 
analysis, the suspensions were passed through a 50-I,m pore filter (Stokvis & Smits 
B.V., Haarlem, The Netherlands). Cell analysis was performed on a FACSCAN flow 
cytometer (Becton Dickinson, Mountain View, California), with interface, and 
"Consort 30" data acquisition (Becton Dickinson). 
Analysis of the FCM data was only performed when sufficient numbers of normal 
host cells were present, as judged from the hematoxylin and eosin-stained slide, to 
assure the position of the diploid stem line. When different histologic components were 
present within one specimen, the ploidy of these different cell populations was 
analyzed by carving the paraffin sections before processing in such a marmer that one 
component was enriched as compared with the others. This allowed the assigmnent of 
an enlarged peak in the flow histogram to the enriched cell population. DNA content is 
expressed as the DNA index, i.e. the ratio of propidium iodide intensity of the modal 
00/01 peak of the aneuploid population and the modal 00/01 peak of the diploid 
normal cells in the suspension. A diploid cell population has, by definition, a DNA 
index of 1.0. 
Image cylomelry 
In addition to FCM, IC was done on 16 total and 17 purified seminoma samples of 
15 cases; i.e. 6 intratubular, 9 invasive, as well as 2 Leydig cell and 2 Sertoli cell 
tumors. A further 11 testis samples (6 normal parenchyma and 5 epididymis samples) 
without tumor were studied, as well as eight human SSs. 
One 50-"m section, adjacent to the sections used for FCM, was prepared for IC. 
Similar to FCM preparation, the sections were deparaffinated and rehydrated using 
decreasing ethanol concentrations. Subsequently, the sections were enzyme-treated with 
0.05% pronase (Sigma) during 30 min at 37'C. The reaction was stopped with cold 
phosphate-buffered saline. The cell suspension was then filtrated and centrifuged. The 
supernatant was replaced by 2 % (g/w) polyethylene glycol in 50% ethanol until a 
concentration of about 20,000 cellslml was reached. Monolayer preparations were then 
made by cytocentrifugation of I ml of the cell suspension. These preparations were 
air-dried and stored at 4"C until staining (45). For the DNA measurements, Feulgen 
AzurA (Chroma, Oermany) staining was used. Image cytometry was carried out with 
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LEYTAS, as previously described (46). Briefly, LEYTAS integrates a microscope 
with automated functions (Autoplan, Leica, Germany) and an image analysis computer 
(MIAC; Leica). The image cytometer is fuUy automated and enables ceU selection at 
low magnification and measurement of selected objects at high magnification. In 
addition, the high magnification images are stored and displayed on a television 
monitor. The procedure in the present investigation consisted of selection and 
measurement of aU epithelial ceUs. Subsequently, the preparation was screened for 
ceUs with higher density and size. The procedure was finished when either the whole 
preparation had been screened or when the maximum number of objects (n = 320) had 
been selected. LEYTAS cytometry includes meticulous artefact rejection to remove 
falsely selected objects (e.g. overlapping nuclei). In addition, the few remaining 
artefacts were removed by visual evaluation of the stored images. Thus the obtained 
histograms were based on single ceUs only. Integrated optical density histograms were 
converted into DNA histograms by using the integrated optical density of the normal 
ceU population as a reference value. For the present investigation, the ratio of the 
number of hyperpentaploid ceUs and the total number of ceUs was compared with the 
stem line determination by FCM. 
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Chapter 8 
HETEROGENEITY IN THE IN VITRO SURVIVAL AND 
PROLIFERATION OF HUMAN SEMINOMA CELLS 
R.A. Olie, L.H.J. Looijenga, M.e. Dekker, F.H. de Jong, 
F.M.F. van Dissel-Emiliani, D.O. de Rooij, B. van der Holt, J.W. Oosterhuis 
Modified from Br J Cancer 71, 13-17, 1995 

Abstract 
The in vitro culture conditions allowing survival and initial proliferation of murine 
primordial germ cells from 10.5 days post coitl/III embryos, which include the use of a 
murine embryonal fibroblast (STO) feeder, were applied to 21 human seminomas, 
composed of tumor cells which are considered as the malignant counterparts of human 
primordial germ cells. Cells from 18 seminomas attached poorly to STO, and only few 
survived through day 10. In contrast, three seminomas showed a higher degree of 
attachment. Two of them showed initial proliferation and enhanced survival: 30 days 
for tumor SEI and 25 days for tumor SE3. Tumor SEI was more extensively studied, 
using the culture conditions allowing the derivation of pluripotent embryonic germ 
cells from 8.5 days post coitl/111 murine primordial germ cells, which include the use of 
STO feeder, stem cell factor, leukemia inhibitory factor and basic fibroblast growth 
factor. The presence of stem cell factor was necessary and sufficient for colonies of 
tumor cells to form during the first 3 days of culture. While the cell number decreased 
after day 3 in medium without fetal calf semm, it increased till day 9 in medium 
containing fetal calf semm. No reprogrannning of SEI cells to pluripotent cells was 
observed. Our data indicate that seminomas form a tumor population with a heteroge-
neous in vitro behavior, not equivalent to that of 8.5-10.5 days post coitl/111 murine 
primordial germ cells. 
Introduction 
In humans, a unique histological entity of testicular germ cell tumors of adolescents 
and adults (TGCTs) exists, namely seminomas (SEs) , which are composed of tumor 
cells that are considered to be the malignant counterpart of human primordial germ 
cells (PGCs) (I). No animal model for these tumors is known, and they cannot be 
cultured in vitro for a prolonged period. To develop an in vitro culture system, we 
studied the use of Sertoli cell feeders and observed an enhanced survival (2). Because 
of the number of animals repeatedly needed as Sertoli cell donors, as well as of the 
heterogeneity of the feeder preparations, we looked for alternatives. 
SE cells are indistinguishable from the cells of carcinoma ill situ (CIS), the 
precursor of all TGCTs (3), except for their invasive behavior (3,4). Both have mor-
phological and immunohistochemical similarities to PGCs (3,5), and like PGCs most 
SEs express the stem cell factor (SCF) receptor c-kit (6,7). Therefore, we assumed 
that SE cells share micro-enviromnental requirements with PGCs. Using a murine 
embryonal fibroblast (STO) feeder, initial proliferation and survival up to day 6 has 
been described for murine PGCs isolated from 10.5 days post coitulIl (d.p.c.) embryos 
(8). The use of soluble or membrane bound SCF, which has an important role in 
gametogenesis (9), and/or leukemia inhibitory factor (LIF) , which maintains the 
pluripotent phenotype of murine emblyonal stem (ES) cells (10,11) and embryonal 
carcinoma (EC) cells (12), allowed enhanced survival and proliferation (13-16). 
Further addition of basic fibroblast growth factor (bFGF), probably involved in the 
regulation of germ cell proliferation (17,18), resulted in long-term proliferation of 
murine PGCs (19,20). Under the latter conditions, pluripotent embryonal germ (EG) 
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cells can be derived from 8.5 d.p.c. PGCs (19,20). This is interesting in view of the 
linear progression model, which assumes the reprogranlffiing of SE cells to pluripotent 
stem cells, subsequently giving rise to embryonic and/or extra-embryonic tissues in 
nonseminomatous TGCTs (NSs) (4). 
Therefore, we have now studied the survival of cells from 21 primary SEs in co-
culture with STO cells. The effect of SCF, LIF and bFGF on the cells from the SE 
with the longest survival on STO feeder was analyzed. 
Materials and methods 
Thmor handling 
Twenty-one orchidectomy specimens from patients suspected of having a germ cell 
tumor were collected during surgery in collaborating hospitals. Macroscopically 
representative parts of the tumor and the adjacent normal parenchyma were partly snap 
frozen using liquid nitrogen, partly put in medium A (DMEM/FI2, with 100 ku/L 
penicillin, 100 mg/L streptomycin, 40 mg/L gentamycin, 365 mg/L-glutamin, Gibco, 
Paisley, UK) and taken to the laboratory for further processing. Fresh representative 
samples of all components were used for imprints and subsequently fixed in 4 % 
formalin (J.T.Baker, Deventer, NL) for paraffin embedding. After imprint and frozen 
section diagnosis of SE (using a hematoxylin and eosin-stained slide), the tumor was 
mechanically disaggregated at room temperature, using two crossed scalpel blades. 
Tissue fragments were allowed to settle in a 50 mI tube in 30 ml of medium A. The 
supernatant, containing almost only single cells (as analyzed by microscopy), was 
washed twice with medium A and either directly cultured or cryopreserved. To the cell 
suspension 10% (final concentration) dimethylsulphoxide (Merck, Dannstadt, FRG), 
was added slowly. The suspension was aliquotted, automatically frozen in a Kryo 10 
Series 2 (planer Biomed, Sunbury-on-Thames, UK) ( -2°C/min to -5°C, -1°C/min to -
40°C, -5°C/min to -160°C) and stored under liquid nitrogen. 
Tumor characterization 
Histological typing of the tumors was performed according to the World Health 
Organization classification (1,21), aided by immunohistochemistry for the expression 
of germ cell specific alkaline phosphatase (detected with antibodies to placental alkaline 
phosphatase (PLAP», a-fetoprotein (AFP) , human chorionic gonadotropin (bCG) 
(Dako, Glostrup, DK) and cytokeratins 8 and 18 (Becton Dickinson, San Jose, USA) 
on representative paraffin sections, while c-kit expression was irnmunohistochemically 
detected on frozen sections. All stainings were carried out using an immunoperoxidase 
technique at room temperature with 3,3' diaminobenzidine tetral'Ydrochloride (Fluka 
Chemie, Buchs, CH) visualization, as described previously (22). 
Feeders 
STO cells were cultured in T25 flasks (Costar, Cambridge, USA) at 37°C in a 
humid atmosphere with 5 % carbon dioxide in air, using 5 ml of medium A containing 
10% fetal calf serum (FCS) (Gibco) and subcultured once a week. The feeders were 
grown in 0.1 % gelatin (Sigma, SI. Louis, USA) coated six or 12-well tissue culture 
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plastic plates (Costar) or T25 flasks and at confluence treated with 10 I'g/ml mito-
mycin C (Sigma) for 3 h. After a triple wash with phosphate-buffered saline (PBS) the 
feeders were kept in medium A containing 10% FCS and SE cells were inoculated on 
the next day. 
Semilloma-STO co-cultures 
Single cell suspensions from 21 SEs (coded SEI to SE21) were seeded onto STO 
feeder. Two tumors were cultured using the cryopreserved suspension. Nineteen 
tumors were cultured using fresh cell suspensions, while from nine of these tumors 
cryopreserved suspensions were also used. Seminoma cells were seeded in either a T25 
flask (10' cells per flask) or a 6-well plate (5x106 cells per well), in respectively 5 and 
2 ml of medium A with 10% FCS. After overnight incubation at 34'C in a humid at-
mosphere with 5% carbon dioxide in air, medium was taken off and half a volume of 
fresh medium was given to the culture. The old medium was spun down at 1000 
r.p.m. for 5 min and half the volume was returned to the culture. Subsequently, half 
of the medium was changed every other day. 
Semilloma proliferatioll ill the presellce oj growth Jactors 
Feeder-containing six-well plates were seeded with 5x106 cryopreserved SE cells 
per well after rapid thawing in a 37'C water bath (experiments I, 2 and 3). In 
experiments 1 and 2 four wells (referred to as wells 1-4) were inoculated for each con-
dition, while in experiment 3 wells were inoculated in duplicate (wells 3 and 4). The 
wells contained 2 ml of medium A, with or without 10% FCS, with or without 60 
ng/ml human recombinant SCF (provided by Amgen, Thousand Oaks, USA) (e-
xperiment 2 and 3) or a combination of 60 ng/ml SCF, 10 ng/ml human recombinant 
LIF (provided by Dr. 1.K. Heath, Dept. of Biochemistry, University of Oxford, UK) 
and 1 ng/ml human recombinant bFGF (Gibco) (experiment 1, 2 and 3) (this com-
bination of growth factors is referred to as SLB). Seminoma cell number and colony 
size in wells 3 and 4 were counted on days 3 and 9 in experiment 1, on days 1, 3 and 
9 in experiment 2 and on days 1, 3 and 6 in experiment 3. Cultures were kept at 34'C 
in a humid atmosphere with 5% carbon dioxide in air, while half of the medium was 
changed every day. 
On day 1 of culture 10 I'M bromodeoxyuridine (BrdU) (Sigma) was added to wells 
I and 2 in experiments I and 2. After overnight incubation, cultures were fixed at 
room temperature in 70% ethanol for 15 min. The bottoms of the wells were cut into 
two sections using a hot scalpel blade. The sections were immunohistochemically stai-
ned either for cytokeratin, using 3,3' diarninobenzidine tetrahydrochloride visualization 
(22), or for germ cell-specific alkaline phosphatase (using antibodies to PLAP) and 
BrdU (Organon Teknika, Boxtel, NL), using a double-staining technique according to 
Hardonk and Harms (23). PLAP was stained using an immunoperoxidase with 3-
arnino-9-ethyl carbazole (Sigma) visualization, while BrdU was stained with an 
immuno alkaline phosphatase with fast blue BB salt (Sigma) visualization. This 
procedure was repeated for wells 3 and 4 (in aU three experiments) after incubation 
with BrdU from day 8 to 9. 
For all conditions, the cells present in three visual fields at a 320 x magnification 
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were counted, using a Zeiss Axiovert phase contrast microscope (Zeiss, Germany), 
equipped with a Sony charge-coupled device camera and screen (Sony, Japan), to 
allow evaluation of the obselved cells by two individuals. 
Statistical analysis 
Welch's t-statistics (24,25) was llsed to analyse the influence of serum and growth 
factors on SE colony number and size. Analysis was done for each culture condition 
separately, comparing the counts of the fixed time points, i.e. days 3 and 9 in 
experiment 1, days 1, 3 and 9 in experiment 2 and days 1, 3 and 6 in experiment 3. 
All calculations were performed using Stata software (26). 
Results 
Tumor characterization 
Irmnunohistochemically, all 21 tumors, which were located in the testis, were 
negative for APP, while they showed consistent membranous staining for PLAP and c-
KIT. Six tumors were negative for cytokeratin and hCG. In five tumors cytokeratin-
expressing cells and in three tumors hCG-positive cells were detected. Seven tumors 
showed cytokeratin as well as hCG expression. 
Seminoma-STO co-cullllres 
The cells of all tumors, except three (SEl, SE2 and SE3), showed poor attachment 
to STO feeder, and only few cells survived through day 10 (not shown). While fresh 
and cryopreserved SE2 cells only showed enllanced attachment, fresh SEI and SE3 
cells also survived for over 24 days. Cryopreserved SEI cells survived for up to 15 
days, while no cryopreserved suspensions of SE3 were available. In all SEI and SE3 
cultures initial proliferation was observed (not shown). 
Figure 8.1. Morphology of SEI cell' on STO feeder on day 9 of cultllre ill medilull wi/haUl fetal 
calf serum (FCS) alld growth jaclors (A) alld ill medium wilh FCS and the combination of stem 
cell factor, lellkemia inhibitory factor and basic fibroblast growth factor (SLB) (B). Only ill the 
presence of FCS and SLB colonies of lip to 40 cells were detectable. Scale bar ~ 30 ~m. 
86 
4,------------------------. 
~ 3 
o 
"0 
.g 
• n 
~ 2 
c 
.. 
o 
c 
• 
• 
" 
/ . .} 
............. , ...... 1.0 i 
...... ;;.::. ....... 
....... ;;:;./. 
~ r""'- I a,I .>.'<::~~ '''' .. "." .. '~'' 
..... .-:::: ±~" .............. " .. , ~ .. yo l>" ............... .. ~ ::::: ...... ,,~.......... . ..... :::::::::;.j 
o 2 3 4 5 6 7 8 9 10 
Days 
·fes ·GF 
·FCS +SCF 
·FCS +SLB 
+FCs ·GF 
+FCS +SCF 
+fCS +SlB 
Figure 8.2. Mean size of SEl colonies over time under tile various culture conditiolls. Results 
are from experiment 2 as a representative example. Vertical bars indicate standard errors. The 
letters a-e indicate a signijicallt (p < O. 01 in all cases, etcept for a and e on day 3 with p < 0.05) 
increase or decrease ill mean colony size as compared to the previous COUllt of the colony size. 
(FCS, fetal calf serum; GF, growth factor(s); SCF, stem cell factor; SLB, the combination of 
stem cell factor, leukemia inhibitory factor and basic fibroblast growth factor). 
Seminoma proliferation in the presence oj growth jactors 
Because of the availability of cryopreserved cell suspensions and the better perfor-
mance in culture of SEI, these cells were used to study the effect of growth factors. 
Therefore, SEI cells were cultured on STO feeder in DMEM/FI2 with or without 
FCS, SCF or SLB. All data shown in the figures and presented in the text are from 
experiment 2; experiments I and 3 yielded essentially similar results. 
The morphology of SEI cells on STO feeder, in medium without FCS and growth 
factors or medium with Fes and SLB at day 9 of culture, is shown in Figure 8.1. In 
medium without FCS, feeder quality had morphologically declined and colonies were 
absent, while large colonies were present in medium with FCS. Under FCS-free 
conditions, SE cells were found on top of the STO cells, while they seemed to sink 
into the feeder layer when exposed to FCS-containing medium. 
The mean colony size of SElover time, under the various conditions, is shown in 
Figure 8.2. The mean increases in the colony number and of the mean colony size for 
the days 1-3 (first period) and days 3-9 (second) period were calculated. Under FCS-
free conditions, without growth factors, no change in total cell number was observed 
during the first period, while this number decreased during the second period (data not 
shown). The colony number significantly (p<O.OI) decreased after day 3 (data not 
shown). During the entire experiment the mean colony size was constant (1.2 cells per 
colony). The use of SCF or SLB with FCS-free medium resulted in an increase in total 
cell number during the first period and a rapid decrease in this number after day 3(data 
not shown). The colony number was constant until day 3, but decreased significantly 
(p<O.OI) during the second period. The mean colony size increased significantly 
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Figure 8.3. Distribution of SEI cells over colonies of variolls sizes at days 1 Vl). 3 (8) and 9 
(e). (Fes. fetal calf serum; GF. growth factor(s); SeF. stem cell factor; SLB. the combination 
of stem cell factor, leukemia inhibitory factor and basic fibroblast growth factor}, 
(p<O.OI) until day 3 and decreased significantly (p<O.OI) afterwards. In PCS-free 
medium no colonies with more than two cells were detected on day 9, irrespective of 
the presence of growth factors. In PCS-containing medium the colony number was 
constant throughout the experiment, irrespective of the presence of growth factors. In 
the absence of growth factors, total cell number (not shown) and mean colony size 
were constant until day 3 (mean size 1.6 cells per colony). Both increased during the 
second period. This increase was only significant (p<O.Ol) for the mean colony size 
(mean size 2.2 cells per colony at day 9). In the presence of SCP or SLB, total cell 
number (not shown) and colony size significantly (p<0.05) increased during the whole 
culture period. In the presence of SCP, the mean colony size on days 3 and 9 was 2.0 
and 3.2 cells per colony, respectively, while in the presence of SLB the mean size was 
2.1 and 3.3 cells per colony, respectively. Figure 8.3 illustrates the range of the 
colony sizes under the various conditions on days I, 3 and 9. In the absence of FCS 
and growth factors only colonies of I and 2 cells were present at day 9, whereas the 
use of these additives resulted in the fonnation of much larger colonies (up to > 10 
cells per colony) at this time point. Only in the cultures with SLB a few colonies of up 
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to 40 cells were detected outside the counted fields. 
No obvious morphological and immunohistochemical (PLAP and cytokeratin 
expression) changes were identified during the in vitro culture (not shown). 
PLAP staining and BrdU incorporation 
The counts of PLAP-positive cells confirmed the data obtained with morphological 
phase-contrast detection of SEI cells in culture. SEI cell cultures were incubated with 
BrdU from day I to 2 or from day 8 to 9 to detect DNA synthesis. The percentage of 
PLAP-positive cells showing BrdU incorporation ranged from 10 to 24 % on day 2, 
while 0.4 to 17% of the cells were labeled at day 9. No differences were found for the 
various culture conditions. On days 2 and 9, cells with incorporated BrdU were 
detected in colonies of all sizes. 
Discussion 
We have previously shown (2) and confirmed in the present study that SE cells 
cultured without feeder layer (on tissue culture plastic, in DMEM/FI2 containing 10% 
FCS) die within 3 days (data not shown). This was also found for the cells (SEI) with 
the longest survival on STO feeder, even in the presence of SCF or SLB (not shown). 
Therefore, we conclude that SE cells need contact with a specific matrix, which might 
be provided by feeder cells, possibly through interactions of the membrane-bound form 
of SCF and the receptor c-KIT, in order to survive and proliferate. This is supported 
by the finding of the same survival of the SEI cells on STO with or without additives 
during the first 3 days of culture. Since the results from the present study, are similar 
to those reported previously on the use of Sertoli cell feeders for SE culture (2), we 
conclude that the homogeneous STO feeders seem to form a good alternative for the 
use of Sertoli cell layers. 
The more extensively studied tumor SEI showed an increase in colony size during 
the first 3 days of culture on STO feeder, using both SCF and SLB, irrespective of the 
presence of FCS. From days 3 to 9, colony size increased in the presence of FCS 
alone, or with added SCF or SLB. Probably because of quality decline (morphological 
changes) of STO in FCS-free medium, the number and colony size of SEI decreased 
from day 3 onwards. Therefore, FCS seems to be necessary to directly support the 
STO cells, while its effect on SE cells seems indirect and through the feeder layer. 
During the first 3 days of culture, the colony number of SEI cells was constant for 
all conditions. This indicates that proliferation of SEI cells, for which the presence of 
SCF was necessary and sufficient, caused the growth of the colonies, instead of 
clustering of the cells owing to (enhanced) cell motility. From day 3 onwards all 
cultures containing FCS showed an increase in colony size. 
Three SEs (SEI, SE2 and SE3) had a plating efficiency on STO similar to that 
found for 8.5 d.p.c. murine PGCs (30%) (19), while two of them (SEI and SE3) 
initially proliferated, just like 10.5 d.p.c. murine PGCs (8). However, 18 of the 21 
SEs studied had a plating efficiency on STO of less than 1%. In spite of survival of 
the attached cells from these SEs to about day 10, no proliferation was found. 
Apparently, SEs form a tumor population with a heterogeneous in vitro behavior, 
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differing in attachment to STO feeder cells and subsequent survival and proliferation. 
The SE cells with an attachment and initial proliferation similar to that of 8.5 d.p.c. 
murine PGCs showed no reprogramming to pluripotent stem cells under any of the 
applied conditions, as judged by their unchanged morphology and continued expression 
of membrane-bound germ cell-specific alkaline phosphatase (detected with antibodies to 
PLAP). Therefore, we conclude that the differentiation state of SE cells is not similar 
to that of 8.5-10.5 d.p.c. PGCs. However, this does not exclude a linear progression 
model for CIS, SE and NS. The differences in the ill vitro behavior of SEs and murine 
PGCs might be related to the crucial role of the age (d.p.c.) of the latter in the ability 
to respond to growth factors; 11.5-12.5 d.p.c. murine PGCs do not proliferate when 
co-cultured with feeder cells in the presence of SCF or LIF (13,16). 
The heterogeneity in the ill vitro behavior did not correlate with the expression of 
the markers hCG and/or cytokeratins 8 and 18. The differentiation status of human 
TGCT cell lines has recently been described to correlate with the expression of distinct 
glycolipids, among others carrying the stage-specific embryonic antigens I, 3 and 4 
(27). Our preliminary results from an extensive study of the glycolipid profile of 
primary human TGCTs, especially SEs (28), revealed no distinct differentiation status 
of SEI, SE2 and SE3 as compared with the other SEs described here. The SCF 
receptor c-KIT was detected on all SEs. 
Recently, we found a possible explanation for the aberrant ill vitro behavior of SEI, 
SE2 and SE3. From 40 SEs analyzed, including 17 of the 21 tumors described in this 
paper, these tumors were the only three containing mutant N- or K-ras (29). Interes-
tingly, suppression of apoptosis by mutant ras has been reported (30), and we have 
indications that mechanical dissociation of SE tissue results in apoptosis of the tumor 
cells (31). These indications are in agreement with the findings by Frisch and Francis 
(32), who recently reported on the induction, and abrogation by mutant ras, of 
apoptosis by disruption of cell-matrix interactions. Therefore, we conclude that a 
higher degree of attachment, alone or in combination with enhanced survival and initial 
proliferation of SE cells ill vitro, might be related to the presence of mutant ras, which 
possibly interferes with the apoptotic pathway. Ras mutations indicate an unfavorable 
prognosis in childhood acute lymphocytic leukemia (33) and non-small cell lung cancer 
(34,35), while an enllanced ill vitro proliferative capacity is reported for adult acute 
myeloid leukemia with a poor prognosis (36). In view of these and our findings we are 
currently investigating the prognostic relevance of the ill vitro behavior and presence of 
ras mutations in SEs. 
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APOPTOSIS OF HUMAN SEMINOMA CELLS 
UPON DISRUPTION OF THEIR MICRO-ENVIRONMENT 
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Abstract 
One of the main obstacles encountered when trying to culture human seminoma cells 
ill vitro is massive degeneration of the tumor cells. We investigated whether dissociati-
on of tumor tissue, to obtain single cell suspensions for ill vitro culture, results in the 
onset of apoptosis. Using morphological analysis and ill situ end labeling, less than 4 % 
apoptotic tumor cells were detected in intact tissue from II out of 14 seminomas. In 
these 11 tumors, apoptosis-specific DNA ladders indicative of internucleosomal double 
strand DNA cleavage, were not detected on electrophoresis gels. In contrast, three 
seminomas with over 12% apoptotic tumor cells in the intact tissue and all analyzed 
(pure) seminoma cell suspensions, obtained after mechanical dissociation of intact 
tumor tissue, showed DNA ladders. Flow cytometric analysis of ill situ end labeled 
seminoma suspensions showed DNA breaks in up to 85% of the tumor cells. Indicated 
by cell morphology and DNA degradation, seminoma cells appear to rapidly enter the 
apoptotic pathway upon mechanical disruption of their micro-environment. No expres-
sion of p53 and of the apoptosis-inhibitor bcl-2 was detectable in intact seminoma 
tissue or cell suspensions. Our data suggest that abrogation of apoptosis might be 
crucial to succeed in culturing human seminoma cells ill vitro. 
Introduction 
Besides proliferation and differentiation, apoptosis (programmed cell death) is a 
main mechanism controling cell fate during embryogenesis, morphogenesis and tissue 
homeostasis (1-5). Recently, Frisch and Francis (6) reported that epithelial cells 
undergo apoptosis upon disruption of their interactions with the extracellular matrix, in 
a process they named anoikis. Apparently, interactions between cells and their matrix, 
mediated by integrins (the matrix receptors), provide the cells with a survival and/or 
proliferation signal, which blocks anoikis. Pesce et al. (7,8) reported that murine 
primordial germ cells (POCs) die apoptotically at extragonadal sites during 
embryogeneSis and during ill vitro handling upon isolation from the embryo. This ill 
vitro apoptosis could be blocked by the presence of specific growth factors, i.e. stem 
cell factor (SCF) or leukemia inhibitory factor (LIF) (7). Thus, besides specific cell-
matrix interactions, growth factor-receptor interactions are involved in prevention of 
apoptosis. 
Not only extracellular factors are correlated with induction of apoptosis. Several 
intracellular factors have also been implicated. BCL-2 (located in the membrane of 
mitochondria, nucleus and endoplasmatic reticulum (9», was the first oncogene 
product reported to interfere with apoptosis, sustaining cell survival without increasing 
proliferation rates in non-Hodgkin's lymphoma (10-14). BCL-2 has been reported to 
block apoptosis upon growth factor withdrawal or disruption of cell-matrix interactions 
(11,15). Nuclear P53, which constitutes a checkpoint for DNA integrity during the cell 
cycle (16), has recently been implicated in the induction of apoptosis (16-18). Upon 
DNA damage, p53 expression is enhanced and the damaged cell enters a P53-depen-
dent apoptotic pathway. Removal of certain growth factors can also result in the onset 
of P53-dependent apoptosis (19,20). In several cell types and upon induction by 
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various stimuli, apoptosis can also proceed in a PS3-independent way (21,22). 
Primary seminomas (SEs), tumors considered to be the malignant counterparts of 
PGCs (23-26), occur at specific localizations, i.e. in the gonads (27,28), mediastinum 
(29) and midline of the brain (30). Like PGCs, SE cells express the SCF receptor c-kit 
(31-33). Thus, SE cell survival and proliferation appear to depend upon a very specific 
micro-environment and growth factor supply. These findings suggest that a lack of 
apoptosis and a differentiation block could have contributed to tumor formation. 
Recently we reported that a!tempts to culture human SE cells in vitro were harupe-
red by massive degeneration of the tumor cells within the first three days of culture 
(33). We now investigated whether SE cells die apoptotically upon disruption of their 
micro-environment, prior to ill vitro culturing. Furthermore, we immunohistochemical-
Iy analyzed whether SE cells express bC/-2, and whether death of the SE cells coin-
cides with enhanced pS3 expression. 
Materials and methods 
Tumor handling and characterization 
Fourteen fresh orchidectomy specimens, macroscopically identified as SEs, were 
collected at the operation theater or pathology department of collaborating hospitals. 
Representative parts of the tumors were snap frozen using liquid nitrogen. The 
remaining was put into medium A (DMEM/FI2, with 103 kU/L penicillin, 103 mg/L 
streptomycin, 43 mg/L gentamycin, 36S mg/L-glutamin, Gibco, Paisley, UK) and 
taken to the laboratory for further processing. The SE histology of the tumor was 
confirmed through microscopic examination of a hematoxylin and eosin stained S I'm 
frozen tissue section. Representative saruples were fixed in 4% formalin (J.T.Baker, 
Deventer, NL) for paraffin embedding. Subsequently, the tumors were conclusively 
diagnosed according to the classification system of the World Health Organization 
(34-36), using immunohistochemistry for germ cell-specific alkaline phosphatase 
(detected with antibodies to placental alkaline phosphatase), a-feto protein, human 
chorionic gonadotropin (Dako, Glostrup, DK) and cytokeratins 8 and 18 (Becton 
Dickinson, San Jose, USA) on representative paraffin sections, as described (37). In 
addition, frozen sections from all SEs were aceton fixed for 10 min and screened for 
bcl-2 expression, using the 100", antibody (1:20) (provided by Drs. F. Pezzella and 
D.Y. Mason) and the streptavidin-biotin detection method. Expression of pS3 in 
aceton-fixed frozen tissue sections and in cytospins of I % formalin-fixed cell suspensi-
ons (see below) was exaruined using the DO-7 antibody (1:7S) (Dako) and a two-step 
detection method (37). 
Fresh tumor tissue was mechanically dissociated in a suitable volume of medium at 
room temperature using two crossed scalpel blades. Tissue fragments were allowed to 
settle in a IS or SO ml tube containing 10 or 30 mi medium, respectively. The 
supernatant contained almost only single cells, as analyzed by phase contrast mi-
croscopy using a Zeiss Axiovert microscope. From the supernatant a volume contai-
ning at least 2 x 10' cells was fixed at DoC in S m1 I % formalin (in phospate buffered 
saline, PBS) for 30 min. Cells were spun down at ISOO rpm for S min and 
resuspended in 200 1'1 ice-cold PBS. Subsequently, the suspension was mixed with 
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4001'1 ice-cold 96% ethanol. Samples were stored at -20'C until further processing for 
flow cytometry (FCM). To the remaining fresh single cell suspension 10 % (final 
concentration) demethylsulfoxide (Merck, Darmstadt, FRG), was added slowly. The 
suspension was aliquotted, automatically frozen in a Kryo 10 Series 2 (Planer Biomed, 
Sunbury-on-Thames, UK) (-2°C/min to _5°C, -1'C/min to -40'C, -SOC/min to -160'C) 
and stored under liquid nitrogen. 
Lymphocyte depletion 
Cryopreserved single cell suspensions from 12 SEs, containing SE cells and lym-
phocytes, were rapidly thawed at 37°C, washed in 10 m1 culture medium, and counted. 
The suspensions were treated with a 2.5 fold excess (relative to the total number of SE 
cells and lymphocytes) of magnetic beads coated with anti-CD2 monoclonal antibody 
(Dynal, Skoyen, N) to deplete lymphocytes. After 15-20 min incubation at room 
temperature with gentle shaking, 4 ml of culture medium was added, and the beads 
were removed using a magnetic particle collector (Dynal). The supernatant, containing 
enriched SE cells was removed. The beads were washed twice with culture medium 
and all supernatants were pooled. Removal of the lymphocytes was verified by 
microscopic examination of a cytospin preparation with hematoxylin and eosin staining. 
After treatment with magnetic beads, all suspensions contained less than 15% lympho-
cytes. Similar packed cell volumes from untreated or beads-treated sanlples were used 
for DNA extraction. 
Detection of DNA breaks 
One of the early events during apoptosis is single or double strand DNA cleavage 
by endogenous endonuclease activity (38). DNA breaks in tissue sections can be 
visualized using in situ end labeling (ISEL) (39), while end labeling in combination 
with FCM can be applied to analyse cell suspensions (40). The occurrence of charac-
teristic internucleosomal breaks is confirmed by the detection in cell Iysates of 200 bp 
DNA fragments, and multimers of that, on electrophoresis gels (38). Morphological 
hallmarks of apoptosis are condensation of chromatin and cytoplasm, and cell fragmen-
tation (41-43). 
In situ end labeling 
For ISEL (39), 2 I'm paraffine sections were deparaffinated, rehydrated and in-
cubated at 80"C, in 2xSSC (0.3 M NaCI, 30 mM sodium citrate) for 20 min. After a 
triple aqua bidest wash, the slides were treated with 20 mg/L pronase E (Sigma, SI. 
Louis, USA) in PBS at room temperature for 30 min, rinsed with running tapwater, in-
cubated in buffer B (50 mM Tris, 5 mM MgCI" 10 mM B-mercapto-ethanol, 0.005% 
BSA, pH7.5), dehydrated using 50, 70 and 100% ethanol, and airdried. Positive 
controls were incubated with 200 I'g/L DNase I (Boehringer, Mannheim, Germany) in 
buffer C (10 mM Tris pH 7.4, 10 mM NaCI, 5 mM MgCI" 0.1 mM CaCl, and 25 
mM KCI) at 37'C for 15 min, and washed with buffer B. Subsequently, all slides were 
incubated at 15'C for 1 hr in buffer B containing dATP, dCTP, dGTP, biotin-16-dUTP 
(0.01 mM each) (Boehringer) and 20 kU/L DNA polymerase I (Promega, Madison, 
USA). Polymerase was not added to negativeeontrols. After PBS wasiles, endogenous 
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peroxidase activity was blocked using 0.1 % H,O,/PBS and, after PBS washes, slides 
were incubated with avidine labeled horseradish peroxidase (I: 1000) (Sigma) in 1% 
BSA/0.5% Tween 20/PBS. Subsequently, slides were PBS washed and the immunore-
action was visualized using 3,3'-diaminobenzidine tetrahydrocloride (Fluka Chemie, 
Buchs, Switzerland)/H,O,. After rinsing with tapwater, slides were counterstained for 
5 sec with I % methyl green (Merck, Darmstadt, Germany). Slides were rinsed with 
aqua bidest and, after removal of excess bidest using filterpaper, with aceton. These 
washes were repeated once. Slides were dipped in two batches of aceton/xylol (1:1), 
for 2 sec/batch, cleared in xylene and embedded in Pertex (Histolab Products AB, 
Viistra Friilunda, Sweden). The percentage of apoptotic cells was scored by counting a 
total of 150-580 viable, or morphologically apoptotic and labeled SE cells in five 
representative low power microscopic fields at a 400x magnification. 
Flow cytometry 
For FCM (40), fixed cells were washed in PBS and resuspended in buffer D (50 
mM Tris pH 7.8, 5 mM MgCI" 10 mM B-mercapto-ethanol, IkVlL DNA polymerase 
1,0.2 mM dATP, dCTP, dGTP and biotin-lI-dUTP). After incubation at 15'C for 90 
min the cells were washed with 0.1 % Triton-X-IOO/PBS, and resuspended in 4xSSC 
(0.6 M NaC!, 60 mM sodium citrate) containing 2.5 mg/L avidin-fluorescein isotiocya-
nate (FITC) (Vector Laboratories, Burlingame, USA), 0.1 % Triton-X-100 and 5% 
(w/v) nonfat dry milk. Staining was performed at 37'C for 30 min. Subsequently, the 
cells were washed in PBS. DNA was counterstained with 5 mg/L propidium iodide 
(PI) (Calbiochem, La Jolla, USA) or 1 mg/L 4',6-dianlidine-2'-phenylindole (DAPI) 
(Calbiochem) in PBS at 4'C for 30 min. Flow cytometry was perfOimed on a FAC-
SCAN (PI stained samples) or VANTAGE (DAP! stained samples) flow cytometer 
(Becton Dickinson) with excitation at 488 mn or 351/364 mn, respectively. The 
following parameters were measured: forward light scatter, perpendicular light scatter, 
FITC fluorescence (515-545 mn), and fluorescence of the DNA-PI complex (563-607 
mn) or DNA-DAPI complex (488 mn). Cell debris was excluded from analysis by ap-
propriate forward light scatter treshold setting. 
Detection of DNA ladders 
DNA was isolated (44) from: 1) three 10 I'm slides from snap frozen SE blocks; 2) 
snap frozen pellets from fresh SE cell suspensions; 3) snap frozen pellets from either 
lymphocytes-containing or -depleted SE cell suspensions, that had previously been 
cryopreserved. Cells were lysed in 400 I" buffer (10 mM Tris, 400 mM NaC!, 2 mM 
EDTA, 100 l,g/mI proteinase K (Boehringer», overnight at 37'C. The lysate was 
extracted with 500 1'1 phenol/chloroform (1: I) and subsequently with chloraformlisoa-
mylalcohol (24: I). DNA was precipitated by addition of 501'1 3M sodium acetate and 
800 1'1 100% ethanol, and overnight incubation at -20'C. The pellet was spun down, 
washed with 70% ethanol, vacuum dried, dissolved in 100 I" TE (10 mM Tris, 0.1 
mM EDTA) with 50 mg/L RNase A (Sigma) and incubated at 37'C for 30 min. Subse-
quently, 201'1 solution was subjected to electrophoresis in a 1.8% agarase gel at 60 V 
for 2-3 hr. 
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Figure 9.1. Deteetioll of apoplotic eRO cells after incubation withoul or with dsplalin, 
indicated as - CisPt and + CisP!, repee/ivefy. lAbeled cells were detected lIsing flow cylometry 
(FCM) or in situ end labeling (lSEL), without (0 lI1ill) or with (30 mill) prol/ase E treatmetlt. 
Results 
Prior to analysis of the tumor samples, it was ensured that results obtained with 
ISEL and FCM were comparable. Therefore, apoptosis was induced in chinese hamster 
ovary (CHO) cell cultures by cisplatin treatment. In a DMEM + 10% FCS (Gibco) 
containing T75 flask, 2xlO' CHO cells were seeded. Upon attachment, cells were 
incubated with 21 I'M cisplatin (Bristol-Myers Squibb, Woerden, the Netherlands) for 
two hours. After washes with medium, the cells were incubated for 48 hr. Floating 
cells were harvested by centrifugation of the culture medium at 1000 rpm for 5 min. 
After addition of 10 ml fresh culture medium, attached cells were harvested from the 
flasks using cell scrapers and spun down. Cells from untreated cultures, harvested by 
scraping, were used as negative control. All sanlples were split into two fractions; one 
was fixed in 4 % formalin at room temperature for I hr and paraffin embedded (for 
ISEL), the other was fixed in I % formalin and stored under ethanol (for FCM). Prior 
to ISEL or FCM, the samples were pronase E treated for 0 or 30 min at room tempe-
rature. Upon ISEL, the percentage of morphologically apoptotic and labeled cells was 
determined by counting a total of at least 100 cells. In the negative controls a low 
percentage of labeled cells was detected (Fig. 9.1). Without pronase treatment, ISEL 
and FCM detected 0.5% and 0.8% labeled cells, respectively. These percentages 
increased to 2 % for ISEL and 1.3 % for FCM when pronase was used prior to 
labeling. In the samples of floating cells from treated cultures, application of pronase 
did not markedly affect the percentage of labeled cells detected with FCM (61 % 
without, 57% with pronase treatment, respectively). However, pronase treatment of 
paraffin sections of these cells was necessary to avoid underestimation of the number 
of apoptotic cells. With pronase treatment, 58% of the CHO cells was found to be 
apoptotic, i.e. comparable to the FCM results, while this number was only 43% 
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Figure 9.2. A representative example of the in situ end labeling of a seminoma with less than 
4% apop/otic cells (l'L229) (A) alld of a seminoma with 20% apoptotic tumor cells (l'L1049) 
(B). 
without pronase (Fig. 9.1). Probably, pronase treatment is necessary to provide full 
access of DNA polymerase to paraffin embedded cells. The ISEL and FCM results 
were confirmed by the presence of DNA ladders only in the cisplatin-treated cultures 
(not shown). 
Based on the above results, paraffin embedded SE tissue blocks were analyzed using 
30 min of pronase treatment at room temperature and ISEL, while SE cell suspensions 
were not pronase treated and analyzed by FCM. In paraffin embedded intact tissue 
from II out of 14 SEs less than 4 % of the tumor cells had morphological characteris-
tics of apoptosis and DNA strand breaks (Fig. 9.2A). In three SEs this number was 
higher, i.e. 20%, 13%, and 15%, respectively (Fig. 9.2B). Apoptosis-specific DNA 
ladders, indicating internucleosomal double strand DNA cleavage, were not detected in 
intact tissue of the SEs with less than 4% apoptotic cells (Fig. 9.3A). In contrast, these 
ladders were present in the three SEs with upto 20% apoptotic cells (not shown). All 
lymphocytes-depleted SE cell suspensions obtained after mechanical dissociation 
showed ladder patterns; for tumors TL614 and TL4942 the ladders had an increased 
intensity as compared to the ladders of not-depleted suspensions (Fig. 9.3B). In not-
lymphocyte-depleted cell suspensions up to 85 % of the SE cells contained nicked 
DNA, as detected with FCM (Fig. 9.4). In the intact tissues of tumors TL614 and 
TL4942 a relatively high anlOunt of lymphocytes was present. The cell suspensions of 
these tumors contained very few SE cells, either viable or apoptotic. In Table 9.1 the 
results on all SE tissue blocks and cell suspensions are summarized. 
Two tumors (TL6209 and TL6329) underwent additional analysis. From each 
tumor, three pairs of tissue blocks of approx. 0.125 cm' were incubated at 4"C and 
three pairs at 34"C, in medium A. At both temperatures, the pairs were incubated for 
I, 4, or 16 hr, respectively. From each pair, one block was fixed in 4% formalin for 
paraffin embedding, while the other was snap frozen in liquid nitrogen for DNA 
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Figure 9.3. III intact tissue from 11 out of 14 seminomas no DNA ladders were detectable upon 
electrophoresis, as shown here for eight tumors (A). In single cell suspensions, obtained upon 
mechanical dissociation of tumor tissue, DNA ladders were detectable, as shown here for three 
tumors. The ladders were sometimes more intellse when lymphocytes were depleted from the 
suspellsiolls (B). -L, depleted of lymphocytes; +L, 1I0t depleted of lymphocytes; M, marker, ill A: 
Pstl-digested phage lambda DNA, ill B: marker 8 (Boehrillger). 
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Figure 9.4. Representative etample of the flow cytometric analysis of end labeled seminoma cell 
suspensions without lymphocyte depletion, obtained upon mechanical dissociation of tumor assue 
(IL3544). SE+, apoptotic seminoma cel/s,' SE-. illtact seminoma cells; L-. intact lymphocytes,' 
FITC, fluorescence signal indicating labeling of DNA strand breaks; DAPl, fluorescence signal 
indicating cellular DNA cOlltelll. 
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Table 9.1. Apoptosis in seminoma tissues and cell suspensions. 
Tumor ISEL FCM DNA Ladder 
% apopt % apopt Tissue Suspension 
SE+L SE-L 
TL229 I 68 - +/- +/-
TL602 2 71 - + + 
TL614 2 17 - - + 
TL1049 20 85 +/- + + 
TLlI87 0 79 - + + 
TLl665 0 80 - +/- +/-
TL2207 13 68 +/- + + 
TL3544 4 45 - + + 
TL4873 2 75 - + + 
TL4942 2 5 - - +/-
TL6209 1 82 - NA NA 
TL6329 2 85 - NA NA 
TL8114 15 NA + + + 
TL8837 0 NA - - NA 
Intact seminoma tissue blocks lVere analyzed by in situ elld labeling (ISEL) of single strand DNA 
breaks. FlolV cytometry (FCM) was applied to allalyse the percentage of apoptotic seminoma 
cells ill cell suspensions. Lysates from frozen sectiolls of intact tissue and cell suspel/sions, either 
depleted of lymphocytes (SE-L) or Itot (SE + L), were analyzed for the preseltce of DNA ladders. -
, absellt; +, present; +/-, weakly present; NA, no sample available for analysis. 
analysis. Figure 9.5 and Table 9.2 show that in both tumors the apoptotic process was 
slowed down by keeping the micro-environment intact, while incubation of the cells at 
4'C resulted in a further delay in the onset of apoptosis. Whereas mechanical dissocia-
tion of tumor tissue resulted in immediate apoptosis of up to 85% of the cells, 
incubation of tissue blocks at 4"C for 4 hr resulted in apoptosis of up to 16% of the SE 
cells. 
Expression of bcl-2 could be immunohistochemically detected in infiltrating 
lymphocytes but was absent from the SE cells in all of the analyzed tumors (not 
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Figure 9.5. DNA ladders ill cultured intact tissue of seminoma TL6209, Tissue was incubated for 
1, 4, or 16 hr at 4 or 34"C ill medium A. M, marker, Ps!1·digested phage lambda DNA. 
Table 9.2. Percentage of morphologically apoptotic and in situ end labeled 
seminoma cells in cultured intact tissue. 
Incubation TL 6209 TL 6329 
Time (hr) 4"C 34"C 4"C 34"C 
0 I I 2 2 
I 23 10 8 8 
4 16 18 5 30 
16 17 41 5 100 
lllfact seminoma tissue blocks (0.125 cm)) were incubated ill vitro, for }, 4, or 16 flr at 4 or 
34°C ill medium A. The percentage of apoptotic cells was determined by cnullting a total of at 
least 250 viable or morphologically apoptotic, labeled seminoma cells. 
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shown). None of the intact tissue samples (either directly fixed or upon incubation in 
medium for I, 4 or 16 hr at 4 or 34'C), nor any of the single cell suspensions were 
found to detectably express p53 (not shown) in the SE cells. 
Discussion 
Apoptosis can be induced by various agents, including disruption of cell-matrix 
interactions (6), growth factor withdrawal (I), oxidative stress (45) and cytotoxic drugs 
(46). We have now shown that SE cell suspensions contain up to 85% apoptotic cells 
immediately after disruption of the cellular micro-environment, while very few «3%) 
apoptotic cells are present in intact SE tissues. 
Several lines of evidence suggest that the ros oncogene can iobibit the process of 
apoptosis (6,46,47). Frisch and Francis (6) reported that cells are (partially) protected 
against anoikis (apoptosis upon disruption of cell-matrix interactions) by mutant ras or 
overexpression of bcl-2. Schlaepfer et al. (48) have shown that the integrin-mediated 
anoikis-suppressing activity of the extracellular matrix is most likely passed by the 
RAS pathway. Using another approach, we recently found that oncogenic ros can 
iobibit drug-induced apoptosis, in cells transfected with the c-Ha-ras oncogene (46). 
Our observation that SEs bearing a mutant ras showed enhanced survival and prolife-
ration in co-cultures with embryonal fibroblast feeder layers, as compared to SEs with 
wild type ras (33,47), could be based on the apoptosis/anoikis-abrogating activity of 
mutant ras .. However, the four ras mutant tumors among the SEs analyzed here 
(TL614, TLl049, TL3544 , TL8837) (33,47), were indistinguishable from the non-
mutant tumors in the performed assays. The exact relation between the onset of apop-
tosis upon tumor dissociation, the presence of a mutant ras gene and ill vitro behavior 
is subject of further study. 
Apoptosis of cultured murine PGCs, which appear to need a specific micro-environ-
ment for both ill vivo and ill vitro survival and proliferation, can be suppressed by SCF 
(7). We previously reported that the addition of SCF to cultures of SE cells (with an 
activated ras gene) resulted in colony formation (33). In analogy with the findings on 
murine PGCs (49,50) this was probably due to abrogation of apoptosis (i.e. extension 
of cell survival) and prolonged proliferation, without an increase in proliferation rate. 
We suggest that in our experiments, SE cells rapidly entered the apoptotic pathway 
upon mechanical disruption of their micro-environment andlor deprivation of cell-
matrix interactions and growth factors. Preliminary tissue culture results indicate that 
in an enviromnent with intact cell-matrix interactions apoptosis of SE cells is delayed. 
The analyzed apoptotic process in SE cells appears to be independent of (enhanced) 
p53 expression, which could not be immunohistochemically detected. In addition, the 
absence of bcl-2 expression is in concordance with the (high) susceptibility of SE cells 
to apoptosis. Future analysis of the expression of bcl-2 family members in SE cells 
should yield more information on the control of apoptosis in these cells. 
Blocking the onset of apoptosis appears crucial for succesfull in vitro culture of SE 
cells. Once apoptosis can be abrogated, the pathobiological relation between the two 
histological types of human primary testicular germ cell tumors of adolescents adults, 
namely SEs and nonseminomatous testicular germ cell tumors (for which in vitro 
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culture conditions and ceIl Iines are available) might be studied ill vitro. 
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Chapter 10 
N- AND K-RAS MU1'All0NS 
IN PRIMARY TESllCULAR GERM CELL TUMORS: 
INCIDENCE AND POssmLE BIOWGICAL IMPLICAll0NS 
R.A. Olie, L.H.J. Looijenga, L. Boerrigter, B. Top, 
S. Rodenhuis, M.P. Mulder, J.W. Oosterhuis 
Modified from Gelles, Chromosomes alld Callcer 12, 110-116, 1995 

Abstract 
Recently, conflicting results have been reported on the incidence of ras mutations in 
primary testicular germ cell tumors of adolescents and adults (TGCTs). In four studies 
a low incidence of mutations (less than IS %) in a variety of TGCTs or derived cell 
lines was found, whereas in two other studies a high incidence of N- or K-ras 
mutations (over 40%) was shown. A total of 62 testicular seminomas and 34 
nonseminomatous TGCTs were studied thus far. The largest series consisted of 42 
TGCTs, studied on paraffin embedded tissue. We present the results of analysis for the 
2presence of N- and K-ras mutations, in codons 12, 13 and 61, in snap frozen samples 
of 100 primary TGCTs, comprising 40 seminomas and 60 nonseminomatous TGCTs. 
U sing the polymerase chain reaction and allele specific oligonucleotide 
hybridization, mutations were found in five SEs (three in N-ras and two in K-ras, all 
codon 12), and in one NS (K-ras, codon 12). To exclude underestimation of the 
incidence of ras mutations in TGCTs due to the presence of an excess of wild type 
alleles in the analyzed sample, a polymerase chain reaction technique preferentially 
anlplitying K-ras alleles with a mutation in codon 12 was applied to all seminomas. 
This approach, allowing a 250 times more sensitive assay, resulted in the detection of 
only one additional seminoma with a mutation. 
Based on critical analysis of published data and on our results from the largest series 
of frozen samples investigated thus far, we conclude that N- or K-ras mutations are 
rare and apparently not essential for initiation or progression of TGCTs. 
Introduction 
The p21 proteins encoded by N-, H- and K-ras are involved in signal transduction 
from activated receptors in the cellular membrane to the nucleus. Mutations in these 
genes, particularly those in codons 12, 13 and 61, cause a decrease in intrinsic 
guanosine triphosphatase activity, leading to constitutive activation of the encoded 
protein (1,2). Ras mutations have been detected in a wide variety of human neoplasms, 
allhough with varying incidence (2), and are considered to represent only one of many 
events in the multistep process of transformation (3). 
A low incidence of K-ras codon 12 mutations (less than 15%) has been found in all 
studies on human primary testicular germ cell tumors of adolescents and adults 
(TGCTs) (4-7). In contrast, conflicting data have been reported for N-ras. One study 
showed mutations at codon 12 or 61 in 13 of 20 seminomas (SEs) and two of three 
nonseminomatous TGCTs (NSs) (5). Another study, comprising only SEs, revealed N-
ras codon 61 mutations in four of 14 tumors (4). No mutations were found in N-ras 
codons 12 or 61 in two studies, comprising 28 SEs and 31 NSs (6,7). A consistent 
finding is the absence of mutations in N-ras codon 13; H-ras codon 12, 13, and 61; 
and K-ras codons 13 and 61 in TGCTs and derived cell lines (4-9). 
Several factors may explain the varying findings on the incidence of ras mutations in 
TGCTs. Besides possible geographical influences (2), technical factors related to the 
method of fixation of the tissue samples, frozen (4,5,7) versus paraffin embedded (6), 
might be involved. In addition, the applied polymerase chain reaction and allele 
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specific oligonucleotide hybridization (PCRf ASO) might underestimate the incidence of 
mutations when an excess of wild type alleles is present, since it allows detection of 
one mutant among 40 wild type alleles (10). This could especially be important for 
SEs, which may contain a high percentage (over 80%) of nonmalignant cells (4,11). 
To overcome this problem, Mulder el al. (4) used suspensions of SE nuclei sorted on 
the basis of their aneuploid DNA content. An alternative is the use of a PCR technique 
which preferentially amplifies mutant alleles (mutant-enriched PCR, MEPCR). It has 
been shown by Kalm el al. (12) that this approach allows detection of one mutant 
among 10,000 wild type alleles using ASO (MEPCRI ASO). 
We have studied snap frozen samples of 100 primary TGCTs, comprising 40 SEs 
and 60 NSs, using PCRfASO for detection of N- and K-ras codons 12, 13, and 61 
mutations. In addition, MEPCRI ASO for K-ras codon 12 was used on all SEs. 
Materials and methods 
Tumor samples 
One hundred primary TGCTs and adjacent parenchyma (when present) were 
collected at the operation theatres of collaborating hospitals. After frozen section 
diagnosis (using a hematoxylin and eosin-stained tissue section), representative parts of 
tumor and adjacent parenchyma were snap frozen in liquid nitrogen. Typing according 
to the World Health Organization classification (II) was based on histology and 
immunohistochemical analysis of expression of germ cell specific alkaline phosphatase 
(detected with antibodies to placental alkaline phosphatase, PLAP) , «-fetoprotein 
(AFP), human chorionic gonadotropin (hCG) (Dako, Glostrup, DK) and cytokeratins 8 
and 18 (Beckton Dickinson, San Jose, USA) using representative paraffin and frozen 
tissue sections, as described (13). 
DNA exlraclion 
DNA was extracted from the snap frozen tumor samples, as described (14). From 
each sample three 10 I'm thick sections were collected in 100 1'1 lysis buffer (10 mM 
Tris, 400 mM NaCI, 2 mM EDTA, 1% SDS, 10 f!g/ml proteinase K (Sigma, St. 
Louis, MO), pH 8.2) and lysed overnight at 37'C. Subsequently the samples were 
extracted twice with an equal volume of phenol/chloroform. After precipitation in 
ethanol/sodium acetic acid, the DNA pellet was dissolved in 10 mM Tris, 0.1 mM 
EDTA to a final concentration of approximately 0.5 f!g/f!l. From each sample 0.5 1'1 
(approx. 250 ng DNA) was used for PCR. The agarose gel electrophoresis performed 
to confirm the presence of PCR products, as described in the next section, was also 
used to confirm the presence of comparable amounts of DNA in each PCR. Matched, 
carcinoma in silu-containing parenchyma of tumors with a ras mutation was also 
studied, when available (n = 4). 
Polymerase chain reaclion 
Amplification was performed in a reaction mixture which consisted of buffer (50 
mM KCl, 2.5 mM MgCl" 10 mM Tris-HCl (pH 8.0), 10 roM NaCl, 0.01 mM 
EDTA, 0.5 mM DTT, 0.1 % Triton X-100) (Promega, Madison, WI), 0.2 mM of each 
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nucleotide (dATP, dTTP, dCTP, dGTP) (Pharmacia, Woerden, the Netherlands), I U 
Taq polymerase (Promega), 0.5 I'M of both sense and anti-sense primer in a total 
volume of 501'1. Four different primer sets, described by Verlaan-de Vries et al. (15), 
were used to amplify the K-ras 12 and 13, K-ras 61, N-ras 12 and 13, and N-ras 61 
regions. The reaction mixture was covered with paraffin oil. Samples were placed in a 
Thermal Cycler (perkin-Elmer, Norwalk, VA) and heated to 94"C for I min. The PCR 
included 35 cycles of denaturation at 94'C for 30 sec, annealing at 54'C for 30 sec, 
and extension at 72'C for I min. Finally, the samples were kept at 72"C for 2 min and 
subsequently stored at 4'C till further analysis. All samples were tested for the 
presence (or absence, in the negative control, containing H,O instead of DNA) of the 
desired fragment by agarose gel electrophoresis and ethidium-bromide staining, using 4 
1'1 of the PCR mixture. 
Mutant-enriched polymerase chain reaction for K-ras codon 12 
Amplification was performed in a reaction mixture which consisted of buffer (3.5 
mM MgCl" IS mM (NH,),SO" 60 mM Tris-HCI pH8.4), 0.2 mM of each nucleotide 
(dATP, dTTP, dCTP, dGTP) , 1.5 U Taq polymerase, I I'M of both sense and anti-
sense primer in a final volume of 50 1'1. Using a mismatched sense primer (introducing 
a BstNI restriction site in the wild type allele) together with an antisense primer (12), 
K-ras 12 regions were amplified. The samples were heated to 96"C for 5 min, 
followed by one cycle at 96'C for 2 min, 55'C for I min, and 73'C for I min. During 
24 cycles, the samples were brought to 96'C for 30 sec, 55'C for 30 sec, and to 73'C 
for I min. Each sample (12.5 1'1) was then digested overnight at 37"C to completion 
with 5 U endonuclease Mval, an isoschizomer for BstNI (Boehringer, Mannheim, 
Germany) in 26 1'1 buffer H (50 mM Tris-HCI, pH 7.5, 10 mM MgCl" 100 mM 
NaC!, I mM dithioerythritol) (Boehringer). In a second round of PCR, under the same 
conditions as described above, except for the use of the mismatched sense primer and 
a nested antisense primer, only the uncleaved (mutated) fragments were amplified. To 
show the effect of mutant-enrichment the second PCR was also applied to undigested 
amplification product of the first PCR. 
Allele specific oligonucleotide hybridization 
Parafrm oil was removed from the PCR-samples by extraction with diethyl ether. 
DNA was denatured at 96'C for 3 min and I 1'1 of PCR mixture from each sample was 
dotted on a dry Nytran-N membrane (Schleicher & Schuell, Dassel, Germany), which 
had previously been soaked in H,O and IOxSSC, and air-dried. DNA from previously 
characterized mutation-carrying samples was used as positive control. These controls 
were available for all K-ras 12 positions (16) and for K-ras 13 position I and K-ras 61 
position 3 (17). As negative control a sample of the PCR mixture without DNA was 
used. DNA was crosslinked to the membrane by exposure to UV light for 2 min. 
The N- and K-ras 12 and 13 wild type alleles were detected by specific wild type 
probes, and identification of K-ras 12 mutations was performed using 6 specific probes 
after conventional PCR, and 6 after mutant-enriched PCR (15,18). Two mixtures of 
three probes (codon positions I and 2) were used for K-ras 13 and N-ras 12 and 13, 
while for K-ras 61 and N-ras 61 three mixtures of three mutation specific probes (for 
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positions I, 2, or 3 of the codons) were applied (15). Five picomoles (11'1) of probe 
was endlabeled using 2.5 U T4 polynucleotide kinase (Gibeo BRL, Breda, the 
Nether/ands) in 4 1'1 reaction mix (50 mM Tris.HCI pH 7.6, 10 ruM MgCI" 5 mM 
DTT, 0.1 ruM EDTA, 0.1 ruM spermidine, 10 I'Ci (11'1) "p 'Y-ATP (Amersham, Den 
Bosch, the Netherlands». After incubation at 37'C for 30 min, 70 1'1 of 10 ruM 
Tris/O.I mM EDTA and I 1'1 tRNA were added and the mix was centrifuged through a 
Clontech-IOO column (Clontech Laboratories, Palo Alto, CAl. 
All blots were soaked in aqua dest in hybridization tubes. The aqua dest was 
replaced by 2 ml hybridization mix (3 M tetramethylammonium chloride, 50 ruM Tris 
pH 7.5, 5 ruM EDTA, I % SDS, I % (w/v) milk protein (Protifar) (Nutricia, 
Zoetermeer, the Netherlands). After prehybridization for 60 min at 56'C, 201'1 labeled 
probe was added and hybridization was done for I hr at 56'C. Blots were washed in 
hybridization mix without milk protein at 56'C for 30 min, taken from the tubes, 
rinsed with 2xSSC (0.3 M NaCI, 0.03 M sodiumcitrate, pH 7.0), dried, and exposed 
overnight to an Xomat"" film (Eastman Kodak, Rochester, Ny) at -70'C. Subsequently, 
blots were washed at higher stringency in 5xSSPE (50 ruM sodium phosphate, 0.9 M 
NaCI, 5 mM EDTA)/O.I % SDS, for 30 min, to remove any probe mismatched to the 
PCR product. In the PCRlASO, temperature was kept at 57'C for N-ras 61, 59'C for 
K-ras 61, 61'C for N-ras 12 and 13, and 63'C for K-ras 12 and 13, while the 
temperature was 61'C in the MEPCRlASO for K-ras 12. The blots were again rinsed 
with 2xSSC, dried, and exposed for I to 4 days, as described. Mutations could be 
detected comparing the dot signals obtained before (to verify the presence of PCR 
products) and after the stringent wash. 
identification of IIllltations 
The exact nature of the N-ras 12 mutations was revealed by cycle sequencing (Cycle 
Sequencing Kit, Perkin-Elmer Cetus, Norwalk, CT) using a "P-Iabeled sense primer. 
In brief, the tumor samples were amplified in triplicate using conventional PCR. The 
PCR products were pooled and subjected to electrophoresis on a 2.5 % preparative 
agarose gel. The fragments were excised from the gel and incubated with 6 U agarase 
(Boehringer) for I hr. at 45'C. The purified DNA fragments were ethanol precipitated 
at -70'C for 15 min and dissolved in 25 1'1 of sterile water. Twenty cycles of 
denaturation at 95'C (I min), annealing at 63'C (1.5 min), and extension at n'c (2 
min) were performed in a thermal cycler (Hybaidnf , Teddington, United Kingdom). 
The sequencing reactions were analyzed on a denaturing 6 % polyacrylamide 
sequencing gel at 60W for 2.5 hr. The gel was exposed at -70'C for 16 hr, as 
described above, with an intensifying screen. 
Results 
Classification of the obtained tumors revealed 40 SEs and 60 NSs. The group of 
NSs comprised 22 pure tumors (12 embryonal carcinomas (ECs), four yolk sac tumors 
(YSs) , five teratomas (T) (both mature and immature) and one choriocarcinoma (CH», 
35 tumors containing EC mixed with one or more other components (CH, SE, T, YS), 
two tumors containing CH and T, and one tumor containing T and YS. 
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Figure 10.1. Dot blot signals (after high stringency wash) of all mutalll tumors after 
amplificatioll of the N·or K-ras 12 regioll, IIsillg PCRJASO or MEPCRJASO. TL, tllmor; P, 
parenchyma adjacent to the tumor; DOT, signal of the mutant tumor; -T, sigllal of a 
represelllative mutation-negative tumor; + C, signal of lite corresponding positive control 
cOlllalnillg a GGT to GCT trallsitioll (for TL614), a GGT to TGT trallsitioll (for TL2308), or a 
GGT to CGT trallsitioll (for TL7573 alld TL8837); - alld + illdicate MEPCRJASO IVithollt, 
respectively IVith MvaI digestioll of the product from the first PCR, resilltillg ill m1llalll 
enrichmelll for the + condition. 
A low incidence of codon 12 mutations was found in both N- and K-ras whereas no 
mutations in N- and K-ras 13 or 61 were detected in any of the analyzed TGCTs. 
Three SEs (TLl049, TL2191, TL3544) were found with a mutation in N-ras 12, while 
two SEs (TL7573, TL8837) and one NS (TL2308, containing EC, T, and YS) with a 
K-ras 12 mutation were detected (Fig. 10.1). 
Using the PCRl ASO approach, mutations in some tumor samples might have 
remained undetected due to the presence of an excess of wild type alleles. Therefore 
suspensions of cell nuclei were prepared from 25 frozen NS sanlples, stained with 
propidium iodide, and analyzed by flow cytometry to detennine the fraction of 
aneuploid (tumor) and diploid (nontumor) cells. The fraction of aneuploid cells varied 
between 22 and 93%, while 18 tumors contained more than 50% aneuploid cells. 
II has previously been shown that in SE samples the fraction of nontumor cells can 
be greater than 90% (4). We therefore decided to repeat the mutation analysis in our 
series of SEs using MEPCR/ASO for K-ras 12. In this procedure mutant alleles are 
preferentially amplified, hereby allowing the detection of one mutant among 10,000 
wild type alleles (12). The analysis revealed one extra mutant SE (TL614). The 
previously detected mutations were confirmed, showing an intensified signal after 
MEPCRl ASO, compared to PCRI ASO and MEPCRI ASO without Mva I digestion 
(Figs. 10.1 and 10.2). 
Parenchyma, adjacent to a mutant tumor was available for TL614, TL2308, 
TL3544, TL7573, and TL8837. Only the parenchyma of TL614 did not contain 
carcinoma ill silll (CIS) and therefore this sample was not studied further. In the 
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Figure 10.2. Example of dot bIoI analyses of mutant-enriched polymerase chain reactioll 
products for detection of K-ras 12 mutants. Dle upper A-D pallel represents results usillg the 
wild-type specific probe, which detects GGT. The lower A-D pallel represellfs results after 
hybridizatioll with the probe specific for the CGr sequence. Both brots were exposed after 
washing at high stringency. The first six positions (AI-A6) represent the positive cOllfro/s for all 
possible IIIlItations of the first or second base of codon 12 (A3 correspodillg with CGT). The 
remaining positiolls (A7, DB) are examples of testicular germ cell tumors, with paired signals 
frOIll each tlllllor: withollt (left dot) alld with MvaI digestion (right dot) after the first 
amplification. For exalllple: C7 (withollt digestion) alld C8 (with digestion), parenchYllla of 
n-iHlor n7573, lIole the enhancement ill signal intensity after Mval digestion using the mutant 
specific probe; B5 alld B6, tlllllor HT85; Dl and D2, IllIIlOr TL7573; D3 alld D4, parenchYlIla of 
tlllllor TL8837; D5 and D6, tlllllor TL8837. 
parenchyma of TL 7573 and TL8837 a weak signal was found using MEPCRJ ASO 
without Mva! digestion, while no signal was found for TL2308 (Figs. 10.1 and 10.2). 
Using MEPCRJASO the signals for the parenchyma of TL7573 and TL8837 were 
intensified while the mutation in TL2308 was now detectable. Since the parenchyma of 
TL7573 and TL8837 contained micro-invasive SE cells we cannot determine whether 
the ras mutation was only present in these SE cells or also in the CIS component. 
However, the findings for the parenchyma of TL2308, containing only CIS, indicate 
that ras mutations can occur in a noninvasive precursor lesion. No N-ras mutation was 
found in the parenchyma of TL3544 (not shown). Since only PCR/ASO was used to 
detect N-ras mutations, the presence of a mutation in CIS cells cmmot be excluded, in 
analogy to the findings for the parenchyma of TL2308. 
The nature of the detected mutations is summarized in Table 10.1, showing identical 
base conversions in both tumor mId the adjacent parenchyma. 
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Table 10.1. Summary of the nature of the N- and K-ras codon 12 mutations, 
in tesHcular seminomas (SE) and testicular nonseminomatous germ ceD tumors (NS), 
and their adjacent carcinoma ill situ containing parenchyma (P). 
Sample Histology N-ras 12 mutation K-ras 12 mutation 
TL6l4 SE GGT -+ GCT 
gly -+ ala 
TLl049 SE GGT -+ GAT 
gly -+ asp 
TL2l9l SE GGT~GAT 
gly -+ asp 
TL2308 NS GGT-+ TGT 
gly -+ cys 
TL2308 P GGT-+ TGT 
gly -+ cys 
TL3544 SE GGT-+ GCT 
gly -+ ala 
TL7573 SE GGT -i> CGT 
gly -+ arg 
TL7573 p GGT -+ CGT 
gly -+ arg 
TL8837 SE GGT~CGT 
gly -+ arg 
TL8837 p GGT -i> CGT 
gly -+ arg 
Discussion 
Since no H-ras mUlations have been detected in TGCTs or derived cell lines (4-9), 
we did not screen our samples for mutations in this gene. To analyse the incidence of 
N- and K-ras codon 12, 13, and 61 mutations, the PCRJASO was applied to 100 
primary TGCTs, while all 40 SEs in this series were also subjected to MEPCRJASO 
to detect mutations in K-ras codon 12. Only six SEs and one NS were found to contain 
a ras mutation. Six of these mutations (five in SEs and one in NS) were already 
detected using PCRJASO. Our data, showing an incidence of K-ras mutations of 4%, 
are concordant with those reported (4-7). Although using the same approach (frozen 
samples and conventional PCRI ASO), we did not find a high percentage of mutations 
in N-ras 12 and 61, as reported by Ganguly el al. (5). This could be due to difficulties 
in their interpretation of the mutation-specific hybridization signals. 
Taking into account the sensitivities of the two detection methods used (one mutant 
among 40 or one mutant among 10,000 wild type alleles for PCRI ASO and 
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MEPCRJASO, respectively), the minimal percentage of mutant alleles that needs to be 
present for detection can be calculated. A consistent overrepresentation of (parts of) 
12p, on which K-ras is located, is found in TGCTs (19-22), with a copy number of 
about six. Assuming the presence of one mutant (codon 12) and five wild type K-ras 
alleles per mutant tumor cell, at least 5.5% of the cells in a sample has to carry the 
mutant allele to allow detection with PCRJASO, while 0.02% is needed using 
MEPCR/ASO. Our comparison of the conventional and mutant-enriched PCR-based 
methods indicates that the low incidence of K-ras 12 mutations in TGCTs must be due 
to the absence of mutations in the sanlples studied, and not to the treshold of the 
PCRJASO. 
The study of flow-sorted SE nuclei by Mulder et al. (4) showed N-ras mutations in 
four out of 14 cases. Three of these mutant tumors were studied for heterogeneity for 
the presence of mutant alleles between separate areas within one tumor. Two tumors 
were shown to be heterogeneous. Of the two K-ras mutant tumors, coded HT31 and 
HT85 in the study of Mulder et al. (4), HT31 was also found to be heterogeneous. We 
confirmed the data on these K-ras mutant SEs, which were analyzed in addition to the 
40 SEs in our series, using MEPCR/ASO (Fig. 2, only shown for HT85). Therefore, 
it cannot be excluded that tumor heterogeneity for ras mutations leads to 
underestimation of the incidence of these mutations. 
A pathogenetic event can be considered of importance for tumor formation when it 
can be demonstrated in a high percentage of malignant cells within one tumor and in 
most independent tumors of the sanle histology. Taking together the results described 
here and those of Mulder et al. (4), Moul et al. (6) and Ridanp1Ui et al. (7), a total 
incidence of ras mutations in primary TGCTs of 11 % is found, with 18% in SEs and 
4% in NSs. Together with the heterogeneity for ras mutations within a single tUlllor 
(4), and the detection of a ras mutation in parenchyma containing CIS and not in the 
adjacent TGCT (6), this supports the contention that ras mutations are not essential in 
the initiation or progression of TGCTs. However, a role of K-ras in the development 
of TGCTs by relative overrepresentation of (parts of) the short arm of chromosome 12 
cannot be excluded. The difference between SEs and NSs concerning the incidence of 
mutations needs further investigation. The question whether mutations can already be 
present in noninvasive CIS, or only in the (micro-)invasive tumor, can be answered 
using microdissection of tissue sections of parenchyma under histological control to 
specifically isolate CIS cells. 
Recently, Arends et al. (23) reported on the suppression of apoptosis in rat 
fibroblast cell lines by mutant H-ras. In this context, it is interesting that ill vitro 
culture analysis revealed a consistent difference between 14 SEs without and three with 
a ros mutation (24). Using a co-culture system with an embryonal fibroblast feeder, 
tumors TLl049, TL3544 and TL7573 (all associated with a strong hybridization signal 
in PCRJASO) showed enllanced survival and proliferation. TL8837 and TL2191 were 
not available for ill vitro culture. Frisch and Francis (25) recently reported on the 
induction, and abrogation by mutant H -ras, of apoptosis by disruption of epithelial 
cell-matrix interactions. Since we have indications that SE cells also enter the apoptotic 
pathway immediately after isolation from their micro-enviromnent (26), suppression of 
apoptosis by mutant ras could explain the enllanced survival and proliferation ill vitro 
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of the mutant tumors. It is unlikely that dysfunction of other proteins in the RAS 
pathway, mimicking the effect of ras mutations, are involved in the development of 
TGCTs, because of the absence of SEs without ras mutations which could be cultured 
ill vitro. The possible tumor heterogeneity of the K-ras mutation in TL614, suggested 
by the presence of less than 5.5% mutant cells, and its relation to ill vitro behavior 
will be studied. 
N- and K-ras mutations indicate an unfavorable prognosis in childhood acute 
lymphocytic leukemia (27) and nonsma11 cell lung cancer, especially adenocarcinoma 
(16,28), respectively. In addition, an enhanced ill vitro proliferative capacity is 
reported for adult acute myeloid leukemia with a poor prognosis (29). In view of these 
and our findings we will investigate the prognostic relevance of ras mutations in 
TGCTs. 
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Chaptel' 11 
APOPTOSIS AND SEMINOMA CELLS 

11.1 Introductiou 
In this chapter, unpublished experiments mainly aimed at abrogation of seminoma 
(SE) cell apoptosis are presented. Our observations are discussed in the light of a 
literature review. 
11.2. Factors possibly influencing the onset of apoptosis ill seminoma cells 
Our study of human SE cells indicates that disruption of the cellular micro-
environment could be an important apoptosis-inducing factor. Our results are in 
agreement with those obtained by Frisch and Francis (1) and Boudreau et 01. (2). The 
latter reported on the induction of interleukin-IB converting enzyme (ICE) and 
apoptosis in mammary epithelial cells when cultured on matrices that do not meet 
(apparent) cellular requirements. The apoptosis abrogating effect of the association of 
insulin receptor substrate-l with the "vB3 integrin in response to insulin stimulation, 
reported by Vuori and Ruoslahti (3), further stresses the importance of the interactions 
between growth factors, integrins and intracellular signalling for cell survival. In the 
case of GCTs, specific cellular requirements could explain the fact that these tumors 
mainly occur at specific anatomical localizations (4-7). 
Schlaepfer et 01. (8) reported that integrin-mediated signal transduction in murine 
fibroblasts is linked to the RAS pathway by the growth factor receptor-bound protein 
GRB2, while Fath et 01. (9) described the apoptosis-inducing effect of a GRB2 isoform 
in rat thymuses which inhibits transactivation of a RAS-responsive element. Moreover, 
mutant ras-expressing rat and hamster fibroblasts do not (or at a lower level) express 
certain matrix receptors (10). Apparently, mutant ras overcomes the need of cells for 
interactions with the extracellular matrix to survive and proliferate. In view of these 
findings, our observation that SE cells with a mutant ras show increased attachment to 
feeder cells and prolonged survival and initial proliferation during ill vitro culture is 
interesting. 
To investigate whether a relation exists between the expression of mutant ras and 
integrins, we studied the presence of the "V integrin subunit in SEs containing either a 
wild type or mutant ras. We detected the "v subunit on SE cells from 8/24 tumors, 
but its absence was not correlated with the presence of mutant ras (unpublished 
observation). Our data on the expression of the "v integrin subunit on SE cells 
corroborate those obtained by Timmer et 01. (11) who described a heterogeneity 
between SEs in the expression of other integrin subunits. 
Knowledge of the· composition of the seminomatous extracellular matrix and the 
presence of integrins on SE cells might help to optimize ill vitro culture conditions by 
providing the cells with the required substratum. However, keeping cell-matrix 
interactions intact does not appear to provide the cells with all the survival and 
proliferation signals needed, since we found intact tissue blocks to undergo apoptosis ill 
vitro within a few days (unpublished observation). In addition, transplantation of SE 
tissue blocks to orthotopic or ectopic sites in 25 nude rats and II scm (severe 
combined immunodeficient) mice never resulted in tumor formation. To confiml the 
apoptotic death of the tumor cells, tissue blocks were removed from three rats and 
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formalin fixed, within four days upon transplantation. Morphologically apoptotic tumor 
cells were subsequently detected in slides from the paraffin-embedded material. The 
other rats were kept under observation for six months to two years. The scm mice 
were observed for one to five months upon transplantation. All animals were 
euthanized, without any signs of tumor formation, when their physical condition had 
declined from old age. At autopsy, fibrotic tissue parts (as analyzed using 
morphological interpretation of formalin fixed material) could be retrieved in two 
mice, one or three months upon transplantation, respectively. In the other mice, no 
transplanted tissue blocks could be retrieved (unpublished observations). 
Not only the disruption of cell-matrix interactions, but also oxidants or stimulators 
of cellular oxidative metabolism were recently shown to be capable of apoptosis 
induction (12). Under physiological conditions, the ability of a cell to maintain an 
appropriate oxidant-antioxidant balance allows cell survival. Cells and organisms have 
"developed" an intricate system of antioxidants, including superoxide dismutase, 
catalase, tocopherol and ascorbic acid, to detoxify reactive oxygen intermediates, 
formed as a result of metabolic processes, and survive the oxidative siege that is 
associated with aerobic life. However, the oxidative agents and the detoxification 
arsenal also endow cells and organisms with some sort of selection system to be used 
for specific cell elimination through apoptosis upon oxidant-antioxidant disbalance (12). 
An example of specific cell elimination through oxidative-stress is found in the 
blastocyst (13). Extracellular H,O, was identified as a direct inducer of apoptosis, 
specifically killing cells with the developmental potential to make trophectoderm that 
might remain in the embryonic tissues, thus protecting the embryo from ectopic 
trophectoderm. The surviving embryonic cells exploit glutathione-dependent protection 
mechanisms against oxidation. Interestingly, Strohmeyer et al. (14) reported an altered 
glutathione S-transferase isoenzyme pattern and a decrease of glutathione S-transferase 
activity in TGCTs as compared to normal testicular parenchyma. This finding could 
explain the high susceptibility of TGCTs to oxidative stress, among others induced by 
antitumor drugs and possibly by the ill vitro manipulations performed by us (Chapters 
8 and 9). 
Reactive oxygen intermediates can rapidly react with cellular macromolecules (15), 
either directly or ultimately resulting in damage to cellular structures such as 
membranes (16). The fact that BCL-2 has been found to be located in the cellular 
membranes of mitochondria, endoplasmatic reticulum and nucleus, points to a role in 
protecting the membranes from reactive oxygen intermediates-induced damage. 
Recently, this protective function was indeed reported (17). Non-physiological agents, 
such as the anti-oxidant Trolox (Hoffmann-La Roche), have also been found able of 
blocking oxidative stress-induced apoptosis (18). Preliminary results, using medium 
supplemented with Trolox in which SE cells were collected right after disruption of 
their micro-enviromnent, indicate that this agent can block the immediate onset of 
apoptosis in these cells, as monitored by the absence of DNA ladders on 
electrophoresis gels and of apoptotic SE cell popUlations upon fluorescent DNA nick 
labeling and flowcytometry (unpublished observation). 
During normal spermatogenesis, apoptotic spermatogonia can be detected in the 
seminiferous tubules (19-21). The exact function of the apoptotic death of these cells 
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remains unclarified but it has been speculated that it serves to eliminate spermatogonia 
with genetic abnormalities (22,23). Since apoptosis occurs in groups of spermatogonia 
linked by intercellular cytoplasmic bridges (20), it is presumed that these bridges are 
involved in mediation of apoptotic signals. Interestingly, intercellular bridges have not 
been found between CIS or SE cells (24). This might explain the survival and 
proliferation of these harmful cells, which will only apoptotically die when more 
stringent conditions are applied (e.g. ill vitro manipulations or the use of cytotoxic 
drugs or irradiation), in spite of their genetic abnormalities. 
11.3. The possible role in seminoma cells of genetic regulators of apoptosis 
We studied the expression of bcl-2 in intact SEs and single cell suspensions and 
found Ihal BCL-2 is not immunohislochemically detectable in either of these. In 
conlrasl 10 findings by olhers (25-30), we could not detecl p53 expression in inlacl 
SEs, using freshly frozen and paraffin-embedded samples. This could be due 10 the use 
of different antibodies in the various laboralories, as well as to Ihe use of paraffin-
embedded samples in some studies and freshly frozen samples in olhers. Since we 
could nol immunohislochemically detecl (enhanced) p53 expression in SE cells upon 
disruplion of Iheir micro-environment, we consider Ihe possibility Ihat their apoptotic 
death under these circumstances is independent of (enhanced) p53 expression. 
Besides bcl-2 and p53, many olher genes are known 10 regulate the apoplolic 
process. Recently, genes belonging to the so-called bcl-2 gene family have been found 
10 encode BCL-2 homologues with either dealh promoling or inhibiting activity. Ollvai 
el al. (31) reported Ihe finding of a BCL-2 associaled prolein which Ihey called BAX 
(BCL-2 associaled X prolein). This protein has extensive amino acid homology with 
BCL-2, especially in Ihe so called BCL-2 homology regions I and 2 (BHI and BH2), 
which are involved in dimerizalion. BAX can helerodimerize with BCL-2 or 
homodimerize 10 counter BCL-2 activity (i.e. accelerale cell death) when 
overexpressed, however only in Ihe presence of a death signal. BCL-2 mulanls Ihat fail 
10 interacl with BAX can no longer inhibit cell death (32). Yang el al. (33) reporled 
Ihe existence of BAD (BCL-xtfBCL-2-associaled dealh promoter homolog), a 
helerodimeric partner for BCL-x, and BCL-2 containing Ihe BHI and BH2 domains. 
BAD was shown 10 be able of displacing BAX in the helerodimers fomled with either 
BCL-x, or BCL-2 and reverse Ihe death repressor activity of BCL-x, but nol of BCL-2. 
No evidence for the exislence of BAD/BCL-2/BAX or BADIBCL-xtfBAX 
heterolrimers was found. The association belween BCL-x, and BAD was slronger than 
Ihal between BCL-2 and BAD. The delecled prole in inleraclions give rise 10 an 
apoptosis regulation model in which BCL-x, and BCL-2 must heterodimerize with BAX 
to inhibil death and BAD can bind 10 BCL-x" displacing BAX inlo homodimers, 10 
induce death. Susceptibility to cell dealh is then besl correlaled with the distribulion of 
BAX over hetero- and homodimers (Fig 11.1). Interestingly, Miyashita and Reed (34) 
reported that P53 is a direcl transcriptional activator of bax, while it was shown by 
Miyashita el al. (35,36) and Selvakumaran el al. (37) Ihal P53 dowmegulates 
expression of bcl-2. 
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BeL-Xl ~ BeL-xl ~ 
BAD ~ BAX +-
BAX 
BAX 
BCL-2 ~ 
BAX ~ 
BCL-2 ~ 
BAD ~ 
BCL-2 
BCL-2 
Figure 11.1. Schematic representation of 1101110- alld heterodimer formatioll between proteins of 
the BCL-2 family. The susceptibility of a eel/to apoptosis-illducing stimuli is best correlated with 
the distribution of BAX over homo- alld heterodimers, with BAX homodimer jormatioll resulting 
ill high slisceptibility. 
Genes not homologous to bcl-2 have been found to code for proteins that interact 
with BCL-2. Takayama el al. (38) described BAG-l (BCL-2-associated athanogene-l 
(from the Greek word athanos, referring to anti-death» to be a novel BCL-2-binding 
protein, without homology to the BCL-2 family. Co-expression of bag-l and bcl-2 
provided markedly increased protection from cell death. BAG-l was shown to have a 
certain homology to ubiquitin and ubiquitin-like proteins, normally involved in 
targeting proteins for degradation. Thus, a possible role for the ubiquitin-like domain 
in BAG-l may be to serve as a site for attachment of ubiquitin and subsequent 
proteolytic degradation. Ubiquitin conjugation has been shown to regulate the turnover 
of other proteins that are thought or known to playa role in cell death regulation, 
including tumor suppressor P53 (39,40). In addition, a requirement for ubiquitin for 
radiation-induced apoptosis in thymocytes has been reported (41). 
A novel group of genes has recently been described to be involved in the execution 
of the apoptotic process. This group comprises the genes encoding ICE (42) and the 
ICE-like proteases CED-3 (43), ICH-I (44), NEDD2 (45), CPP32 (46) and TX (47), 
which are thought to act at the point in the apoptotic pathway at which the various 
routes of inducing stimuli finally converge, i.e. at the beginning of the final common 
pathway. Interestingly, the cowpox virus gene ermA has been reported to encode a 
powerful inhibitor of ICE (48). Transfection or injection of this gene into certain cells 
renders them resistent to apoptosis (49). Because ICE family members are thought to 
act at the start of the final common pathway, the use of inhibitors like ermA should 
result in blocking of apoptosis in response to a wide variety of stimuli. 
As mentioned, we could not innnunohistochemically detect BCL-2 in intact SEs. 
This finding could offer an explanation for the high susceptibility of these cells to 
apoptosis-inducing stimuli, like disruption of cell-matrix interactions and radiation (50) 
(which results in the fommtion of reactive oxygen internlCdiates (16». Since specific 
cell types have been shown to respond to specific apoptosis inducing stimuli in a 
specific way, data obtained on the regulation of apoptosis in various cell types can not 
be directly applied to SE cells. It appears necessmy to fully elucidate the control of 
apoptosis in SE cells in reponse to various stimuli, before progress can be made in 
blocking these processes. Further infommtion on the genes involved in regulation of 
the apoptotic processes in SE cells might be obtained from additional 
immunohistochemical studies. These could first focus on the expression of bcl-2 and 
ice family members. Western blot analysis of immunoprecipitates from extracts of pure 
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SE cell suspensions, obtained after lymphocyte removal through negative selection 
using anti-lymphocyte antibodies or through positive selection using anti-placental 
alkaline phosphatase (detecting germ-cell specific alkaline phosphatase) coated 
magnetic beads, might reveal which molecules are involved in the regulation of SE cell 
apoptosis and interact prior to and upon the induction of apoptosis. These studies could 
lead to a specific intervention with the endogenously important regulators of SE cell 
apoptosis. 
Transfection with apoptosis-abrogating genes, especially those controling the final 
common pathway, could be useful to improve SE cell survival ill vitro. We have 
already tried to transfect SE cells with the gene encoding SV 40 large T antigen, using 
the calciumphosphate precipitation technique and a micro-injection approach. In 
addition, we applied electroporation in an attempt to transfect SE cells with bcl-2. All 
these attempts were unsuccessful and results are unpublished. Since only proliferating 
cells can be transfected successfully and since only cells from the few ras-mutant SEs 
initially proliferate ill vitro, it might be better to directly bring anti-apoptosis proteins 
into SE cells, in stead of genes. The use of micro-injection methods or fusion 
strategies using liposomes containing the required factors could be considered. 
Regarding the induced overexpression of proliferation-inducing genes in SE cells, 
attention has to be paid to the fact that these genes might also induce apoptosis. This 
observation was first reported for c-myc (51-55). Under favorable cell culture 
conditions, e.g. the presence of sufficiently high growth factor and/or serum 
concentrations, c-myc (overexpression) promotes cell proliferation. However, in the 
(virtual) absence of these factors, high c-myc expression results in the onset of 
apoptosis. Apparently, when an intracellular proliferation signal is not accompanied by 
suitable external stimuli the apoptotic pathway is switched on. This phenomenon could 
occur upon transfection of SE cells kept under suboptimal in vitro conditions and could 
already be involved in the onset of apoptosis in SE cells as described in Chapter 9. A 
cell cycle/apoptosis controling gene that offers a growth advantage in vivo could induce 
the onset of apoptosis once the tumor cells are transferred to a suboptimal growth 
condition lacking vital factors, e.g. growth factors and/or extracellular matrix. 
11.4. Possible involvement of ligand-receptor interactions in tumor developmeut 
and prevention of seminoma cell apoptosis 
Primary SEs appear to depend upon a specific micro-environment and growth factor 
supply since they occur at specific localizations and express the stem cell factor (SCP) 
receptor c-kit. This suggests that a lack of apoptosis could have contributed to tumor 
formation, in keeping with the finding that SCP can abrogate apoptosis of murine 
primordial germ cells (56). Immunohistochemically, we (unpublished observation) and 
others (57) could not detect scf expression in SEs (except for rare individual cells), 
which indicates the absence of autocrine c-KIT stimulation. In human serum the 
concentration of SCP is in the 3 I'/L range (58). This is high, as compared to for 
example erythropoietin which circulates in the 30 ng/L range (59,60). Whether 
circulating SCP can support SE cells remains to be investigated. 
Interestingly, Stevens and Mackensen (61) reported that introduction of mutant scf 
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into 129J mice resulted in an increased incidence of testicular teratoma (from 2.5 to 
6.9%). Since tumors were not formed in all animals, it appears that the mutant gene 
contributed to tumor formation but was not causal. No mutation analyses of human scf 
in TGCT patients have been reported thus far. Fleischhacker el al. (27) reported the 
absence of point mutations from c-kit codon 936 (analogous to the codon of the c-fms 
gene which encodes a homologous receptor, often mutated in cellular transformation 
and cancer) in a series of 44 TGCTs. 
Not only c-KIT/SCF interactions might playa role in the development of TGCTs 
and especially SEs. Recent investigations point to a possible involvement of Mullerian 
inhibiting substance (anti-Mullerian hormone). This factor was shown to be involved in 
the differentiation of murine gonocytes to spermatogonia A (62,63). Whether this 
factor is also involved in (human) PGC development remains to be investigated. 
Interestingly, in humans a peak in Mullerian inhibiting substance serum levels can be 
detected between 4 and 12 months of age (64), the time at which differentiation from 
gonocytes to spermatogonia A occurs (65). In addition, lower levels of Mullerian 
inhibiting substance are correlated with cryptorchidism (66), as previously mentioned a 
risk factor for TGCT development. 
Recently, two groups reported enhanced proliferation of murine PGCs when 
cultured ill vitro in the presence of tumor necrosis factor-a or retinoic acid, 
respectively (67,68). We have not yet studied the involvement of retinoic acid and its 
receptor in SE development. Concerning tumor necrosis factor-OI, we did not observe 
enhanced SE cell survival or proliferation ill vitro in its presence, as investigated for a 
few SEs (unpublished data). Although an anti-tumor effect has been auributed to the 
SE-infiltrating lymphocytes (69), it can be speculated that these cells support SE cell 
survival and proliferation through the production of certain cytokines and/or growth 
factors, e.g. tumor necrosis factor-OI and SCF. In view of these findings, the fact that 
the gene encoding the tumor necrosis factor receptor-I has been mapped to 
chromosome 12pl3 (70) is interesting, since this chromosome arm is frequently 
overrepresented in TGCTs (71-78). 
To investigate the involvement of candidate ligand-receptor interactions in the 
development of TGCTs and especially SEs, familial cases of TGCTs might be used in 
a search for mutations in ligand-receptor systems that are possibly involved in TGCT 
development. 
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Chapter 12 
DISCUSSION AND FUTURE RESEARCH 

12.1. Introduction 
In this chapter the results of the experiments performed on human seminomas (SEs), 
a subgroup of the testicular geml cell tumors of adolescents and adults (TGCTs), will 
be discussed. In addition, suggestions for future research will be given. 
12.2. Relation between seminomas and nonseminomas 
To describe the relation between the two entities of TGCTs, SEs and 
nonseminomatous TGCTs (NSs) , two models are used: the independent origin model 
and the linear progression model. Neither one of these models has been proven. We 
tried to shed light on the pathobiological relation between SEs and NSs by analysing 
the glycolipid content of primary TGCTs. This investigation was based on the finding 
that glycolipid expression in embryonal carcinoma (EC) and other NS cell lines relates 
to their differentiation lineage (1-3). 
Our results are in agreement with the findings on TGCT cell lines (I) and indicate a 
close relation between SEs and ECs. Furthermore, our findings could indicate the 
existence of a less and a more mature type of SEs. Mature SEs might be committed to 
the germ line and not able to give rise to NSs. This would only be possible for less 
mature SEs, which can be reprogrammed to ECs and subsequently give rise to 
differentiated NSs. 
Studies comparing the glycolipid profile of carcinoma ill situ and adjacent tumor, 
either SE or NS, should be performed to further investigate the relation between SEs 
and NSs, since the present data cannot confirm either model on the development of 
TGCTs. 
12.3. Models for human seminomas 
In search of an animal model for human SEs, we investigated whether canine 
seminomas could be used as an experimental system. In keeping with earlier 
suggestions by Scully (4,5), we found canine seminomas to resemble human 
spermatocytic seminomas and not human SEs. Recently, the occurrence of 
seminomatous tumors in mice infected with human papilloma virus has been reported 
(6). However, since the tumor cells resemble pachytene-stage spermatocytes containing 
numerous mitochondria, which are reportedly sparse in SEs (7) we suppose that these 
tumors are not primordial germ cell (PGC)-derived. Takatera et al. (8) claim the 
establishment of a human SE cell line. However, their data also point to a 
spermatogonial origin of the tumor cells. They do not report whether the tumor cells 
express germ cell-specific alkaline phosphatase, which is a marker for PGCs, CIS and 
SE cells. Moreover, the tumor cells do not contain the chromosomal marker of human 
TGCTs, isochromosome 12p (9-16), but a chromosome 1 inversion (lpI3-q21) which 
can be related to spermatogenetical anomalies (17). The ploidy of the tumor cells was 
not reported. Thus, the above mentioned models appear inappropriate for human SEs. 
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12.4. Development of an ill vitro cuiture system for human seminomas 
We tried to develop an ill vitro culture system for human SEs, because dlese tumors 
appear to represent a unique tumor type for which no animal model is known. Using 
the conditions that gave rise to the derivation of murine embryonic genn (EO) cell 
lines from PGCs (18), we could not obtain SE cell lines. A major obstacie encountered 
in our attempts to culture SE cells ill vitro was the onset of apoptosis upon disruption 
of cell-matrix interactions prior to ill vitro culturing. This is in keeping with the 
observations made by Frisch and Francis (19) and Boudreau et al. (20). Deprivation of 
growth factor(s) might also have contributed to the onset of apoptosis. This contention 
is supported by the observed enhanced ill vitro survival of SE cells in the presence of 
stem cell factor, a growth factor known to block apoptosis of murine POCs (21). 
Interestingly, SEs bearing mutant N- or K-ras showed enhanced survival and initial 
proliferation during ill vitro culture, which might reflect the apoptosis abrogating 
activity of mutant ras (22). The biological and prognostic significance of our finding 
could be further studied, using TOCT (especially SE) samples from patients who did 
not respond to therapy. 
To succeed in the development of a culture system for human SE cells and the 
subsequent derivation of cell lines, it appears necessary to abrogate apoptosis. This 
might be achieved by collection of SE cells in medium supplemented with the anti-
oxidant Trolox (Hoffmann-La Roche), an apoptosis inhibitor (23), which we found to 
inhibit apoptotic DNA fragmentation in suspended SE cells. In addition, transfection 
with apoptosis blocking genes, such as bcl-2 and ermA, or direct transfer of apoptosis 
blocking proteins into SE cells, for example using liposomes, can be used. These 
attempts to intervene with apoptosis should be based on a thorough understanding of 
the endogenous presence in SE cells of apoptosis regulators. 
The fact that, until now, no NS cells could be derived from SE cells ill vitro does 
not invalidate the linear progression model, since this finding could be due to the 
absence of the required growth and differentiation conditions from the applied culture 
system. In addition, our glycolipid and ill vitro analyses might indicate a subgroup of 
SEs committed to the germ cell lineage, which are no longer able to give rise to NSs. 
12.5. Insights in the development of germ cell tumors 
Teratocarcinomas can develop in the 129J murine strain, either spontaneously 
(24,25) or upon induction through transplantation of early embryo's or genital ridges to 
ectopic sites (26-29). This model has often been used in the study of human NSs 
(30-34), although it has been reported that the murine tumors merely resemble human 
(immature) teratomas and yolk sac tumors, occurring in the gonads and extragonadal 
sites in infants and children, which probably may develop from primitive germ cells 
and pluripotent embryonal stem (ES) cells, respectively (35,36). Recently, the 
derivation of pluripotent EG cells from murine POCs upon ill vitro culture (18) and the 
subsequent differentiation of the EO cells to embryonic and extra-embryonic cells, 
renewed the interest in a murine model of human TOCTs, and especially SEs. Matsui 
el al. (18) suggested that "reprogramming" of PGCs resulted in the formation of EO 
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cells. In our view this process could resemble the transition from CIS or SE to EC, 
subsequently giving rise to the formation of differentiated nonseminomatous tissues. 
However, this reprogramming could also be comparable to the forementioned 
neoplastic transformation of pluripotent ES cells and primitive germ cells in infants and 
children. This latter contention is supported by data on ploidy and cytogenetics, which 
show that murine EG cells, tumors in 129J mice, murine embryo and genital ridge-
derived tumors as well as human (immature) teratomas in infants and children are 
diploid. These latter tumors can give rise to yolk sac tumor upon polyploidization 
(18,24-29,37,38). Thus (at least) with respect to ploidy the ill vivo and ill vitro murine 
models do not resemble human TGCTs, which are reportedly near triploid (39-41). 
Moreover, seminomas are absent in the ill vivo murine models. In Figure 12.1 the 
development of murine and human germ cell tumors is schematically depicted. 
McLaren (42) and Rossant (43) suggested that PGCs are (highly) differentiated, not 
pluripotent cells, explaining why these cells cannot give rise to chimeras when injected 
into blastocysts (43). This is in contrast to murine ES, EG and EC cells which can 
give rise to chimeras, with ES and EG cells contributing to the germ line (18,42-48). 
The fact that EC cells, which are malignant cells, can contribute to normal 
development (except for contribution to the germ line) in chimeras is intriguing. 
Apparently, murine EC cells can "easily" switch from a normal developmental 
program to a malignant state and back to normal. This supports the suggestion put 
forward by Walt et al. (37) who state that murine germ cell tumors develop by direct 
activation of PGCs without an intermediate stage of neoplastic proliferation of PGCs. 
Therefore, no CIS or SE occur. In contrast, in adolescent and adult men a neoplastic 
transformation of PGCs occurs and CIS and SE develop. It remains unclear why 
neoplastic, reprogranlmed diploid ES cells and PGCs have a limited developmental 
potential (giving rise to (immature) teratoma, and yolk sac tumor upon 
polyploidization) as compared to reprogrrumued CIS/SE cells, which give rise to 
pluripotent EC. This might be due to differences in genomic imprinting (i.e. the fact 
that homologous genes are differentially expressed, based on their parental origin 
(49-51», which may be progression and aneuploidy related. 
Once apoptosis of SE cells can be abrogated, SE cell lines might be obtained. These 
cell lines can be used to answer questions relating to the different developmental 
potentials observed for murine GCTs and human infantile GCTs on the one hand and 
human TGCTs on the other. The involvement of genomic imprinting and genetic 
constitution in the establishment of the developmental potential of malignant germ cells 
can also be investigated. 
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SUMMARY 

Two hypotheses exist on the development of human testicular germ cell tumors of 
adolescents and adults (TGCTs). One hypothesis assumes that the two histological 
subtypes of TGCTs, the seminomas (SEs) and nonseminomatous TGCTs (NSs) arise from 
independent carcinoma ill situ (CIS) precursor cells. The other hypothesis, the linear 
progression model, assumes that a CIS cell can give rise to NS through a seminomatous 
stage. We used various approaches, mainly aimed at the development of an ill vitro culture 
system for SE cells and the derivation of SE cell lines to gain more insight into the 
relationship between SEs and NSs. 
Information necessary to understand the rationale of the perfoffiled experiments is 
presented in Chapters 2 to 4. In Chapter 2 an overview is given of the present knowledge 
on TGCTs. Chapter 3 provides information on the involvement of stem cell factor and 
its receptor c-KIT in the development of primordial germ cells and pathology. The role 
of apoptosis in normal development and carcinogenesis is addressed in Chapter 4. 
The differentiation lineage of NS cell lines has been shown to correlate with the 
expression of certain combinations and amounts of glycolipids on the cell surface. 
Whether these data are representative of the situation in primary tumors is unknown. In 
addition, the glycolipid profile of SEs has not been specifically studied. We analyzed the 
glycolipids of a large series of primary SEs and NSs, in order to shed light on the 
relationship between these tumor types. We used thin-layer chromatography in 
combination with orcinol and immunostaining to detect specific glycolipids. Our results, 
presented in Chapter 6, confirm the data on NS cell lines and furthermore show that SEs 
and embryonal carcinomas (ECs, containing the undifferentiated stem cells of NSs) 
express similar amounts of globo-series glycolipids, indicative of the presence of stem 
cells in these tumors. In addition, our data suggest the existence of two subpopulations of 
SEs, a less mature gangliosides-negative and a more mature gangliosides-positive one. We 
found ECs to contain the lacto-series glycolipid Le" which might be carried by EC cells 
that are derived from globo-series-expressing stem cells upon reprogramming. Our 
glycolipid analysis does not prove either hypothesis on the development of TGCTs. 
Since an animal model representative of human SEs would facilitate the set up of 
experiments, we looked for such a model. The murine systems of spontaneous or induced 
teratocarcinomas appeared inappropriate since no SE-like tumors have ever been detected 
in these systems. In addition, the tumors merely resemble human (immature) teratomas 
and yolk sac tumors, occurring in the gonads and at extragonadal sites in infants and 
children, but not TGCTs. We studied a series of canine testicular tumors, comprising 
many seminomas, using flow and image cytometry. In addition, we performed an 
epidemiological study. Our data, presented in Chapter 7, show that canine seminomas are 
comparable to human spermatocytic seminomas (that were included in this study) and not 
to human SEs. We thus conclude that canine seminomas carmot be used as a model for 
human SEs. 
We have previously shown that under culture conditions for NSs, i.e. the use of 
medium with fetal calf serum, SE cells die within three days. In Chapter 8, the 
development of an improved ill vitro culture system for human SE cells is described, 
which could be used in the study of the pathogenetic relationship with NSs. Using a 
murine embryonal fibroblast (STO) feeder, a low percentage of SE cells attached to this 
feeder and few cells survived to day 10. However, three SEs showed a higher degree of 
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attachment and two of them initially proliferated. One of these two tumors was cultured 
using the conditions resulting in the derivation of pluripotent embryonal germ cells from 
murine primordial germ cells, i.e. the use of a STO feeder in combination with the 
growth factors stem cell factor, leukemia inhibitory factor and basic fibroblast growth 
factor, in serum-containing medium. These conditions resulted in prolonged survival, 
proliferation and colony formation. However, in contrast to the situation for murine 
primordial germ cells, no SE cell lines could be derived nor could reprogramming to a 
pluripotent phenotype be observed. 
We investigated whether the cell degeneration described in Chapter 8 was due to the 
onset of apoptosis. As described in Chapter 9, very few apoptotie cells were detected in 
intact SE tissues, using ill situ end labeling. In single cell suspensions, obtained upon 
disruption of the SE cell micro-enviromnent up to 85 % of the SE cells was apoptotic, 
based on end labeling and flow cytometric analysis. In addition, DNA ladders on 
electrophoresis gels, characteristic for the occurrence of apoptosis, were not detected in 
intact tissues, but only in cell suspensions. We conclude that disruption of the SE cell-
matrix interactions results in the onset of apoptosis and that blocking of this pathway 
might be necessary to succeed in the development of an optimal ill vitro culture system 
for human SEs. We could not immunohistochemically detect bcl-2 expression, which 
might explain the high susceptability of SE cells to apoptosis-inducing stimuli. Furthermo-
re, SE cell apoptosis upon disruption of the micro-environment appears independent of 
(enhanced) p53 expression, since P53 could not be immunohistochemically detected. 
Conflicting results on the incidence of N- and K-ras mutations in TGCTs have been 
reported. In Chapter 10, our analysis for N- and K-ras mutations in a series of 40 SEs 
and 60 NSs, using a polymerase chain reaction and allele specific oligonucleotide 
hybridization, is described. To exclude underestimation of the incidence of ras mutations, 
we additionally used a technique preferentially amplifying mutant K-ras (codon 12) alleles. 
In total, six mutant SEs and one mutant NS were detected. We conclude that N- or K-ras 
mutations are rare and apparently not essential for initiation and progression of TGCTs. 
Interestingly, three ras mutant SEs, included in the ill vitro culture assays, were the only 
tumors showing enhanced attachment to feeder layer, while two of them initially prolife-
rated (as already mentioned above). These findings are concordant with the apoptosis-
abrogating activity, recently found for mutant ras genes. Whether the presence of ras 
mutations in TGCTs has prognostic relevance should be investigated. 
Chapter 11 contains the results of unpublished studies, mainly aimed at the prevention 
of SE cell apoptosis. These results are discussed in view of a literature study concerning 
factors that possibly influence the onset of apoptosis in SE cells, as well as the possible 
role in SE cells of apoptosis regulators. 
In Chapter 12, the results obtained during this project are discussed and future studies 
indicated. 
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Twee hypotheses beschrijven de ontwikkeling van humane testiculaire kiemceltumo-
ren van adolescenten en volwassenen (TKCT). De ene hypothese gaat er van uit dat de 
twee histologische subtypen van de TKCT, de seminomen (SE) en de nonseminomateuze 
TKCT (NS) ontstaan uit onafhankelijke carcinoma ill situ (CIS) voorlopercellen. De 
andere hypothese, het lineaire progressie model, stelt dat NS ontstaat uit CIS, na 
doorlopen van een SE stadium. Wij hebben verscheidene benaderingen gevolgd, met name 
gericht op het ontwikkelen van een ill vitro kweeksysteem voor SE en het verkrijgen van 
SE cellijnen, om meer inzicht te krijgen in de relatie tussen SE en NS. 
Infonnatie betreffende de rationale van de uitgevoerde experimenten wordt 
gepresenteerd in de Hoofdstukken 2 tot en met 4. In Hoofdsluk 2 wordt een overzicht 
gegeven van de huidige kennis van TKCT. Hoofdsluk 3 geeft informatie over de 
betrokkenheid van stamcelfactor en diens receptor c-KIT bij de ontwikkeling van 
primordiale kiemcellen en pathologie. De rol van apoptose tijdens de nonnale ontwikke-
ling en bij tumorigenese wordt beschreven in Hoofdsluk 4. 
De richting van differentiatie van NS cellijnen blijkt gecorreleerd te zijn met de 
expressie van bepaalde combinaties en hoeveelheden van glycolipiden op het celoppervlak. 
Of deze gegevens representatief zijn voor primaire tumoren is onbekend. Bovendien is het 
glycolipidenprofiel van SE niet specifiek bestudeerd. Wij analyseerden de glycolipiden van 
een grote serie primaire SE en NS, om meer licht te werpen op de relatie tussen deze 
tumortypen. Wij gebruikten dunne-Iaag chromatografie in combinatie met orcinol -en 
immunokleuring om specifieke glycolipiden aan te tonen. Onze resultaten, gepresenteerd 
in Hoofdsluk 6, bevestigen de gegevens betreffende NS cellijnen en laten zien dat SE en 
embryonaalcel carcinoom (EC, de ongedifferentieerde stamcellen van NS) vergelijkbare 
hoeveelheden globo-serie glycolipiden tot expressie brengen. Dit geeft aan dat in deze 
tumoren stameellen aanwezig zijn. Bovendien suggereren ouze gegevens het bestaan van 
twee subpopulaties SE, de ene minder uitgerijpt en lOnder gangliosiden, de ander meer 
uitgerijpt en met gangliosiden. In EC vonden wij het lacto-serie glycolipide Le" dat 
aanwezig kan zijn op EC cellen die na reprogrammering zijn ontstaan uit globo-serie 
expresserende stameellen. Ouze glycolipidenanalyse kan geen van de beide modellen voor 
de ontwikkeling van TKCT bewijzen. 
Aangezien een diennodel, representatief voor humaan SE, het opzetten van 
experimenten lOU vergemakkelijken, hebben wij naar een dergelijk model gezoeht. De 
muizesystemen met spontane of geinduceerde teratocarcinomen leken niet bruikbaar, 
aangezien SE-aehtige tumoren nooit in deze systemen zijn aangetroffen. Bovendien lijken 
deze tumoren meer op humane (immature) teratomen en dooierzaktumoren, optredend in 
de gonaden en op extragonadale locaties in pasgeborenen en kinderen, dan op TKCT. Wij 
bestudeerden cen serie testiculaire tumoren van handen, waaronder veel seminomen, 
gebruikmakend van flow- en beeldeytometrie. Bovendien werd epidemiologiseh onderzoek 
gedaan. Ouze gegevens, gepresenteerd in Hoofdsluk 7, laten zien dat seminomen van de 
hond vergelijkbaar zijn met humane spermatoeytaire seminomen (die ook in deze studie 
zijn geanalyseerd) en niet met humane SE. Wij concluderen dat seminomen van de hond 
niet geschikt zijn als model voor humaan SE. 
In een eerder stadium hebben wij laten zien dat onder de ill vitro kweekcondities 
voor NS, dat wil zeggen het gebruik van medium met foetaal kalverserum, SE eellen 
binnen drie dagen doodgaan. In Hoofdsluk 8 wordt de ontwikkeling van een verbelerd 
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ill vitro kweeksysteem voor humaan SE beschreven, dat gebruikt kan worden in de studie 
van de pathogenetische relatie met NS. Gebruikmakend van een muize embryonale 
fibroblast (STO) cellaag, bleek een laag percentage SE cellen aan deze cellaag te hechten, 
terwijl een deel van de cellen tot dag 10 overleefde. Cellen van drie SE, daarentegen, 
vertoonden een betere hechting en twee van hen prolifereerden initiee!. Een van deze twee 
tumoren werd gekweekt onder de condities die resulteerden in het verkrijgen van 
pluripotente embryonale kiemcellen uit muize primordiale kiemcellen, d. w.z. gebruikma-
kend van een STO cellaag in combinatie met de groeifactoren stamcelfactor, leukemie 
inhiberende factor en basische fibroblast groeifactor, in serumhoudend medium. Deze 
condities resulteerden in langere overleving, proliferatie en de vorming van kolonies. In 
tegenstelling tot de situatie met muize primordiale kiemcellen konden geen SE cellijnen 
verkregen worden, noch kon reprograrnrnering tot een pluripotent fenotype worden 
waargenomen. 
Wij onderzochten of de in Hoofdstuk 8 beschreven celdegeneratie het gevolg was van 
het optreden van apoptose. Zoals beschreven in Hoofdstuk 9 werden in intacte 
weefselstukjes van SE zeer weinig apoptotische cellen gedetecteerd met ill situ 
eindlabeling. In celsuspensies, verkregen na het losmaken van de SE cellen uit hun micro-
omgeving, bleek tot 85 % van de SE cellen apoptotisch te zijn, gebaseerd op analyses met 
eindlabeling en flowcytometrie. Bovendien konden DNA ladders op electroforese gels, 
karakteristiek voor het optreden van apoptose, niet worden gevonden in intacte weefsels, 
maar alleen in celsuspensies. Wij concluderen dat verstoren van de SE cel-matrix 
interacties leidt tot het optreden van apoptose en dat blokkeren van deze route noodzake-
lijk kan zijn om te slagen in het ontwikkelen van een optimaal ill vitro kweeksysteem voor 
humaan SE. Immunohistochemisch konden wij geen expressie van bcl-2 aantonen, wat de 
hoge ontvankelijkheid van SE cellen voor apoptose-inducerende prikkels kan verklaren. 
Daarbij lijkt apoptose van SE cellen na verstoren van hun micro-omgeving onafhankelijk 
van (verhoogde) expressie van p53, daar P53 niet immunohistochemisch aangetoond kon 
worden. 
Betreffende de incidentie van N- en K-ras mutaties in TKCT zijn tegenstrijdige data 
gerapporteerd. In Hoofdstuk 10 wordt onze analyse van het voorkomen van N- en K-ras 
mutaties in een serie van 40 SE en 60 NS beschreven. Hierbij is gebruik gemaakt van een 
polymerase kettingreactie en allelspecifieke oligonucleotide hybridisatie. Om onderschat-
ting van de incidentie van ras mutaties uit te sluiten hebben wij ook een techniek gebruikt 
die preferentieel mutante K-ras (codon 12) allelen amplificeert. Iu totaal werden zes SE 
en een NS met een mutatie gedetecteerd. Wij concluderen dat N- of K-ras mutaties 
zeldzaarn zijn in TKCT en niet essentieel voor initiatie en progressie van deze tumoren. 
Belangwekkend is het feit dat drie yas mutante SE die bij de ill vitro kweekassays gebruikt 
zijn, als enige tumoren verhoogde hechting aan de cellaag vertoonden, terwijl twee van 
deze tumoren initieel prolifereerden (zoals hierboven reeds beschreven). Dit is in overeen-
stemming met de apoptose-blokkerende werking die recent is gerapporteerd voor mutante 
ras genen. Of het aanwezig zijn van ras mutaties in TKCT prognostisch relevant is, zou 
onderzocht moeten worden. 
Hoofdstuk 11 bevat de resultaten van ongepubliceerde studies, gericht op het 
tegengaan van apoptose in SE cellen. Deze resultaten worden besproken in het kader van 
een literaturstudie betreffende factoren die mogelijk apoptose van SE cellen veroorzaken 
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en de mogelijke rol van apoptose regulatoren in deze cellen. 
In Hoofdstuk 12 worden de resultaten van dit project bediscussieerd en toekomstig 
onderzoek aangegeven. 
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DANKWOORD 
Het is zover: het ei is gelegd, het "boekje" is af. U heef! dit proefschrif! gelezen en 
bent nu op deze pagina terechtgekomen. Dat geef! mij de gelegenheid om iedereen die op 
enigerlei wijze heeft bijgedragen aan de totstandkoming van dit proefschrift te bedanken. 
De volgende mensen wil ik in het bijzonder noemen. 
Ten eerste mijn ouders, Aad en Joke. Zelfs toen ik voor een anderssoortige opleiding 
en loopbaan koos, dan met name pa voor mij in gedachten had, waren jullie steeds 
gelnteresseerd in mijn studie en werk. Altijd kon ik bij jullie terecht, lOwel in de 
Wageningse als de Ylaardingse periode. Ik vind het heel fijn om te weten dat jullie, 
ondanks tegenslagen, genieten van de vrije tijd die jullie sanlCn hebben en plannen maken 
voor de toekomst. Over wat mijn zus Jolanda voor mij betekent lOU ik veel kunnen 
schrijven, maar alles laat zich het beste in een paar woorden vaUen: z6'n zus!!! 
De hechte vriendschap met Robert van de Yegte en Sijmon Timmers begon tussen 
de HEMA-worsten. Ook al zien of spreken we elkaar tijden niet, onze band blijft. 
Gezamenlijke uitstapjes naar Parijs en Londen deden de stress van alledag vergeten. Wat 
is onze volgende bestenlllling? 
Er nooit genoeg van krijgend, Iiepen Marcel "hey dude" Thalen, Corike Toxopeus 
en ik, ons elk jaar weer als een stel "oudere jongeren" te vermaken tijdens de AID, de 
algemene introductiedagen van de Landbouwuniversiteit. Ook bij de proppenfeesten waren 
we steevast van de partij om ons lekker uit te leven. Bij het volgende lustrum van 
Moleculaire Wetenschappen zijn we er toch ook weer bij? 
Tijdens een vakantie in de Proven~e maakte ik kennis met Sacha Erwteman en 
Annette Mertens. Al tien jaar kunnen we het goed vinden en hebben We altijd oor voor 
elkaa ... Kortom: we hebben "best wat leuks" aan die vakantie overgehouden. 
Onder de mensen die "op de werkvloer" hebben bijgedragen aan dit proefschrif! zijn 
aile medewerkers van het Laboratorium voor Experimentele Patho-Oncologie van de Dr. 
Daniel den Hoed Kliniek. Leendert Looijenga en Wolter Oosterhuis hebben mij gedreven 
begeleid. Marjolein Dekker wil ik bedanken voor haar enthousiaste bijdrage als analiste. 
Marjolein, ons geklets bij de flowkaS! resulteerde al snel in een fijne werksfeer. Je hebt 
een groot aantal van de experimenten, beschreven in dit boekje, met veel inzet uitgevoerd. 
Riette de Bruijn wil ik graag bedanken voor het opzetten van het ratten -en muizenbe-
stand. Na haar vertrek heef! Mirjam van de Pol zich enthousiast met het onderhouden van 
"de beestjes" beziggehouden. Mirjanl, 't bijpraten tijdens het verschonen vond ik altijd erg 
leuk. De vrolijkheid van Ruud van Gurp en Helene Roelofs zorgde, samen met de 
smeulge verhalen van Ad Gillis, voor een maoie combinatie van serieus werken en 
ontspamling. Jacqueline Groenewoud bracht gezelligheid, Marijke Mostert verzorgde een 
gelOemde omlijsting. B1ij was ik met de komst van Annemieke Yerkerk, die mij heeft 
ondersteund met haar kijk op het doen van onderzoek en die regelmatig praatpaal voor mij 
was. 
De vergaderingen met Frank de Jong, Dick de Rooij en Federica van Dissel-
Emiliani, in het kader van 91-19, waren erg plezierig en leuk om bij aanwezig te zijn. 
Ons brainstormen heef! helaas niet geleid tot het verlengen van de "tien dagen in kweek". 
Frank en Dick, bedankt voor jullie bijdrage in de promotieconnllissie. Federica, ik hoop 
dat we elkaar blijven zien en spreken als meer dan aileen collega's. 
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Kees Nooter wi! ik bedanken voor zijn inbreng in het apoptosewerk en zijn bijdrage 
aan mijn promotie. Oak Ton Boersma had een belangrijk aandeel in het apoptose-
onderzoek. Ton, je had aile data altijd prima op een rijtje. 
Het zoeken naar /'as mutaties in kiemceltumoren was erg aangenaam door de goede 
samenwerking met Lucie Boerrigter in de groep van Bert Top en Sjoerd Rodenhuis (Ex-
perimentele Therapie, Nederlans Kankerinstituut). Lucie, door jouw gezelligheid was het 
"dotten" van de vele filters een minder vervelend karweitje. 
De medewerkers van het Audio-Visueel Centrum van de Daniel, met name Arie 
Kievit, wil ik bedanken voor het afdrukken van aile foto's voor publicaties, posters en 
natuurlijk dit boekje. Arie, je leverde altijd precies wat ik wilde. De dames van de biblio-
theek hebben mij altijd vriendelijk geholpen bij het zoeken naar en het aanvragen van 
literatuur. 
A big "thanks" goes to Bruce Fenderson (Jefferson Medical School, Philadelphia). 
Bruce, I had a very nice stay in your lab, working together was a pleasure. You, your 
wife Faith, your two sons, Carl and Keith, and your dog Freckles gave me such a 
wonderful time. I really enjoyed all the time we spent at REI's. 
Bernd Kazmirczak (Zentrum fijr Humangenetik und Genetische Beratung der 
Universitiit, Bremen) machte ich geme danken rur seine Beitrage an unsere Untersuchun-
gen, mittels Micro-injection und Transfection Seminoma Zell-linien zu bekommen. Leider 
waren wir nicht erfolgreich. Jedoch hat mir die Besuchen nach Bremen ganz gut gefallen. 
Een niet te onderschatten bijdrage is geleverd door Bart Kranenburg, PC-duizendpoot 
met creatieve vingers, die een aantal figuren in dit proefschrift vorm heeft gegeven. En 
natuurlijk door Annelies van de Ree en Jessica de Bruin, bij wie ik altijd binnen kon lopen 
om lIeven te printen", Bovendien kon ik met Annelies lekker ervaringen met gave 
vakantie-bestemmingen uitwisselen. 
Een sportieve set-up kwam van Mamma's Testikels, het volleybalteam van de 
afdelingen Biochemie, Moleculaire Biologie en LEPO, waarin ik met erg veel plezier heb 
meegespeeld. Fanatisme, gecombineerd met een prima sfeer, resulteerde regelmatig in 
taarten en bokalen. 
De meest intensieve begeleiding tijdens de afgelopen jaren heb ik gekregen van 
Nicole Schrijver, mijn vriendin. Nicole, ruim vier jaar zijn we nu samen, jij in 
Wageningen en ik in Vlaardingen, maar toch samen. Altijd was je er voor mij: bij 
gemopper of tegenslag ving je me op, bij succes was je blij voor twee. Sinds enige tijd 
ben je Wagenings ingenieur en op zoek naar een werkplek. Ik ben ervan overtuigd dat we 
onze ideeen zodanig op elkaar kumlen afstenullen, dat we ;;cht samen de toekomst 
tegemoet kunnen gaan, in Nederland of Frankrijk. 
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